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Interaction with our environment shapes us as we develop as human beings and 
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Drug development in oncology was initially focused on inducing DNA damage in 
proliferating cancer cells, with currently more emphasis on targeted agents and 
immunotherapy. New approaches are critical as many patients still have recurrence of their 
disease and develop resistance to their cancer treatment.  
More recently it was demonstrated that the environment of cancer cells play a role in 
cancer progression (1-7). Apart from cancer cells, tumors also contain endothelial cells, bone 
marrow-derived progenitor cells, immune cells, cancer-associated fibroblasts, and other 
stromal cells (8). Through cell-cell contact and under the influence of soluble molecules, these 
cells can interact during tumorigenesis. This cross-talk between tumor and microenvironment 
cells is increasingly acknowledged as an important characteristic of cancer, hence, a potential 
target for treatment. 
Sustained angiogenesis is a key component of the tumor microenvironment that fosters 
cancer growth by providing oxygen and nutrients. In turn, the levels of oxygen and nutrients 
that determine the metabolic and transcriptional profile of cancer cells (8). Low levels of 
oxygen are related to glycolysis, activated oncogenes that support cancer cell proliferation, 
and upregulated proinvasive pathways in cancer cells. Furthermore, the oxygen shortage 
occurring in fast-growing tumors or after antiangiogenic therapy activates the hypoxia-
inducible factor 1α (HIF1α)-mediated synthesis of proangiogenic factors. In a vicious cycle, 
these proangiogenic factors will help to expand the neoplastic vasculature and thus promote 
cancer growth and dissemination. Apart from tumor vessels, stroma-derived chemokines also 
foster growth, dissemination, and survival of cancer cells. Chemokines are low-molecular-
weight proteins involved in (tumor)cell migration that are produced by stromal cells, and their 
receptors are expressed by cancer cells. Together, ligands and receptors form an important 
network supporting cancer cell proliferation and distant spread (9). Furthermore, cancer cells  





that reside in a chemokine-rich microenvironment like the bone marrow can be protected from 
chemotherapy induced damage (10, 11).  
Treatment directed at cancer cells elicits a response in the tumor microenvironment. 
Chemotherapy induces cellular stress and the release of a variety of cytokines, growth factors 
and chemokines by stromal cell depending on the drug's mechanism of action (6). 
Radiotherapy causes hypoxia, cellular stress and the production of reactive oxygen species 
which can also stimulate the stromal cells (12). This way released chemokines and growth 
factors from the stroma bind to receptors on cancer cells and stimulate cancer cell growth and 
survival. These events can alter the sensitivity of tumors to chemotherapy and radiotherapy. 
These events are present in several malignancies. However, little is known about rectal 
cancer, which is a major contributor to cancer-related morbidity and mortality worldwide 
(13).  
Until recently molecular heterogeneity within a tumor between patients and lesions, 
within lesions, and in time was neglected. This is however currently drawing more attention 
(14). Tumor heterogeneity may be missed with only one biopsy. Therefore, standard biopsy 
analyses for presence of growth factors and chemokines, combined with in vivo whole-body 
imaging of these factors are an attractive opportunity to get insight into the behavior of these 
targets in normal and tumor tissues. This can be achieved by labeling compounds directed 
against these factors with radioactive isotopes or fluorescent dyes. Imaging can then be 
performed with single-photon emission computed tomography (SPECT) or positron emission 
tomography (PET) for radionuclides, or optical imaging for fluorescent probes (15, 16). 
Furthermore, molecular imaging with radiolabeled therapeutic antibodies against soluble 
growth factors would allow us to assess the biodistribution and tumor uptake of these 
therapeutics, and could serve as a readout for target saturation (17). This, in turn, may support 
the rational dosing of these agents in the clinic. 





The aim of the thesis 
The aim of this thesis was to explore targets in the microenvironment of rectal cancer with a 
focus on angiogenic growth factors and chemokines. 
Outline of the thesis  
In Chapter 2 a literature review was performed about clinical and biological differences and 
similarities between rectal and colon cancer, and it was analyzed how they influence current 
standard treatment and might influence the design of future clinical approaches. PubMed and 
Google Scholar were searched for research and review articles in English, as well as meta-
analyses published up to May 2015. We used the following search terms: "rectal cancer", 
"colon cancer", "epidemiology", "histology", "gene" "(neo)adjuvant treatment", "metastasis", 
"targeted drugs", "tumor microenvironment", in various combinations. We also consulted 
current European Society for Medical Oncology, Dutch, and National Comprehensive Cancer 
Network Clinical Practice Guidelines for rectal and colon cancer, and the registry for clinical 
studies of the  ClinicalTrials.gov site (National Institute of Health, United States of America) .  
There are increasing attempts to treat primary metastasized rectal cancer with curative 
intent. The antiangiogenic agent bevacizumab – a humanized antibody against vascular 
endothelial growth factor A (VEGFA) – administered in combination with standard treatment 
has improved survival of metastatic (colo)rectal cancer patients. These data provided the 
rationale for a phase 2 study in patients with primary metastatic rectal cancer. Chapter 3 
describes this study. Fifty therapy-naive patients presenting with a primary rectal tumor and 
simultaneous metastases to the liver or lungs received short-course radiotherapy followed by 
preoperative bevacizumab, capecitabine and oxaliplatin, and subsequent radical surgical 
treatment. The primary end point was the percentage of patients receiving radical curative 





treatment at all tumor sites. Secondary end points were 2-year survival, 2-year recurrence rate, 
and treatment-related toxicity.  
  In Chapter 4, we evaluated the expression of chemokine receptor CXCR4 and its 
ligand CXCL12 which are both involved in the microenvironment in rectal tumors. Tumors of 
46 stage IV patients participating in the phase 2 trial as described in Chapter 3 were studied 
before and after local radiotherapy and systemic treatment with bevacizumab, capecitabine 
and oxaliplatin, and subsequent radical surgery. The protein expression of CXCR4 and 
CXCL12 was analyzed immunohistochemically in paraffin-embedded primary rectal cancer 
diagnostic biopsies collected before and in surgical rectal specimens collected after 
radiochemotherapy and bevacizumab. Expression of both factors was assessed in the 
cytoplasm and nucleus of tumor cells, adjacent stromal cells and normal rectal crypts. In 
addition, baseline expression of CXCR4 and CXCL12 was correlated with patients' 
pathologic response to treatment. 
 Expression of placental growth factor (PlGF) – a VEGFA homolog – is related 
preclinically to tumor angiogenesis and survival of cancer cells, and correlated with poor 
survival of colorectal cancer patients (18-20). Moreover, bevacizumab alone or in 
combination with radiotherapy or chemotherapy increased circulating PlGF levels in 
(colo)rectal patients (21, 22). In Chapter 5 we examined immunohistochemically the 
expression of VEGFA and PlGF, and the mean vessel density (MVD) in the paraffin-
embedded rectal tumors of 46 patients enrolled in the clinical study reported in Chapter 3. The 
protein expression of VEGFA and PlGF was assessed in tumor and stromal cells, and in the 
epithelial cells of tumor-neighboring rectal crypts before and after radiochemotherapy and 
bevacizumab. Additionally, VEGFA and PlGF protein expressions at diagnosis were 
correlated with pathologic response to treatment. The pathologic response was chosen as it 





provides early and accurate information on the local effect of pelvic radiotherapy and 
systemic bevacizumab, capecitabine and oxaliplatin.  
Preclinical PlGF inhibition restricts growth and metastasis of various tumors, 
including those resistant to VEGF receptor (VEGFR) inhibitors, and enhances the efficacy of 
chemotherapy and VEGFR inhibitors (23). Early clinical trials of humanized monoclonal anti-
PlGF antibody RO5323441 showed that anti-PlGF therapy was well tolerated (24, 25). In a 
randomized trial in patients with recurrent glioblastoma (n=22; ClinicalTrials.gov identifier, 
NCT01308684), RO5323441 combined with bevacizumab did not improve the response rate 
compared to single agent bevacizumab (26). However, in the initial study its administration 
did not coincide with dose-limiting toxicity, therefore, no optimal therapeutic dose is yet 
defined. Rational dosing might be achieved when tumor and normal body tissues uptake of 
the antibody is defined by 89Zr-RO5323441 PET. Therefore, as described in Chapter 6, we 
labeled RO5323441 with radioactive Zirconium-89 (89Zr) in order to develop a PlGF-specific 
PET tracer. The radiochemical purity of the tracer was tested by size-exclusion high-
performance liquid chromatography. The stability of the tracer was assessed at 4 °C in solvent 
(0.9% NaCl), and at 37 °C in buffer (phosphate-buffered saline) and in human serum by 
trichloroacetic acid precipitation. In vitro immunoreactivity of 89Zr-RO5323441 was tested in 
a competitive radio-immuno assay with PlGF coated ELISA plates. Ex vivo biodistibution of 
the tracer was studied in tumor-bearing and in healthy mice. The tumor uptake was 
determined by small-animal PET imaging in athymic nude mice xenografted with human 
PlGF-expressing hepatocellular carcinoma or human renal cell carcinoma without detectable 
human PlGF expression. Indium-111 labeled immunoglobulin G (111In-IgG) served as a 
control for non-specific tumor uptake and organ distribution assessment. Ex vivo 
immunofluorescent staining of tumor slides with anti-CD68 antibody labeled with Alexa 488 





and RO5323441 labeled with cyanine 5 (Cy5) were used to detect tumor-associated 
macrophages, and to study the molecular mechanisms behind the specific tracer tumor uptake. 
Chapter 7 contains the English summary of this thesis, followed in Chapter 8 by a 
discussion and future perspectives. Chapter 9 contains the Dutch summary and Chapter 10 
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Due to differences in anatomy, primary rectal and colon cancer require different staging 
procedures, different neo-adjuvant treatment and different surgical approaches. For example, 
neoadjuvant radiotherapy or chemoradiotherapy is administered solely for rectal cancer. 
Neodjuvant therapy and total mesorectal excision for rectal cancer might be responsible in 
part for the differing effect of adjuvant systemic treatment on overall survival, which is more 
evident in colon cancer than in rectal cancer. Apart from anatomic divergences, rectal and 
colon cancer also differ in their embryological origin and metastatic patterns. Moreover, they 
harbor a different composition of drug targets, such as v-raf murine sarcoma viral oncogene 
homolog B (BRAF), which is preferentially mutated in proximal colon cancers, and the 
epidermal growth factor receptor (EGFR), which is prevalently amplified or overexpressed in 
distal colorectal cancers. Despite their differences in metastatic pattern, composition of drug 
targets and earlier local treatment, metastatic rectal and colon cancer are, however, commonly 
regarded as one entity and are treated alike.  
In this review, we focused on rectal cancer and its biological and clinical differences 
and similarities relative to colon cancer. These aspects are crucial because they influence the 
current staging and treatment of these cancers, and might influence the design of future trials 










Colorectal cancer (CRC) is the third most commonly diagnosed cancer globally, accounting 
for 10.0% of the estimated 14.1 million new cancer cases registered in 2012 [1]. Moreover, it 
is the third leading causes of cancer-related death in women and the fourth in men, with more 
than 693,600 deaths occurring worldwide in 2012. About one-third of CRCs are rectal 
cancers, which in 2008 corresponded to approximately 450,000 new cases worldwide.  
Several biological and clinical hallmarks indicate that rectal cancer is different from 
colon cancer. The rectum and colon have a different embryological origin, anatomy and 
function [2-4]. Consequently, the treatments for primary rectal and colon cancer are different. 
Primary rectal cancer requires specific surgical treatment: total mesorectal excision (TME), 
preceded by neoadjuvant radiotherapy or chemoradiotherapy [5, 6]. This reduces the risk of 
local recurrence, but does not improve survival compared to surgery alone [7]. Adjuvant 
systemic chemotherapy following curative surgery improves survival of lymph node-positive 
(stage III) colon cancer patients [8, 9]. At present, fluoropyrimidine-based adjuvant 
chemotherapy is also recommended in stage II-III rectal cancer by the European Society for 
Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN) 
guidelines [10, 11]. In case of rectal cancer, however, the maximal overall survival benefit at 
10 years is only 3.4%. Presently, the divergent treatment for localized rectal and colon cancer 
is not accompanied by therapy differences in the metastatic setting. Metastasized rectal and 
colon cancer are commonly regarded as one entity and treated alike [11-13]. 
Despite a substantial rise in survival over the last two decades, the 5-year disease-
specific overall survival rate is approximately 59% for colon cancer and 61% for rectal cancer 
[14]. This indicates that there is still much room for improvement. In this review, we have 
summarized the reported differences and similarities in rectal and colon cancer biology as 
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well as the differences and similarities in their clinical behavior. This could provide further 
guidance for the design of novel clinical approaches. 
Search strategy 
PubMed and Google Scholar were searched for research articles, reviews and meta-analyses 
published in English up to May 2015. We used the following search terms: "rectal cancer", 
"colon cancer", "epidemiology", "histology", "gene", "(neo)adjuvant treatment", "metastasis", 
"targeted drugs", and "tumor microenvironment", in various combinations. We also consulted 
current ESMO [10, 13, 15], Dutch [16, 17] and NCCN [11, 12] Clinical Practice Guidelines 
for rectal and colon cancer, and the registry for clinical studies of the ClinicalTrials.gov site. 
Epidemiology and lifestyle risk factors for sporadic colorectal cancer 
According to the 2011 National Statistics of Cancer Incidence in the United Kingdom, 
approximately 31% of CRCs occur in the proximal colon and 25% in the distal colon, as 
divided at the splenic flexure, whereas approximately 34% are rectal and rectosigmoid 
junction tumors [18, 19]. In recent decades, however, tumors of the proximal colon and 
rectum have shown different incidence trends [20]. In a number of Western countries, 
including the United States of America (USA) [21-23], Canada [24, 25], Australia [26], New 
Zeeland [27], Japan [28, 29] and European countries [30-33], there has been a rising incidence 
of proximal colon cancer during the last five decades, but a decreasing incidence of rectal 
cancer during the last three decades. Proximal colon cancer is more common in women, 
whereas rectal cancer occurs more frequently in men [34-36]. Moreover, several studies 
addressing environmental factors such as diet, smoking, and physical activity, found that these 
factors might have a different effect in colon cancer than in rectal cancer. Most 
comprehensive systematic reviews and meta-analyses of epidemiological studies concluded 
that—at least in Western countries—physical activity decreased the risk of colon  
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but not of rectal cancer [37-39]. This observation is in line with a prospective cohort analysis 
of the National Institutes of Health of 506,488 participants followed between 1995-2006 in 
the USA [40]. In that analysis, behavioral factors (physical activity, diet, smoking) and body 
mass index were stronger  mediators of risk for colon cancer than for rectal cancer. Overall, a 
healthy lifestyle seems to have less impact in preventing rectal cancer compared to colon 
cancer.  
Primary tumor histology, molecular characteristics and anatomic site  
Three major histological subtypes of CRC can be identified: intestinal type adenocarcinoma, 
mucinous adenocarcinoma and signet-ring cell carcinoma. The occurrence of mucinous and 
signet-ring cell tumors is higher in the proximal colon (approximately 45%) than in the distal 
colon or rectum (approximately 20%)  [41]. 
Two main syndromes resulting from germ line mutations play a role in the occurrence 
of CRCs. The first is familial adenomatous polyposis syndrome (FAP), which is associated 
with mutations in the adenomatous polyposis coli (APC) tumor suppressor gene. In patients 
with this syndrome, tumors develop in the distal colon in approximately 60% of the cases, and 
in the rectum in 25% of patients [42]. The second is Lynch syndrome (hereditary 
nonpolyposis colorectal cancer, HNPCC), which results from inactivating mutations in DNA 
mismatch repair (MMR) genes (commonly MutL homolog 1 (MLH1) and MutS homolog 2 
(MSH2); 55% of these tumors are present in the proximal colon and 15% in the rectum [42, 
43]. 
(Epi)genetic instability in colorectal cancer 
Three main types of (epi)genetic instability have been established so far in CRC (Table 1) 
[44-46]. The first type is chromosomal instability (CIN), characterized by aneuploidy and 
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Table 1. Types of (epi)genetic instability in colon and rectal carcinomas, and their molecular, 
histological and anatomical characteristics [44-55]. 
 
Parameter CIN MSI CIMP 
Histology Adenocarcinoma Mucinous adenocarcinoma 
sessile serrated        
adenocarcinoma 
Traditional 
serrated        
adenocarcinoma 
KRAS mutation +++ + − − 
BRAF mutation + +++ +++ + 
MLH1 methylation − +++ +++ − 
MGMT methylation − − − +++ 
Anatomical site No preference Proximal colon Proximal colon Distal colorectum 
 
CIN, chromosomal instability; MSI, microsatellite instability; CIMP, CpG island methylator 
phenotype; KRAS, Kirsten rat sarcoma gene; BRAF, v-raf murine sarcoma viral oncogene homolog B; 
MLH1, MutL homolog 1 gene; MGMT, O-6-methylguanine-DNA methyltransferase gene; +++, 




















loss of heterozygosity. CIN predominantly occurs in sporadic tumors developing from 
adenomas along the large bowel, irrespective of their anatomical site [47]. CIN is also present 
in the inherited condition FAP [48]. Activating Kirsten rat sarcoma (KRAS) oncogene 
mutations represent an important feature of sporadic CIN tumors [47], and constitute the 
major cause for clinical resistance to standard epidermal growth factor receptor (EGFR)-
inhibitory therapy [49]. The second type is microsatellite instability (MSI), which results from 
deficient DNA mismatch repair. This can be caused by inactivating germ line mutations, as 
present in Lynch syndrome, or by MLH1 promotor hypermethylation, as present in sporadic 
carcinomas. Activating mutations in v-raf murine sarcoma viral oncogene homolog B (BRAF, 
mainly mutation V600E) are enriched in sporadic tumors with MLH1 hypermethylation [50, 
51], which can render them resistant to currently used EGFR-inhibitors [52]. Sporadic tumors 
harboring MSI are very rare in the rectum; they are localized especially in the proximal colon, 
and are often mucinous adenocarcinomas [53]. The third type of epigenetic instability is the 
CpG island methylator phenotype (CIMP), characterized by excess methylation of some CpG 
islands. This type occurs in sporadic sessile serrated adenocarcinomas of the proximal colon 
that show MLH1 hypermethylation [44, 51, 54, 55], or in traditional serrated adenocarcinomas 
of the distal colon and rectum that show O-6-methylguanine-DNA methyltransferase 
(MGMT) methylation [43]. 
A comprehensive characterization of human colon and rectal carcinomas was carried 
out by the Cancer Genome Atlas Network to identify possible genetic differences between 
them [56]. Genome-wide analysis of 224 colorectal tumor/normal tissue pairs showed that 
84% of the colon and rectal tumors had a low mutation rate < 8.24/106 bases (defined as non-
hypermutated). The remaining 16% of the tumors had a high mutation rate (>12/106 bases, 
defined as hypermutated). The mutation frequency of the well-known CRC-related genes 
APC, tumor protein TP53, KRAS oncogene and BRAF was respectively 81%, 59%, 43%, and 
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3% in the non-hypermutated tumors, and 51%, 17%, 30%, and 47% in the hypermutated 
tumors. The mutational profile of non-hypermutated colon and rectum tumors was similar, 
whereas three quarters of the hypermutated and most of the hypermethylated tumors 
originated in the proximal colon. As a possible explanation for these results, the authors 
proposed their differing origins: the proximal colon originates in the embryonic midgut, while 
the distal colorectum originates in the embryonic hindgut [56]. These data suggest that the 
non-hypermutated tumors in the Cancer Genome Atlas Network study basically correspond to 
the CIN phenotype, while the hypermutated tumors correspond with MSI phenotypes [57].  
Overall, several histological, genetic and methylation findings support the idea that 
rectal and distal colon carcinomas share characteristics and are different from tumors of the 
proximal colon [58-61]. The concept of abrupt dichotomy at the splenic flexure [62] has 
recently been challenged by a study in 1,443 stage I-IV CRC patients [63]. In that study, the 
incidence of MSI-high, BRAF mutations and CIMP-high in tumors gradually decreased from 
the proximal colon to the rectum (Table 2). An assessment of molecular features along 
anatomical sites in colon carcinomas of patients enrolled in the Pan European Trial Adjuvant 
Colon Cancer-3 (PETACC3) chemotherapy trial found that proximal tumors were more often 
MSI, hypermutated, BRAF mutant, of serrated signature, densely infiltrated by tumor 
infiltrating lymphocytes. Distal tumors were CIN, human epidermal receptor (HER) 1 and 2 
amplified, with an active EGFR signaling, and largely non-BRAF-like [64]. This analysis 
supported the gradual decrease of MSI-high distribution from the ascending colon to the 
rectum (n = 194), and reported a dichotomous character of distribution for BRAF mutations in 
proximal (higher frequency) vs distal carcinomas (lower frequency) as divided at the splenic 
flexure (n = 110). In a pooled analysis of 560 stage I-IV CRCs from three independent 
population-based studies, the molecular difference between microsatellite stable primary 
tumors according to site were studied [65]. Differences were apparent in the overexpression 
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of homeobox (HOX) genes, which was decreased in a gradient from the proximal colon 
toward the distal colon and rectum [65]. Consolidating an answer on discrete vs gradual 
molecular differences in CRCs according to their location in the bowel is needed because it 
can influence stratification of patients in studies with targeted drugs.  
Table 2. Microsatellite instability-high (MSI-high), BRAF mutation and CpG island 
methylator phenotype-high (CIMP-high) frequency (%) in colon and rectal carcinomas 
according to anatomical subsites [63]. 
 
Parameter MSI-high (%) BRAFmutant (%) CIMP-high (%) 
Cecum 22 12 22 
Ascending colon 37 36 40 
Hepatic flexure 29 32 35 
Transverse colon 20 23 30 
Splenic flexure 19 19 14 
Descending colon 6.7 11 8.1 
Sigmoid 2.8 3.8 3.6 
Rectosigmoid junction 3.3 4.3 2.3 
Rectum 1.6 1.6 2.2 
MSI-high, microsatellite instability-high (instability in ≥30% of markers); BRAF, v-raf murine 
sarcoma viral oncogene homolog B; CIMP-high, CpG island methylator phenotype-high (≥6/8 
methylated promoters). Adapted by permission from BMJ Publishing Group Limited. 
 
Clinical outcome in relation to molecular subtype and site of colorectal cancer 
CRC can develop through (in)activation of several pathway, involving combinations of 
genetic and epigenetic changes. Biologically distinct subtypes of CRC could translate into 
stage-independent survival differences in patients. A recent analysis of 2,720 stage III colon 
cancer samples of patients participating in the randomized phase 3 NCCTG (Alliance) N0147 
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adjuvant chemotherapy trial found that stage III colon cancer patients with a MMR proficient 
primary tumor harboring mutant KRAS (n = 945) or BRAF (n = 189) had a shorter 5-year 
disease-free survival than patients whose tumors lacked these mutations (HR 1.48 and 1.43 
respectively) [66]. Patients with MMR proficient tumors without BRAF or KRAS mutations (n 
= 1331) and those with MMR deficient tumors (n = 255) had a similar 5-year disease-free 
survival. A trend toward a better 5-year disease-free survival rate was observed in stage III 
patients with distal (n = 880; 73.7%) vs proximal MMR proficient tumors lacking KRAS or 
BRAF mutations (n = 437; 65.0%), and in those with BRAF mutation (n = 45; 66.0% for 
distal and n = 140; 50.9% for proximal), as divided at the splenic flexure. 
Patients with stage II proximal colon carcinoma (cecum to hepatic flexure; n = 353) 
enrolled in the PETACC3 adjuvant chemotherapy trial relapsed less frequently than patients 
with distal tumors (splenic flexure to sigmoid colon; HR 0.6; n = 488) [64]. In contrast, 
patients with stage III disease displayed no site-dependent risk for relapse. Survival after 
relapse was worse in proximal stage III colon tumors than in distal tumors in a multivariate 
analysis including MSI, KRAS and BRAF mutation status (HR 1.95, 95% CI 1.6-2.4; n = 285), 
possibly in relation to a protective behavior of MSI in stage I-II, before any metastasis is 
present. 
A large-scale, community-based analysis carried out by the Colorectal Cancer 
Subtyping Consortium (CRCSC) on 4,000 stage II-III CRC samples identified four molecular 
subtypes of CRC (colorectal cancer molecular subtypes, CMS 1-4) [74]. These subtypes were 
distinct in their (epi)genetic characteristics, disturbed signaling pathways, and clinical 
presentation (Table 3). Subtype CMS1 is a MSI, immune-activated tumor, hypermutated and 
enriched for BRAF mutations with propensity for the proximal colon. The CMS2 subtype is a 
microsatellite stable tumor with high CIN, strong WNT/MYC pathway activation, EGFR 
amplification or overexpression and mutant TP53, and is located especially in the distal 
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colorectum. The CMS3 subtype is a tumor with low CIN, moderate WNT/MYC pathway 
activation, mutant KRAS and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic 
subunit alpha gene (PIK3CA), and insulin-like growth factor binding protein 2 (IGFBP2) 
overexpression. The CMS4 subtype is a CIN/MSI heterogeneous tumor of mesenchymal type, 
with transforming growth factor beta (TGF-β) activation, and neurogenic locus notch 
homolog protein 3 (NOTCH3)/vascular endothelial growth factor receptor 2 (VEGFR2) 
overexpression. CMS3 and CMS4 showed no anatomical site preference. Patients with a 
CMS2 tumor had better survival, and those with a CMS4 tumor had worse survival, whereas 
survival of patients with a CMS1 or CMS3 tumor was intermediate [67].  
 
Table 3. Molecular subtypes of colon and rectal carcinomas: genetic instability, signaling 
pathway and clinical features [67]. 
 
Molecular subtype (%)                                  Parameters 
   
CMS1   (14%) MSI, immune pathway activation/expression, right-side tumors, older age 
at diagnosis, females, hypermutation, BRAF mut, intermediate survival 
CMS2   (41%) High CIN, MSS, strong WNT/MYC pathway activation, left-side 
tumors,TP53 mut, EGFR amplification/overexpression, better survival 
CMS3   (8%) Low CIN, moderate WNT/MYC pathway activation, KRAS mut, PIK3CA 
mut, IGFBP2 overexpression, intermediate survival 
CMS4   (20%) CIN/MSI heterogeneous, mesenchymal/TGF-beta activation, younger age 
at diagnosis, NOTCH3/VEGFR2 overexpression, worse survival 
   
 
(%), percentage of samples; CMS, 1-4 colorectal cancer molecular subtypes 1-4; MSI, microsatellite 
instability; BRAF mut, mutant v-raf murine sarcoma viral oncogene homolog B; CIN, chromosomal 
instability; MSS, microsatellite stability; TP53 mut, mutant tumor protein p53; EGFR, epidermal 
growth factor receptor; TGF-β, transforming growth factor beta; KRAS, Kirsten rat sarcoma oncogene; 
PIK3CA mut, mutant phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha gene; 
IGFBP2, insulin-like growth factor binding protein 2; NOTCH3, neurogenic locus notch homolog 
protein 3; VEGFR2, vascular endothelial growth factor receptor 2. Reprinted with permission. ©2014 









Apart from influencing patient's survival, biologically distinct subtypes of colorectal 
cancer might be also important for the design of future clinical trials. For instance, MSI 
tumors produce neo-proteins, often called neo-antigens in literature, due to multiple frame 
shift mutations and nucleotide repeat replication deficiency. These neo-proteins are 
subsequently processed into neo-peptides that are presented on major histocompatibility 
complexes 1 (MHC-1) and result in more tumor infiltrating lymphocytes [68]. Patients with 
MSI CRCs might be optimal candidates for immune therapy trials. In the phase 2 trial with 
the programmed cell death protein-1 (PD-1) inhibitor pembrolizumab, objective response rate 
was 40% (n = 10) in MMR-deficient metastatic CRC patients, whereas no objective response 
was observed in the MMR-proficient cases (n = 18) [69].  
Metastatic patterns  
Venous drainage of the large bowel is achieved via the portal system. Therefore, the first site 
of hematogenous dissemination for CRCs is usually the liver, followed by the lungs, bone, 
and many other sites, including the brain [70]. However, tumors arising in the distal rectum  
can metastasize initially to the lungs because the inferior rectal vein drains into the vena cava 
inferior rather than into the portal venous system. An analysis of 567 patients with colon 
cancer and 1,013 with rectal cancer showed that 11.5% of rectal cancer patients had 
pulmonary metastasis, compared to only 3.5% of colon cancer patients [71]. In an autopsy 
study including 1,238 patients with metastatic colon and 441 patients with metastatic rectal 
cancer, no differences were found in the frequency of liver metastases according to the 
primary tumor site (colon, 69.6% vs rectal, 67.4%) [41]. However, for adenocarcinoma and 
mucinous carcinoma histological subtypes, intra-abdominal metastases were more frequent in 
case of colon cancer (peritoneal 28.8% vs 16.0%, omental 9.1% vs 2.9%, and ovarian 3.2% vs 
1.1%), whereas extra-abdominal metastases occurred more often in rectal cancer patients 
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(lungs 42.0% vs 30.7%, and brain 5.0% vs 2.6%). Another study reported an increased risk 
for lung-only metastasis among rectal adenocarcinoma patients (odds ratio (OR) 3.32; n = 35) 
relative to colon adenocarcinoma patients (n = 108) [72]. This study found a KRAS mutational 
status discordance rate of 32.4% between the paired 37 primary tumors and lung metastases, 
compared to the 12.3% discordance rate between the paired 106 primary tumors and 
metastatic sites other than lungs. Another study described a concordance rate of 95% for 
KRAS status of primary colorectal tumors and matched liver metastasis [73]. These studies 
suggest a difference in KRAS mutational status between the primary tumor and hepatic vs 
extrahepatic metastases, and KRAS mutational status discordances between the primary tumor 
and lung metastases can be more common in rectal cancer patients. 
Staging procedures, neoadjuvant treatment and surgery of the primary tumor  
Following detection by endoscopy and confirmation by histopathology, rectal and colon 
tumors present important staging and treatment differences.  
The rectum is located in the narrow pelvis and is surrounded by numerous vital 
structures such as large vessels, nerves, bladder, internal genital organs or sacrum. Therefore, 
the local treatment for rectal cancer is more aggressive than that for colon cancer. 
Neoadjuvant short-course radiation or chemoradiation followed by total mesorectal excision 
(TME) is the current standard of care for locally advanced rectal cancer, with a 5-year local 
recurrence rate of <10% [5,6,74].  
Optimal neoadjuvant and surgical treatment assignment for rectal cancer patients 
according to the risk for local recurrence requires a reliable preoperative assessment of the 
tumor status (T), the nodal status (N), and the surgical circumferential resection margin 
(CRM). Distinct from colon tumors, preoperative endorectal ultrasound (EUS) and magnetic 
resonance imaging (MRI) play important roles in the diagnostic management of rectal tumors. 
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EUS supports differentiation between superficial cancers invading into the submucosa (T1) 
that are treated by transanal endoscopic microsurgery (TEM), and those that breach the 
muscularis propria (T2) [75]. A meta-analysis of 90 studies published between 1985-2002 
demonstrated a high pooled sensitivity (94%) of MRI for assessing the depth of tumor 
penetration through the rectal wall and for providing an accurate image of the surrounding 
soft pelvic structures [76]. Therefore, MRI is part of the current standard preoperative work-
up for non-superficial rectal tumors, i.e. large tumors limited to the bowel wall (T2), tumors 
penetrating through the muscular wall (T3), those that penetrate  the visceral peritoneum 
(T4a), or those invading adjacent organs (T4b) [10,11].  
Several studies and meta-analyses have been conducted to define the accuracy of 
preoperative MRI in predicting the CRM and the nodal status [77-82]. A multivariate analysis 
correlated MRI and histopathological CRM assessment in 374 rectal cancer patients enrolled 
in the MERCURY trial [81]. This showed that primary tumors located at >1 mm from the 
mesorectal fascia on the MRI scan have a low risk for CRM tumor involvement as judged by 
the pathologist (hazard ratio (HR) 3.72, 95% confidence interval (CI) 1.43-9.71). Hence, MRI 
is currently the preoperative examination of choice for establishing the relationship between 
the edge of the rectal tumor and the mesorectal fascia, which is the anatomical cornerstone for 
the feasibility of curative TME.  
Compared with colon cancer, the preoperative nodal status in rectal cancer has a 
higher impact on the choice of neoadjuvant treatment. A meta-analysis of 84 studies 
published between 1985-2004 on histologically proven rectal cancer patients showed a size-
based N-staging accuracy for pelvic MRI of 57%-85% [80]. This moderate sensitivity could 
be explained by MRI overlooking mainly small (<5 mm) metastatic lymph nodes, and in 
rectal cancer, the majority of metastatic nodes are smaller than 5 mm [83]. A study in 42 
rectal cancer patients who underwent TME suggested that defining MRI node positivity by 
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irregular border or heterogeneous signal rather than size might improve MRI sensitivity and 
specificity [84]. In current clinical practice, therefore, lymph nodes are defined as metastatic 
based on the above mentioned morphological criteria: if they are round-shaped with a 
diameter ≥5 mm, if they have a heterogeneous signal and/or show irregular border on MRI 
[85].  
A palliative colectomy is often justified in case of patients with metastatic colon 
cancer. However, in rectal cancer patients, due to a high risk of postoperative morbidity, TME 
is usually only justified in a curative setting. Therefore, an accurate staging that takes into 
account the higher rate of lung metastases in rectal cancer is crucial before a curative TME 
surgery decision can be made. Hence, for screening of metastatic disease in the liver and 
lungs, several guidelines recommend state-of-the-art CT of the abdomen and chest (11-13,86).  
Adjuvant chemotherapy  
In lymph node-positive (stage III) colon cancer, systemic adjuvant chemotherapy can improve 
survival [8, 9]. When started within 8 weeks after surgery, 5-FU, leucovorin, oxaliplatin 
(FOLFOX) or capecitabine, oxaliplatin (CAPOX) administered in 3-weekly cycles over 24 
weeks yielded overall survival benefits of 5-25% [87, 88]. In a recent retrospective 
multicenter study of 433 stage II-III MSI colon carcinoma patients, an improved relapse-free 
survival was found with FOLFOX therapy (HR 0.46, 95% CI 0.23-0.79; n = 119) compared 
to surgery alone (n = 263), whereas no survival benefit effect was observed with 5-FU therapy 
(HR 1.02, 95% CI 0.60-1.73; n = 51) [89].  Therefore, the Dutch national guideline for colon 
cancer recommends that patients with MSI stage II-III colon carcinoma who have a 
contraindication for oxaliplatin should not receive adjuvant 5-FU monotherapy [17]. 
Importantly, MSI status should not be determined or used to define treatment in stage III 
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colon cancer patients for whom a standard of care oxaliplatin-based regimen is being planned 
[12,15].  
It is still controversial whether rectal cancer patients should receive adjuvant 
chemotherapy after neoadjuvant radiotherapy or chemoradiotherapy [90, 91]. Lack of activity 
might be due to the fact that after neoadjuvant treatment and the surgically complex TME, 
which often has prolonged recovery period, there is a chemotherapy-free period of 
approximately 20 weeks until adjuvant systemic treatment can be administered. Furthermore, 
adjuvant chemotherapy following neoadjuvant chemoradiation and TME can, at times, only 
be administered at a reduced dose [74]. The long-term follow-up of the European 
Organization for Research and Treatment of Cancer 22921 randomized study in rectal cancer 
(EORTC 22921; n = 1,011) found no survival benefit for adjuvant bolus 5-FU/leucovorin 
following neoadjuvant radiotherapy or chemoradiotherapy in T3 or T4 disease, including 
node-positive patients [92]. Ten-year disease-free survival was 47.0% in the adjuvantly 
treated arm and 43.7% in the surveillance arm (HR 0.91, 95% CI 0.77-1.08, P = 0.29). The 
10-year overall survival was 51.8% in the arm with adjuvant treatment and 48.4% in the arm 
without (HR 0.91, 95% CI 0.77-1.09, P = 0.32). Of the 506 patients who received adjuvant 
chemotherapy, 57% did not receive the intended 4 cycles as scheduled, and 27% could not 
start adjuvant treatment at all [7]. In another randomized trial, 635 rectal cancer patients with 
clinical stage T3-T4 disease were given long-course 5-FU-based neoadjuvant 
chemoradiotherapy, followed by adjuvant bolus 5-FU/leucovorin or observation [93]. The 10-
year overall survival rates did not differ, with 63.4% in the adjuvant treatment group and 
63.0% in the observation group. Similarly, the randomized PROCTOR/SCRIPT trial of 
adjuvant 5-FU/leucovorin or capecitabine vs observation (n = 470), showed no long-term 
survival benefit for adjuvant systemic chemotherapy in stage II-III rectal cancer following 
neoadjuvant (chemo)radiotherapy [94]. In that study, 75% of the included patients received 
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the assigned adjuvant chemotherapy. Furthermore, the CHRONICLE trial, consisting of 
adjuvant oxaliplatin/capecitabine treatment after neoadjuvant chemoradiation, had to be 
terminated prematurely due to scanty accrual [95]. Of the 113 patients enrolled, only 48% 
completed the assigned 6 cycles of adjuvant chemotherapy.  
A recent phase 2 randomized study in 321 patients with postoperative pathologic stage 
(yp) II or stage III rectal cancer following preoperative fluoropyrimidine-based 
chemoradiotherapy found that adjuvant oxaliplatin/5-FU/leucovorin improved 3-year disease-
free survival (71.6%) compared to 5-FU/leucovorin (62.9%; HR 0.657, 95% CI 0.434-0.994, 
P = 0.047) [96]. A main strengths of this study is that 96% of the patients completed the 
intended 4 cycles of adjuvant chemotherapy. A limitation is the inherent lower statistical 
power of a phase 2 study. Furthermore, there are no exact data provided on the interval from 
surgery to the start of adjuvant chemotherapy. Hence, there could be an imbalance here 
between arms that might explain the lower-than-expected 3-years disease-free survival in the 
bolus 5-FU/leucovorin arm, and favor the FOLFOX arm. Overall, while these results could 
suggest that patients with yp II-III rectal cancer following fluoropyrimidine-based 
neoadjuvant chemoradiotherapy might benefit from the addition of oxaliplatin to adjuvant 
chemotherapy, long-term survival data are warranted to confirm it. 
Due to the shortcomings of these trials, adjuvant systemic therapy for rectal cancer is 
currently recommended by the ESMO [10] and NCCN [11] guidelines, but not by the Dutch 
[16] clinical practice guidelines.  
Systemic treatment of metastatic disease   
In metastatic rectal and colon cancer, there are no differences in indications for systemic 
chemotherapy or targeted treatment with EGFR inhibitors and antiangiogenic drugs [11-13, 
97]. However, it may be questionable whether a rectal carcinoma with a different metastatic 
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pattern, composition of drug targets, often previous local treatment, and metastasizing after 
radiotherapy has the same sensitivity for systemic treatments as a colon carcinoma.  
A retrospective analysis of 399 chemorefractory metastatic CRC patients that received 
cetuximab monotherapy vs best supportive care in a randomized phase 3 study (NCIC-CTC-
CO.17) observed that the efficacy of cetuximab was modulated by the location of the wild 
type KRAS primary tumors [98]. The median progression-free survival was 5.4 months in the 
cetuximab-treated patients with a primary tumor located distally (from the splenic flexure to 
the rectosigmoid), and 1.9 months (P = 0.002) in the cetuximab-treated patients with a 
proximal primary tumor (from cecum to the transverse colon). A prospective analysis of 
metastatic CRC patients whom received first-line cetuximab in combination with 
chemotherapy in a randomized phase 2 study (AIO KRK-0104) reported that patients with a 
distal KRAS codon 12/13 wild type primary tumor (n = 68; tumors of the splenic flexure, 
descending and sigmoid colon, and rectum) had a better median progression-free survival (HR 
0.54) and median overall survival (HR 0.42) compared to patients with a proximal KRAS 
codon 12/13 wild type primary tumor (n = 27; tumors from the cecum to the distal part of the 
transverse colon) [99]. A retrospective analysis of a cohort of 435 chemorefractory metastatic 
colon cancer patients treated with cetuximab in combination with chemotherapy found that 
patients with a distal KRAS and BRAF wild type primary tumor (n = 158; splenic flexure, 
descending and sigmoid colon) had a longer median progression-free survival (30 weeks, 95% 
CI 26-34 week, univariate P = 0.02) than those with a proximal (n = 45; cecum, ascending 
colon, and hepatic flexure) KRAS and BRAF wild type tumor (18 weeks, 95% CI 11-31 
weeks) [64]. These studies also showed that KRAS or BRAF mutant CRCs of metastatic stage 
showed no difference in overall or progression-free survival according to the primary tumor 
location [64, 98, 99]. The higher frequency of human epidermal receptor (HER) family 
members amplification, of epiregulin overexpression, and the stronger EGFR signaling in 
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distal colon and rectal tumors versus proximal colon tumors might explain these results [56, 
64, 67]. Whether the HER pathway enrichment findings of stage II-III CRC mentioned above 
also hold in metastatic disease could be evaluated in patients presenting with synchronous 
primary tumor and visceral metastatic lesions. Preferential assignment of EGFR inhibitors to 
metastatic patients with (K)RAS wild type primary tumors located in the distal colon or 
rectum would require reanalysis by primary tumor site of major CRC trials such as 
CRYSTAL, PRIME, and FIRE 3 [99].  
Drug targets in the microenvironment of colorectal cancer   
Sustained angiogenesis is a key feature of the tumor microenvironment that drives cancer 
growth and metastasis [100]. VEGFA is the main regulator of angiogenesis that binds to the 
VEGF receptor VEGFR2, which is present on endothelial cells. Bevacizumab is a humanized 
monoclonal antibody against VEGFA. A retrospective analysis of two independent, non-
randomized cohorts of metastatic CRC patients that received first-line chemotherapy with (n 
= 667) or without bevacizumab (n = 213) suggested that the addition of bevacizumab may 
primarily benefit patients with primary tumors located in the sigmoid colon and rectum vs 
patients with primary tumors arising from the cecum to the descending colon [101]. Another 
retrospective analysis of metastatic CRC patients from three independent datasets including 
two randomized phase 3 trials (AVF2107 and NO16966), whom received either first-line 
chemotherapy (n = 1209) or chemotherapy plus bevacizumab (n = 818), found that the effect 
of bevacizumab is independent of the primary tumor location in the proximal colon or the 
distal colorectum, as divided at the splenic flexure [102]. However, several studies have 
reported survival differences between patients with rectal or colon cancer treated with 
bevacizumab-containing regimens. In the seminal phase 3 study that demonstrated survival 
benefit by adding bevacizumab to 5-FU and irinotecan [103], metastatic rectal cancer patients 
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(n = 92) had a 24.2 months median overall survival compared to 19.5 months for metastatic 
colon cancer patients (n = 310) in the bevacizumab arm [104]. In a randomized phase 3 study 
comparing bevacizumab in combination with capecitabine (n = 140) vs capecitabine alone (n 
= 140) as first line treatment of metastatic CRC patients aged 70 years and older (AVEX 
trial), median progression-free survival of rectal cancer patients was better than that of colon 
cancer patients in the bevacizumab arm (accordingly HR 0.41 vs 0.67) [105]. The 
Investigation of Treatment Efficacy and Safety (BRiTE) trial showed a better median overall 
survival for metastatic rectal cancer patients compared to metastatic colon cancer patients 
[106]. In this observational  study (n = 1,445) with bevacizumab added to the first line 
chemotherapy, a median survival of 29.2 months was found in metastatic rectal cancer (n = 
293) compared to 21.9 months in metastatic colon cancer (multivariate P < 0.02). Overall, 
these findings are hypothesis-generating and need to be validated by data relating precise 
primary tumor location to the efficacy of antiangiogenic drugs in additional randomized 
metastatic CRC studies. 
The fact that the primary rectal tumor is often irradiated, while the colon tumor is not, 
might lead to differences in the microenvironment of cancer cells. For example, chemokine 
receptor 4 (CXCR4) and its corresponding chemokine ligand 12 (CXCL12), which are 
expressed by both cancer and microenvironment cells such as stromal and immune cells, form 
an important communication network between cancer cells and their microenvironment [107]. 
Binding of the ligand to its receptor activates downstream signaling that leads to the 
promotion of cancer cell migration and metastasis, and protects cancer cells from genotoxic 
stresses such as chemotherapy. Hypoxia-inducing cancer treatments such as radiotherapy can 
increase CXCR4 and CXCL12 protein expression levels in the tumor, as demonstrated in a 
glioblastoma mouse model [108] and in irradiated human nasopharyngeal tumors [109]. 
Moreover, paired tumor tissue analysis showed that pelvic radiotherapy followed by systemic 
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treatment with bevacizumab, capecitabine and oxaliplatin upregulated nuclear CXCL12 
expression in cancer cells of the primary tumors of 50 de novo metastatic rectal cancer 
patients [110]. These data suggest that disrupting the interaction of cancer cells with their 
microenvironment might be of interest to study in rectal cancer. Phase 1 trials in patients with 
advanced solid cancers with the CXCR4 inhibitor CTCE-9908 and CXCR4 peptide antagonist 
LY2510924 were recently completed and showed that these drugs were well tolerated 
[111,112]. The CXCR4 antagonist AMD3100 is currently being tested in combination with 
bevacizumab as treatment for patients presenting with recurrent high-grade glioma 
(ClinicalTrials.gov Identifier: NCT01339039). Further studies are warranted to determine the 
precise role of the CXCR4/CXCL12 axis in rectal cancer, and whether its inhibition could 
increase the efficacy of conventional therapies. 
Concluding remarks and implications for clinical practice 
Rectal cancer is differentiated from colon cancer by the addition of neoadjuvant radiotherapy 
or chemoradiotherapy and the lack of robust evidence of a role for adjuvant chemotherapy. 
This later difference might be due to the delayed start of adjuvant treatment following 
neoadjuvant radiotherapy or chemoradiotherapy, and the complexity of the TME procedure. 
This delay can be avoided by neoadjuvant administration of systemic chemotherapy, as is 
currently being tested in the RAPIDO study "Radiotherapy And Preoperative Induction 
therapy followed by Dedicated Operation" (ClinicalTrials.gov Identifier: NCT01558921) 
[113]. In the RAPIDO trial, patients with non-metastatic rectal cancer at high risk of local or 
systemic failure are randomly assigned to either capecitabine-based long-course 
chemoradiation with TME at 6-8 weeks or short-course radiotherapy followed by 6 cycles of 
preoperative CAPOX and TME at 2-4 weeks after the last cycle of chemotherapy. The 
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hypothesis is that a short-course radiotherapy and systemic neoadjuvant chemotherapy would 
increase disease-free and overall survival without compromising primary tumor control. 
The degree of rectal tumor involvement with the mesorectal fascia and the clinical 
nodal status are particularly important in rectal cancer, as these are two major selection 
criteria when choosing the optimal neaodjuvant treatment for these patients. High-resolution 
T2-weighted pelvic MRI is a reliable tool for the preoperative assessment of mesorectal fascia 
involvement [80, 81, 85]. The morphological nodal status is more difficult to define in clinical 
practice. Modern functional MRI techniques, such as diffusion and perfusion MRI including 
MRI with lymph node specific contrast, are currently being tested to further improve the 
staging and restaging accuracy in rectal cancer [114].  
Accurate exclusion of metastatic disease is imperative before taking a TME decision 
in rectal cancer patients. Rectal cancer is more frequently associated with lung-only 
metastases than colon cancer. Therefore, given its higher accuracy, staging with chest CT 
rather than chest X-ray seems more appropriate.  
It is still unknown whether different targeted therapy should be considered for colon 
and rectal cancer. The overall mutational patterns of well-known CRC genes, not only KRAS, 
but also recently identified genes such as PIK3CA or F-box/WD repeat-containing 7 
(FBXW7), show no obvious differences between colon and rectal tumors [56]. However, the 
molecular characteristics of proximal and distal colon carcinomas are substantially different, 
and the intrinsic biology and corresponding drug targets of rectal tumors are likely very 
similar to distal colon tumors [56, 64, 67]. Divergences in the genetic make-up between 
proximal colon and distal colorectal carcinomas include differences in the mutational status of 
BRAF and the EGFR pathway activation, which can have consequences for treatment with 
targeted agents such as EGFR and BRAF inhibitors [115]. Furthermore, MSI-high tumors, 
originating mainly in the proximal colon, are expected to be more sensitive to immune 
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therapy. This concept is being addressed by a phase 2 clinical trial with the PD-1 inhibitor 
pembrolizumab, which showed impressive results [69]. Moreover, patients with BRAF 
mutational status- and mucinous histology-independent association of primary tumor location 
in the proximal colon with resistance to current standard chemotherapy in metastatic CRC, 
possibly related to their higher level of excision repair cross-complementation group 1 
(ERCC1) mRNA compared to distal colorectal tumors, substantiates the importance of 
biological differences in colorectal tumors by site [102]. Stratifying patients according to 
primary tumor location in the proximal colon vs distal colon vs rectum should be therefore 
considered in clinical trials testing chemotherapy or targeted agents in colorectal cancer, as it 
would provide direct molecular comparison between tumors according to site, and it is 
potentially relevant for therapeutic decision-making. 
In both rectal and colon cancer, there can be discordances between the mutational 
profile of the primary tumor and the metastatic lesions. For instance, there is a relatively high 
discordance in KRAS mutational status between the primary tumor and lung metastases [72]. 
The clinical significance of this disparity could be greater in rectal cancer, given the higher 
incidence of lung metastases compared to colon cancer [41]. Furthermore, it might be 
preferable to determine the KRAS status in lung metastasis tissue, since treatment with anti-
EGFR antibodies is restricted to patients with tumors that do not harbor the KRAS mutation 
[97]. Additionally, a molecular profiling study of 115 pairs of primary and metastatic tissues 
of CRC patients found high discordance rates in the mutational profile of PIK3CA and 
FBXW7 between the primary tumor lesions and corresponding metastases [116]. Moreover, 
the rate of discordance was augmented by chemotherapy (3.5 fold higher odds for patients 
that received chemotherapy compared to those that did not).  
 In conclusion,  CRC is not one disease. Future studies on subtyping can contribute to 
determine the most optimal treatment in the adjuvant and metastatic setting  
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Background: To evaluate the efficacy and tolerability of preoperative short-course 
radiotherapy followed by capecitabine and oxaliplatin treatment in combination with 
bevacizumab and subsequent radical surgical treatment of all tumor sites in patients with stage 
IV rectal cancer. 
Patients and methods: Adults with primary metastasized rectal cancer were enrolled. They 
received radiotherapy (5 x 5 Gy) followed by bevacizumab (7.5 mg/kg, day 1) and oxaliplatin 
(130 mg/m2, day 1) intravenously and capecitabine (1000 mg/m2 twice daily orally, days 1-
14) for up to six cycles. Surgery was carried out 6-8 weeks after the last bevacizumab dose. 
The percentage of radical surgical treatment, 2-year survival and recurrence rates, and 
treatment-related toxicity was evaluated.  
Results: Of 50 included patients, 42 (84%) had liver metastases, 5 (10%) had lung 
metastases, and 3 (6%) had both liver and lung metastases. Radical surgical treatment was 
possible in 36 (72%) patients. The 2-year overall survival rate was 80% [95% confidence 
interval (CI) 66.3-90.0%). The 2-year recurrence rate was 64% (95% CI, 49.8-84.5%). Toxic 
effects were tolerable. No treatment-related deaths occurred.   
Conclusions: Radical surgical treatment of all tumor sites carried out after short-course 
radiotherapy, and bevacizumab-capecitabine-oxaliplatin combination therapy is a feasible and 
potentially curative approach in primary metastasized rectal cancer.  
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Optimal treatment of patients with primary metastasized rectal cancer is controversial. 
Curative treatment would include resection of the primary tumor and all metastases, and many 
treatment options are available.  
Most of the primary tumors are T3 (extending into the outer lining of the bowel or into 
adjacent tissue) or T4 (extending to the visceral peritoneum or other organs) rectal lesions 
with regional lymph nodes involved, and these tumors require downstaging before resection. 
Preoperative long-course radiotherapy is used with radiosensitizers, such as 5-fluorouracil, to 
downsize the primary tumor and reduce the risk of locoregional failure after resection [1, 2]. 
Nevertheless, 5-fluorouracil as a radiosensitizer has limited effects on systemic metastases. 
Systemic chemotherapy can be sequenced with chemoradiotherapy either before or after, but 
disadvantages include the extended period without systemic doses of chemotherapy and the 
additional acute toxicity of chemoradiotherapy when compared with radiotherapy alone. 
Furthermore, molecularly targeted agents that improved the survival of patients with 
advanced colorectal cancer are being tested as neoadjuvant therapy for rectal cancer [3-9]. 
Although there is limited evidence, the "liver first" approach has been proposed. It 
includes systemic chemotherapy followed by resection of liver metastases, and subsequent 
surgery for the primary rectal tumor [10]. This treatment sequence seems safe and effective, 
but it includes two surgical interventions and delayed treatment of the primary tumor. 
To overcome the logistical problem of combining radiotherapy for primary rectal 
cancer with an adequate dose of systemic chemotherapy for metastatic disease, we propose a 
treatment sequence including preoperative short-course pelvic radiotherapy of five fractions 
of 5 Gy each (5 x 5 Gy), followed by capecitabine and oxaliplatin (CapeOx) given in 
combination with bevacizumab. Radical surgical treatment at all tumor sites is carried out 6-8 
weeks after the last dose of bevacizumab. This short-course radiotherapy (5 x 5 Gy) has 
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comparable biological effective dose as a long-course regimen of 28 fractions of 1.8 Gy each 
(28 x 1.8 Gy) [11]. Furthermore, similar clinical outcomes have been shown when 
preoperative 5 x 5 Gy radiotherapy has been compared with 5-fluorouracil based 28 x 1.8 Gy 
chemoradiotherapy for T3 and T4 rectal carcinoma [12]. 
The purpose of the present study was to evaluate the efficacy and tolerability of this 
proposed regimen in a prospective, interventional, multicenter trial in patients with resectable 
primary metastasized rectal cancer in The Netherlands. 
Patients and methods 
Study design and end points 
Between April 2006 and December 2010, 50 patients with primary metastasized rectal cancer 
were enrolled in seven centers in The Netherlands. This open-label, single-arm phase II 
clinical study was approved by the ethical committee of University Medical Center Groningen 
and registered with the Dutch health authorities (METc2005/270; NTR2029). All patients 
provided written informed consent. The primary endpoint was the percentage of patients 
receiving radical surgical treatment for all tumor sites (R0). Secondary endpoints were 2-year 
survival, 2-year recurrence rate, and treatment-related toxicity. 
Eligibility criteria and pretreatment evaluation 
Main inclusion criteria were age >18 years and histologically confirmed rectal 
adenocarcinoma, with resectable or ablatable metastases in the liver (total, ≤6 metastatic 
lesions in both lobes; lesions requiring ≤trisegmentectomy in either lobe; and adequate 
remaining vascular flow and biliary drainage) or lungs. Additional inclusion criteria were an 
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; adequate bone 
marrow function (white blood cell count ≥3.0 x 109/l; platelet count ≥100 x 109/l); adequate 
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hepatic function (serum bilirubin ≤1.5 mg/dl x upper normal limit; aspartate and alanine 
aminotransferase ≤1.5 mg/dl x upper normal limit); and adequate renal function (calculated 
creatinine clearance rate >50 ml/min, using Cockcroft-Gault formula).  
Main exclusion criteria were extrahepatic or extrapulmonary metastases detected by 
clinical examination, computed tomography (CT) or fluorine-18 fluorodeoxyglucose positron 
emission tomography (FDG-PET); previous pelvic radiotherapy; previous fluorouracil-based 
therapy for any malignancy; other concurrent chemotherapy; and the presence of or treatment 
for any malignancy other than non-melanoma skin cancer or in situ carcinoma of any organ 
within 5 years before the present study.  
 Baseline evaluation encompassed medical history, physical examination, laboratory 
tests, colonoscopy and rectal tumor biopsy. Baseline imaging of the primary tumor was with 
contrast-enhanced multidetector pelvic CT scan, and optionally magnetic resonance imaging 
(MRI). Liver and lung metastases were evaluated with abdominal and thoracic CT scans. 
Whole-body FDG-PET was done optionally to exclude extrahepatic and extrapulmonary 
metastases. Baseline imaging of the primary tumor and metastases were evaluated during the 
study by the investigators and retrospectively confirmed by an independent radiologist. 
Preoperative treatment and clinical reassessment 
Preoperative pelvic three-dimensional radiotherapy (total, 25 Gy; five fractions in 5 days) was 
delivered with an isocentric three- or four-field technique and mega-voltage radiation 
produced by a linear accelerator (Figure 1). The clinical target volume included the tumor, 
mesorectum, and internal iliac lymph nodes. Patients were positioned in either the supine or 
prone with a full bladder to decrease the volume of irradiated small bowel.  
Systemic therapy was started within 2 weeks of completing radiotherapy. Patients 
were treated with six cycles of bevacizumab-CapeOx unless unacceptable toxicity occurred 
(Figure 1). On the first day of each cycle, bevacizumab (7.5 mg/kg, intravenous) and 
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oxaliplatin (130 mg/m2, intravenous) were administered, each in a 2-h infusion. Capecitabine 
(1000 mg/m2 twice daily, oral) was given during the first 2 weeks of each cycle. Radiological 
evaluation of the response of liver and lung metastases was carried out with contrast-
enhanced multidetector CT scanning after two cycles of systemic therapy. If no progression 
was detected as assessed by RECIST criteria (version 1.0) [13], four additional cycles were 
administered.  
After completing preoperative treatment, patients were reassessed for resectability by 
clinical examination and CT, optionally MRI. Decision for surgery was made in each 
participating center by a multidisciplinary team. 
Surgery and histopathologic evaluation 
Surgical treatment was scheduled at 6-8 weeks after the last dose of bevacizumab. Optimal 
surgical resection of the primary tumor was carried out by total mesorectal excision 
(TME).The choice of surgical procedure was at the surgeon's discretion, such as diverting 
ileostomy after low anterior resection. Surgical treatment of metastases included partial liver 
or lung resection, radiofrequency ablation (RFA) of liver lesions, or a combination of 
resection and RFA; the procedure was selected in each study center according to local 
practice. Radiofrequency ablation was considered possible for lesions with largest diameter 
<30 mm.  
Specimen dissection and mesorectum evaluation were carried out by the local 
pathologist as previously described [14]. Pathologic primary tumor response was assessed 
with Mandard's classification [15, 16]. Pathologic complete response after neoadjuvant 
treatment (ypCR) was defined as the absence of residual tumor cells in the primary tumor and 
lymph node specimens (ypT0N0). Downstaging was assessed by comparing pathologic stage 
(ypT) with baseline clinical T-stage. RFA was defined as radical (R0) if the 1-week post-
procedural CT scan showed an ablation zone with tumor-free margins ≥5 mm.  
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Figure 1.  Flowchart for the study of short-course radiotherapy followed by capecitabine 
and oxaliplatin in combination with bevacizumab and subsequent radical surgical 
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Toxicity and follow-up 
Events related and unrelated to treatment were both evaluated. Toxic effects were categorized 
using the National Cancer Institute Common Terminology Criteria for Adverse Events, 
version 3.0 (available at: http://ctep.cancer.gov/reporting/ctc.html). Operative and 
postoperative complications were recorded on surgical postoperative forms. Patients treated 
with curative intent were evaluated according to the guidelines of the Dutch Association of 
Comprehensive Cancer Centers. No adjuvant chemotherapy was recommended after R0 
resection. 
 Regular follow-up visits were performed every 3 months during the first 3 years and 
included clinical examination, serum carcinoembryonic antigen measurement, and CT or 
ultrasonographic imaging. Evaluation of ablation zones of liver metastases that had been 
treated with RFA was carried out as previously described [17]. In patients with recurrent 
disease, further treatment was done according to the local practice in each study center. 
Statistical analysis 
Sample size calculations were based on the two-stage design for phase II trials [18]. The 
minimal percentage of patients to achieve resectable disease after preoperative treatment was 
set at 30% [19]. A 50% R0 resection rate was targeted. It was calculated that 46 patients 
would be needed, with type I and type II errors each set at 10%. In the initial stage, 22 pre-
planned patients were entered. After the pre-planned interim analysis showed R0 resections in 
16 patients (>30%), the protocol was amended to include 24 additional patients. A total of 50 
patients were included to compensate for potential losses caused by ineligible participants.  
Overall survival for the intent-to-treat population was evaluated from the beginning of 
radiotherapy until death from any cause. Recurrence-free survival was calculated as the time 
from radical surgery to the diagnosis of the first distant or local recurrence. The 2-year 
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recurrence rate was calculated only for patients in whom radical surgical treatment was 
possible at all tumor sites. Overall survival rates in the intent-to-treat population and 
recurrence rates after radical surgical treatment were estimated using the Kaplan-Meier 
method. For statistical analyses GraphPad Prism (version 5.00 for Windows, GraphPad, La 
Jolla, California) was used. 
Results 
Patients and preoperative treatment 
The intent-to-treat population consisted of all 50 patients. Demographic and baseline disease 
characteristics are presented in Table 1. All patients had an ECOG performance status of 0 or 
1. The most commonly observed clinical stage was cT3N1-2 with liver metastases. Forty-two 
patients (84%) had liver metastases, 5 (10%) lung metastases, and 3 (6%) both liver and lung 
metastases. Eleven patients (22%) with obstructive bowel disease at presentation received a 
diverting colostomy.  
Preoperative radiotherapy was given to all 50 patients and subsequent preoperative 
bevacizumab-CapeOx treatment was started in 49 patients (98%) (Table 2). One patient was 
withdrawn from the study because of bone metastases detected after radiotherapy. Most of the 
patients received six cycles of preoperative bevacizumab-CapeOx. No metastatic disease 
progression was reported by radiological reassessment after two cycles or completion of 
preoperative bevacizumab-CapeOx. There was one patient removed from the study because of 
irresectable lung metastases noted after completion of six cycles of preoperative 
bevacizumab-CapeOx. Median follow-up time was 32 months (95% CI, 29.4-38.7 months). 
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Forty-eight (96%) patients were scheduled for surgical treatment with curative intent. Radical 
surgical treatment at all tumor sites (R0) was possible for 36 (72%) patients (Table 3). There 
was no radiological evidence of progression after preoperative treatment, but irresectable 
disease was found at surgery in 8 of the 48 patients (17%). All liver and lung 
metastasectomies were considered microscopically radical. RFA was carried out in 11 
patients (isolated treatment, 4 patients and combined with liver resection, 7 patients). CT 
scans at 1 week after ablation showed adequate margins in all lesions that had been treated 
with RFA. 
Of the 48 patients scheduled for curative surgery, the primary rectal tumor was 
resected in 43 (90%) individuals (Table 3). Simultaneous TME and surgical treatment of 
metastases was carried out in 26 patients. In seven patients, surgery for metastases was carried 
out first, followed by TME in five patients at a later time. In 12 patients, the primary tumor 
was resected before surgical treatment of the metastases. In four patients, the rectal resection 
margins showed tumor cells microscopically (R1). The initial stages of the primary tumor in 
these four patients were T3N2 (n = 2), T3N1 (n = 1) and T4N1 (n = 1). 
A complete pathologic response of the primary rectal tumor (ypCR) was reported in 
11 of 43 patients (26%), and a near-complete response (ypNCR; only a few residual tumor 
cells present) in 7 (16%) (Table 3). Local tumor (ypT) downstaging was documented in 20 
(47%) patients who had rectal tumor resection (supplementary Table S1).  
The 2-year overall survival rate was 80% (40 of 50 patients; 95% CI, 66.3 to 90.0%) 
in the intent-to-treat group (Table 3 and Figure 2). The 2-year recurrence rate was 64% (23 of 
36 patients; 95% CI, 49.8 to 84.5%) after R0 resection. Median time to recurrence was 13 
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ª Results shown as n (%) unless otherwise indicated. 




Characteristic          Resultsª (n = 50) 
Sex   
  Men 27 (54) 
  Women 23 (46) 
Age (y) 
 Median               59 
 Range               (35-75) 
Clinical tumor category    
  T2N0  0 (0) 
  T2N1  4 (8) 
  T3N0  6 (12) 
  T3N1-2  32 (64) 
  Substagingb      
  T3a (< 1mm)  7 (14) 
  T3b (1 to 5 mm)  23 (46) 
  T3c (5 to 15 mm)  8 (18) 
  T4N0  1 (2) 
  T4N1-2  7 (14) 
  Perforation into visceral peritoneum  4 (8) 
  Invasion of other organs 3 (6) 
 T3-4N2 13 (26) 
Tumor localization   
  Low (0 to 5 cm)  23 (46) 
  Middle (5 to 10 cm)      21 (42) 
  High (10 to 15 cm) 6 (12) 
Metastatic site  
  Liver  42 (84) 
  Lung  5 (10) 
  Lung and liver  3 (6) 
Liver metastases  
  Unilobar  21 (47) 
  Bilobar  24 (53) 
  1 to 3 36 (72) 
  > 3   9 (18) 
Lung metastases  
  1 5 (10) 
  >1 3 (6) 
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Table 2.  Summary of patient exposure to study drugs. 
Drug exposure     Resultsª (n = 50) 
Bevacizumab-capecitabine-oxaliplatinb           49 (98) 
Chemotherapy duration (week), median (range)           18     (3-20) 
Cyclesc   
  Cycles started, median (range)            6                                                                                    (1-6)
Patients receiving six cycles 42 (84) 
  Patients with 1 week delay during cycles  10 (20) 
  Patients with 2 weeks delay during cycles 2 (4) 
Patients with 20% dose reduction   
  Bevacizumab   1 (2) 
  Capecitabine  4 (8) 
  Oxaliplatin  2 (4) 
Patients with drug discontinuation   
  Bevacizumab   3 (6) 
  Capecitabine  1 (2) 
  Oxaliplatin  1 (2) 
 
ª Results shown as n (%) unless otherwise indicated. 
b One patient was discontinued from the study because of bone metastases noted after 
radiotherapy. 
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months (range 7-20 months). Curative treatment of recurrent disease was possible in 13 of the 
23 patients (57%). Local pelvic relapse occurred in two patients—at 5 and 15 months after 
surgery for the primary tumor. One of these patients subsequently had an abdominoperineal 
resection with curative intent. 
  
Figure 2. Overall survival rate 
of patients in the intent-to-
treat group, with numbers of  







Safety and compliance 
There were no grade 3-4 adverse events during or after preoperative radiotherapy in all 50 
enrolled patients (Table 4). In 38 (76%) patients, bevacizumab-CapeOx treatment was 
initiated as planned within 2 weeks after radiotherapy. In seven (14%) patients, there was a 
delay of 1 week because of grade 2 radiotherapy-related toxicity (proctitis, diarrhea, pain). A 
more than 1-week delay (range 1-6 weeks) occurred in four (8%) patients, caused by ileus 
(one patient) or logistical reasons (three patients). In 42 (84%) patients, all six cycles of 
bevacizumab-CapeOx treatment were administered. The most common non-surgical grade ≥3 
toxic effects were diarrhea and pulmonary embolisms (Table 4). The most frequent grade 1-2 
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adverse reactions to bevacizumab-CapeOx treatment were fatigue, sensory neuropathy, and 
nausea (supplementary Table S2).  
Median time between completion of neoadjuvant treatment and surgery was 39 (range 
17-205; interquartile range 36-50) days. Median hospitalization time was 8 (range 6-135) 
days in patients who had TME alone , and 13.5 (range 6-65) days in patients who had 
simultaneous TME and metastases surgery. The most frequent postoperative complications 
within 60 days after surgery were wound and abdominal cavity infections (nine patients; 
Table 4 and supplementary Table S3). No patient died within 90 days after surgery. 
Discussion 
The present results support the hypothesis that short-course radiotherapy followed by 
bevacizumab-CapeOx combination therapy is an effective preoperative treatment for patients 
with primary metastasized rectal cancer. Subsequent radical surgical treatment at all sites (R0) 
was achieved in 72% of the 50 patients (Table 3).  
 There are few data about resection rates in patients who initially present with 
metastases to the liver and lungs. A strong relation had been reported between response to 
chemotherapy and subsequent resection rate of metastatic disease [20], but those findings 
were primarily for initially irresectable metastatic disease [21, 22]. In the present study, short-
course radiotherapy followed by bevacizumab-CapeOx treatment provided good control of 
the primary rectal tumor before surgery; progression of the rectal tumor was not observed 
during the interval between the start of radiation therapy and surgery (median 180 days, range 
132-360). This treatment scheme yielded a pathologic complete response of the primary 
tumor in 26% of patients and a pathologic near-complete response in 16% of patients (Table 
3). These response frequencies are comparable or better than those with other neoadjuvant 
chemoradiation schemes, that have pathologic complete response from 10% to 30 % in 
patients with locally advanced rectal cancer [3-9, 23-25]. The schedule and doses of 
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Table 3.  Surgical procedures and efficacy results. 
 
Characteristic Resultsª (n = 50)             Total n 
Patients who had surgery with curative intent   48 
Radical operation at all tumor sites (R0) 36 
  Retum   
       Hartmann procedure  19 (53)   
       Abdominoperineal resection 11 (30)   
       Low anterior resection 6 (17)   
  Metastases   
       Liver resection  8 (22)   
       Liver resection (> 3 segments)  11 (30)   
       Liver resection and radiofrequency ablation 7 (20)   
       Radiofrequency ablation alone  4 (11)   
       Lung resection  5 (14)   
       Liver and lung resection  1 (3)   
Primary rectal tumor resectionb  43 
 Resection type 
       R0 resection of primary tumorc   39 (91)   
       R1  resection of primary tumor  4 (9)   
 Response 
       Pathologic complete response  11 (26)   
       Pathologic near-complete response 7 (16)   
 Nonradical treatment/irresectable disease  14 
  R1 resection rectum   
       Tumor at circumferential resection margin 3 (21)   
       Tumor at distal resection plane  1 (7)   
  Incurable/irresectable disease     
       Peritoneal carcinomatosis  2 (14)   
       Liver metastases                                                                      5 (37)   
       Lung and liver metastases 1 (7)   
       Incurable disease before surgery 2 (14)   
Results of treatment   
  Overall   50 
       2-year overall survivald 40 (80)   
  After R0  36 
       2-year recurrence rate after R0e 23 (64)   
       Local recurrence, rectum, after R0 2 (6)   
       Distant recurrence after R0  21 (58)   
            Liver  10 (28)   
            Lung  7 (19)   
            Liver and lung  2 (6)   
            Other/diffuse 2 (6)   
 
ª Results shown as n (%) unless otherwise indicated. 
b  Forty-three primary rectal tumors resected; 39 R0 and 4 R1. Three patients with R0 rectal tumor 
resection were not resected for metastases. 
c  R0: radical resection with >1mm margin in the resected tumor; R1: microscopic tumor at the 
resection margin. 
 d  Forty of 50 patients (80%); 95% confidence interval, 66% to 90%.  
 e  Twenty-three of 36 patients (64%); 95% confidence interval, 50% to 84.5%. 
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Table 4.  Toxicity and treatment compliance.  
 
Variable Patients exposed to 
treatment, n 
Total n  
Grade 3 to 4 toxicity (radiotherapy) 0 50 
Timing of initiating bevacizumab and CapeOxª  49 
  As planned, within 2 weeks after radiotherapy 38    
  Delayed 1 week because of grade 2 toxicityb 7   
  Delay > 1 weekc 4    
Compliance bevacizumab and CapeOx    49 
   6 cycles  42   
   4 cycles  3    
   3 cycles  3    
   1 cycle 1    
Grade 3 to 4 toxicity bevacizumab and CapeOx   19  49 
   Gastrointestinal  6    
   Vascular  6   
   Pain (tumor)  4   
   Dermatologic 1   
   Infection        1    
   Other 1    
Surgical complications within 60 days after surgery   48  
   Infection / abscess 12    
            Wound  6    
            Abdominal cavity  3    
            Perineal  2    
            Thorax  1    
   Anastomotic leak  1    
   Rectal stump leak  1    
   Bleeding  1    
   Death 0    
Reoperation    48  
    1 4    
    ≥ 2  6    
   Radiological intervention 5    
 
ª CapeOx: capecitabine and oxaliplatin. 
b  Proctitis, diarrhea, and pain. 
c  Delay >1 week (range, 1-6 weeks): logistical reasons, three patients; necessity of colostomy because 
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bevacizumab-CapeOx used in the present study may have contributed to the high response 
frequencies. The present findings are substantiated by results of trials that report pathologic 
complete response as an early prognostic marker of better disease-free survival [26, 27]. 
 Neoadjuvant long-course chemoradiotherapy, with surgery planned 6-10 weeks later, 
has been recommended for patients with locally advanced (T3 or T4) rectal cancer. In the 
present study, there was a 47% primary rectal tumor downstaging from clinical to pathologic 
stage (supplementary Table S1), consistent with results from preoperative long-course [28, 
29] and short-course regimens for locally advanced rectal cancer [30-33]. 
RFA was used in 11 patients in the present trial as adjunct or single treatment of 
metastases (Table 3). This procedure has not been well studied for liver metastases from 
rectal cancer, and no randomized controlled trials have been reported [34]. Local recurrence 
rates are not significantly different after RFA than anatomic or wedge resections of the liver 
metastases <30 mm [35, 36]. In the present study all metastatic lesions treated with RFA were 
<17 mm.  
A main finding of this study is the high tolerability of the regimen, with 84% of the 
patients completing radiotherapy and systemic treatment without major delay (Table 2). The 
safety profile of preoperative bevacizumab-CapeOx treatment after short-course radiotherapy 
is comparable with that reported in other studies, with diarrhea, hand-foot syndrome, and 
thromboembolic events among the most common adverse events [37]. Surgery-related 
morbidity occurred mainly from infection (supplementary Table S3). Postoperative 
complications may occur after major pelvic surgery, especially when bevacizumab is added to 
neoadjuvant chemoradiotherapy [37-40]. Surgery-related morbidity we report does not exceed 
morbidity reported in these studies. The frequency of surgical intervention for these 
complications in this study was relatively high. Persistent abdominal infections led in a few 
patients to frequent interventions. We were not able to attribute toxicity to a specific drug or 
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modality with certainty. A Hartmann procedure was chosen over immediate anastomosis in 
19 patients to avoid possible anastomotic complications that could delay further treatment. 
The 2-year overall survival rate in the present study (80%) (Table 3) is comparable to 
published results for patients with disease of similar severity [41, 42]. There were 23 (64%) 
patients that had recurrent disease within 2 years after radical surgical treatment. In the 
present study, most recurrences were in the liver, and only two patients had local pelvic 
relapse. Patterns of recurrence have not been well documented in patients with primary 
metastasized rectal cancer who undergone complete resection. Recurrences may involve 
distant sites, rather than the local pelvic sites [43], but most studies included patients with 
both colon and rectal cancer in the same analysis [44, 45]. 
A potential shortcoming of the present and similar studies is the definition of 
resectable metastatic disease before treatment. In daily clinical practice, it may be difficult to 
determine resectability of metastases. In the present study, assessment of the resectability of 
metastatic disease was based on leaving a functional remnant of the noninvolved organ. This 
assessment may be inherently subjective [46]. Despite good response and absence of clinical 
and radiological progression during preoperative treatment, 10 of the present patients 
eventually had irresectable disease. 
In conclusion, short-course radiotherapy followed by preoperative bevacizumab-
CapeOx treatment may be a feasible and potentially curative approach for primary 
metastasized rectal cancer. This approach may enable treatment of metastatic disease and 
good control of the primary rectal tumor. The present study is the basis of the experimental 
arm of the RAPIDO study (NCT01558921; 5 x 5 Gy/ CapeOx/surgery versus long-course 
chemoradiotherapy/surgery), which has a primary end point to evaluate 3-year disease-free 
survival in patients with locally advanced rectal cancer without metastatic disease. 
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     Supplemental data 
Supplementary Table S1.  Downstaging of primary rectal cancer. 
   
  
Initial imaging of rectal cancerª 
Allb  T2  T3  T4  
(n = 43) (n = 4) (n = 32) (n = 7) 
Pathologic staging after surgery   
    ypT0  11 (26)   1 (25)   8 (25)   2 (29)  
    ypT1  0 (0) 0 (0) 0 (0) 0 (0) 
    ypT2   8 (18)   2 (50)   5 (16)   1 (14)  
    ypT3  22 (51)   1 (25)  18 (56)   3 (43)  
    ypT4  2  (5) 0 (0)  1 (3)  1 (14) 
T downstaging 20 (47)  1 (25) 13 (41)  6 (86) 
T progression  2 (5)  1 (25)  1 (3) 0 (0) 
 
ª Results shown as n (%) unless otherwise indicated. 
b  Forty-three primary rectal tumors resected: 39 R0 and 4 R1; 3 patients with radical 
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Supplementary Table S2.  Preoperative treatment-related grade 1 to 2 toxicity.  
  
Toxic effectª n (%)b 
Gastrointestinal   
    Nausea  17 (34)  
    Vomiting    9 (18)  
    Constipation    7 (14)  
    Diarrhea   7 (14) 
    Anorexia    3 (6)  
    Mucositis    1 (2)  
Constitutional   
    Fatigue  27 (54)  
    Weight loss    3 (6)  
    Fever   2 (4) 
Dermatologic  
    Phlebitis   8 (16) 
    Hand-foot syndrome    6 (12)  
    Extravasation    4 (8)  
Infection   
    Urinary tract    2 (4)  
    Lung    1 (2)  
    Gallbladder               1 (2) 
    Other   2 (4) 
Pain   
    Abdominal    5 (10)  
    Tumor   4 (8) 
Neurologic   
    Sensory neuropathy  26 (52)  
    Dizziness   1 (2) 
Cardiac   
    Hypertension   4 (8)  
    Ischemia  0 (0) 
Vascular    
    Embolus    1 (2)  
    Vasculitis   1 (2) 
Allergic reaction    5 (10)  
Bleeding     4 (8)  
Other    7 (14) 
 
ª Toxic effects were categorized using the National Cancer 
Institute Common Terminology Criteria for Adverse Events, version 3.0.  
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Supplementary Table S3.  Surgical complications.  
60 day surgical complications TMEª alone TME simultaneous 





Infection / abscess  
  Wound  1 5 0 
  Abdominal cavity  2 1 1 
  Perineum 1 1 0 
  Thorax  0 1 0 
Anastomotic leak 0 1 0 
Rectal stump leak 0 1 0 
Bleeding  0 1 0 
Reoperation     
  1 operation 2 2 0 
  ≥2 operations 2 4 0 
Radiological intervention  2 2 1 
Death  0 0 0 
Hospital stay (d) 8 (6-135) 13.5 (6-64) 6.5 (3-12) 
 













  Chapter 3 




1. Ceelen WP, Van Nieuwenhove Y, Fierens 
K. Preoperative chemoradiation versus         
radiation alone for stage II and III 
resectable rectal cancer. Cochrane 
Database Syst Rev 2009; 1: CD006041. 
2. Gerard JP, Conroy T, Bonnetain F et al. 
Preoperative radiotherapy with or without 
concurrent fluorouracil and leucovorin in 
T3-4 rectal cancers: results of FFCD 9203. 
J Clin Oncol 2006; 24: 4620-4625. 
3. Czito BG, Bendell JC, Willett CG et al. 
Bevacizumab, oxaliplatin, and 
capecitabine with radiation therapy in 
rectal cancer: Phase I trial results. Int J 
Radiat Oncol Biol Phys 2007; 68: 472-478. 
4. Czito BG, Willett CG. Beyond 5-
fluorouracil: the emerging role of newer 
chemotherapeutics and targeted agents 
with radiation therapy. Semin Radiat 
Oncol 2011; 21: 203-211. 
5. Willett CG, Duda DG, Czito BG et al. 
Targeted therapy in rectal cancer. 
Oncology (Williston Park) 2007; 21: 1055-
1065. 
6. Willett CG, Duda DG, di Tomaso E et al. 
Complete pathological response to 
bevacizumab and chemoradiation in 
advanced rectal cancer. Nat Clin Pract 
Oncol 2007; 4: 316-321. 
7. Dipetrillo T, Pricolo V, Lagares-Garcia J 
et al. Neoadjuvant bevacizumab, 
oxaliplatin, 5-fluorouracil, and radiation 
for rectal cancer. Int J Radiat Oncol Biol 
Phys 2012; 82: 124-129. 
8. Resch G, De Vries A, Öfner D et al. 
Preoperative treatment with capecitabine, 
bevacizumab and radiotherapy for primary 
locally advanced rectal cancer--a two stage 
phase II clinical trial. Radiother Oncol 
2012; 102: 10-13. 
9. Helbling D, Bodoky G, Gautschi O et al. 
Neoadjuvant chemoradiotherapy with or 
without panitumumab in patients with 
wild-type KRAS, locally advanced rectal 
cancer (LARC): a randomized, 
multicenter, phase II trial SAKK 41/07. 
Ann Oncol 2012 
10. Verhoef C, van der Pool AE, Nuyttens JJ 
et al. The "liver-first approach" for patients 
with locally advanced rectal cancer and 
synchronous liver metastases. Dis Colon 
Rectum 2009; 52: 23-30. 
11. Glimelius B, Grönberg H, Järhult J et al. A 
systematic overview of radiation therapy 
effects in rectal cancer. Acta Oncol 2003; 
42: 476-492. 
12. Bujko K, Nowacki MP, Nasierowska-
Guttmejer A et al. Sphincter preservation 
following preoperative radiotherapy for 
rectal cancer: report of a randomised trial 
comparing short-term radiotherapy vs. 
conventionally fractionated 
radiochemotherapy. Radiother Oncol 
2004; 72: 15-24. 
13. Therasse P, Arbuck SG, Eisenhauer EA et 
al. New guidelines to evaluate the response 
to treatment in solid tumors. European 
Organization for Research and Treatment 
of Cancer, National Cancer Institute of the 
United States, National Cancer Institute of 
Canada. J Natl Cancer Inst 2000; 92: 205-
216. 
14. Quirke P, Durdey P, Dixon MF, Williams 
NS. Local recurrence of rectal 
adenocarcinoma due to inadequate surgical 
resection. Histopathological study of 
lateral tumour spread and surgical 
excision. Lancet 1986; 2: 996-999. 
15. Mandard AM, Dalibard F, Mandard JC et 
al. Pathologic assessment of tumor 
regression after preoperative 
chemoradiotherapy of esophageal 
  Chapter 3 
 Neoadjuvant and surgical treatment of primary stage IV rectal cancer 
80 
 
carcinoma. Clinicopathologic correlations. 
Cancer 1994; 73: 2680-2686. 
16. Nagtegaal ID, van de Velde CJ, van der 
Worp E et al. Macroscopic evaluation of 
rectal cancer resection specimen: clinical 
significance of the pathologist in quality 
control. J Clin Oncol 2002; 20: 1729-1734. 
17. Kele PG, de Jong KP, van der Jagt EJ. 
Increase in volume of ablation zones 
during follow-up is highly suggestive of 
ablation site recurrence in colorectal liver 
metastases treated with radiofrequency 
ablation. J Vasc Interv Radiol 2012; 23: 
537-544. 
18. Simon R, Wittes RE, Ellenberg SS. 
Randomized phase II clinical trials. Cancer 
Treat Rep 1985; 69: 1375-1381. 
19. Adam R, Avisar E, Ariche A et al. Five-
year survival following hepatic resection 
after neoadjuvant therapy for nonresectable 
colorectal. Ann Surg Oncol 2001; 8: 347-
353 
20. Folprecht G, Grothey A, Alberts S et al. 
Neoadjuvant treatment of unresectable 
colorectal liver metastases: correlation 
between tumour response and resection 
rates. Ann Oncol 2005; 16: 1311-1319. 
21. Nordlinger B, Van Cutsem E, Rougier P et 
al. Does chemotherapy prior to liver 
resection increase the potential for cure in 
patients with metastatic colorectal cancer? 
A report from the European Colorectal 
Metastases Treatment Group. Eur J Cancer 
2007; 43: 2037-2045. 
22. Okines A, Puerto OD, Cunningham D et 
al. Surgery with curative-intent in patients 
treated with first-line chemotherapy plus 
bevacizumab for metastatic colorectal 
cancer First BEAT and the randomised 
phase-III NO16966 trial. Br J Cancer 
2009; 101: 1033-1038. 
23. Bosset JF, Calais G, Mineur L et al. 
Enhanced tumorocidal effect of 
chemotherapy with preoperative 
radiotherapy for rectal cancer: preliminary 
results-EORTC 22921. J Clin Oncol 2005; 
23: 5620-5627. 
24. de Campos-Lobato LF, Stocchi L, da Luz 
Moreira A et al. Pathologic complete 
response after neoadjuvant treatment for 
rectal cancer decreases distant recurrence 
and could eradicate local recurrence. Ann 
Surg Oncol 2011; 18: 1590-1598. 
25. Garcia-Aguilar J, Smith DD, Avila K et al. 
Optimal timing of surgery after 
chemoradiation for advanced rectal cancer: 
preliminary results of a multicenter, 
nonrandomized phase II prospective trial. 
Ann Surg 2011; 254: 97-102. 
26. Maas M, Nelemans PJ, Valentini V et al. 
Long-term outcome in patients with a 
pathological complete response after 
chemoradiation for rectal cancer: a pooled 
analysis of individual patient data. Lancet 
Oncol 2010; 11: 835-844. 
27. Martin ST, Heneghan HM, Winter DC. 
Systematic review and meta-analysis of 
outcomes following pathological complete 
response to neoadjuvant 
chemoradiotherapy for rectal cancer. Br J 
Surg 2012; 99: 918-928. 
28. Yeo SG, Kim DY, Kim TH et al. Tumor 
volume reduction rate measured by 
magnetic resonance volumetry correlated 
with pathologic tumor response of 
preoperative chemoradiotherapy for rectal 
cancer. Int J Radiat Oncol Biol Phys 2010; 
78: 164-171. 
29. de Bruin AF, Nuyttens JJ, Ferenschild FT 
et al. Preoperative chemoradiation with 
capecitabine in locally advanced rectal 
cancer. Neth J Med 2008; 66: 71-76. 
30. Radu C, Berglund A, Påhlman L, 
Glimelius B. Short-course preoperative 
  Chapter 3 
 Neoadjuvant and surgical treatment of primary stage IV rectal cancer 
81 
 
radiotherapy with delayed surgery in rectal 
cancer - a retrospective study. Radiother 
Oncol 2008; 87: 343-349. 
31. Graf W, Dahlberg M, Osman MM et al. 
Short-term preoperative radiotherapy 
results in down-staging of rectal cancer: a 
study of 1316 patients. Radiother Oncol 
1997; 43: 133-137. 
32. Hatfield P, Hingorani M, Radhakrishna G 
et al. Short-course radiotherapy, with 
elective delay prior to surgery, in patients 
with unresectable rectal cancer who have 
poor performance status or significant co-
morbidity. Radiother Oncol 2009; 92: 210-
214. 
33. Pettersson D, Holm T, Iversen H et al. 
Preoperative short-course radiotherapy 
with delayed surgery in primary rectal 
cancer. Br J Surg 2012; 99: 577-583. 
34. Wong SL, Mangu PB, Choti MA et al. 
American Society of Clinical Oncology 
2009 clinical evidence review on 
radiofrequency ablation of hepatic 
metastases from colorectal cancer. J Clin 
Oncol 2010; 28: 493-508. 
35. Mulier S, Ni Y, Jamart J et al. 
Radiofrequency ablation versus resection 
for resectable colorectal liver metastases: 
time for a randomized trial? Ann Surg 
Oncol 2008; 15: 144-157. 
36. Elias D, Baton O, Sideris L et al. Local 
recurrences after intraoperative 
radiofrequency ablation of liver 
metastases: a comparative study with 
anatomic and wedge resections. Ann Surg 
Oncol 2004; 11: 500-505. 
37. Tol J, Koopman M, Rodenburg CJ et al. A 
randomised phase III study on 
capecitabine, oxaliplatin and bevacizumab 
with or without cetuximab in first-line 
advanced colorectal cancer, the CAIRO2 
study of the Dutch Colorectal Cancer 
Group (DCCG). An interim analysis of 
toxicity. Ann Oncol 2008; 19: 734-738. 
38. Willett CG, Duda DG, di Tomaso E et al. 
Efficacy, safety, and biomarkers of 
neoadjuvant bevacizumab, radiation 
therapy, and fluorouracil in rectal cancer: a 
multidisciplinary phase II study. J Clin 
Oncol 2009; 27: 3020-3026. 
39. Crane CH, Eng C, Feig BW et al. Phase II 
trial of neoadjuvant bevacizumab, 
capecitabine, and radiotherapy for locally 
advanced rectal cancer. Int J Radiat Oncol 
Biol Phys 2010; 76: 824-830. 
40. Scappaticci FA, Fehrenbacher L, 
Cartwright T et al. Surgical wound healing 
complications in metastatic colorectal 
cancer patients treated with bevacizumab. J 
Surg Oncol 2005; 91: 173-180. 
41. Mentha G, Majno PE, Andres A et al. 
Neoadjuvant chemotherapy and resection 
of advanced synchronous liver metastases 
before treatment of the colorectal primary. 
Br J Surg 2006; 93: 872-878. 
42. Van der Pool AE, de Wilt JH, 
Lalmahomed ZS et al. Optimizing the 
outcome of surgery in patients with rectal 
cancer and synchronous liver metastases. 
Br J Surg 2010; 97: 383-390. 
43. Butte JM, Gonen M, Ding P et al. Patterns 
of failure in patients with early onset 
(synchronous) resectable liver metastases 
from rectal cancer. Cancer 2012; 1:5414-
5423. 
44. Malik HZ, Gomez D, Wong V et al. 
Predictors of early disease recurrence 
following hepatic resection for colorectal 
cancer metastasis. Eur J Surg Oncol 2007; 
33: 1003-1009. 
45. Yamashita Y, Adachi E, Toh Y et al. Risk 
factors for early recurrence after curative 
hepatectomy for colorectal liver 
metastases. Surg Today 2011; 41: 526-532. 
  Chapter 3 
 Neoadjuvant and surgical treatment of primary stage IV rectal cancer 
82 
 
46. Folprecht G, Gruenberger T, Bechstein 
WO et al. Tumour response and secondary 
resectability of colorectal liver metastases 
following neoadjuvant chemotherapy with 
cetuximab: the CELIM randomised phase 


























































CXCR4 and CXCL12 Expression in Rectal 
Tumors of Stage IV Patients Before and After 
Local Radiotherapy and Systemic Neoadjuvant 
Treatment  
 
Karin Tamas1#, Urszula M. Domanska1,2#, Tonnis H. van Dijk3,  
Hetty Timmer-Bosscha1, Klaas Havenga3, Arend Karrenbeld4, Wim J. Sluiter5, 
 Jannet C. Beukema6, Marcel A.T.M. van Vugt1, Elisabeth G.E. de Vries1, 




Departments of 1Medical Oncology, 3Surgery, 4Pathology and Medical Biology, 
5Endocrinology, 6Radiation Oncology,  
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 
2Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, 
Technische Universität München, Munich, Germany 
  
This research was originally published in Curr Pharm Des 2015;21:2276-2283 








Metastatic rectal cancer patients could benefit from novel therapeutic approaches. The 
signaling network formed by chemokines and their receptors can promote metastasis and 
resistance to current anticancer treatments. This study assessed the expression of chemokine 
receptor 4 (CXCR4) and its ligand CXCL12 immuhistochemically in stage IV rectal tumors. 
Paraffin-embedded primary tumor collected before and after local radiotherapy and systemic 
treatment with bevacizumab, oxaliplatin and capecitabine was analyzed. Receptor and ligand 
expression was assessed in the cytoplasm and nucleus of tumor, stromal and normal rectal 
crypt cells. Baseline expression of CXCR4 and CXCL12 was correlated with patients' 
pathologic response to treatment. At diagnosis (n=46), 89% of the rectal tumors expressed 
cytoplasmic CXCR4 and 81% CXCL12. Nuclear CXCR4 expression in tumor cells was 
present in 30% and nuclear CXCL12 expression in 35% of the tumors. After 
radiochemotherapy and bevacizumab, nuclear CXCL12 expression was present in 79% of 
residual tumors, as compared to 31% of the paired tumor samples expressing nuclear 
CXCL12 before treatment (P=0.001). There were no differences in CXCR4 or CXCL12 
expression at baseline between the patients that had (n=9) and did not have (n=30) a 
pathologic complete response. Our results show that CXCR4 and CXCL12 are extensively 
expressed in primary rectal tumors of patients presenting with metastatic disease, while 
radiochemotherapy and bevacizumab further upregulate CXCL12 expression. These data 
indicate the importance of the CXCR4/CXCL12 axis in rectal tumor biology, and may 
suggest the CXCR4/CXCL12 receptor-ligand pair as a potential therapeutic target in 
metastatic rectal cancer. 
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In non-metastatic rectal cancer, pelvic radiotherapy accompanied by 5-fluorouracil 
(5FU)-based chemotherapy administered as a radiosensitizer helps to successfully downstage 
the tumor prior to surgery, leading to better local disease control [1, 2]. Nonetheless, rectal 
cancer-related mortality is mainly due to liver and lung metastasis. Phase 2 and 3 trials and 
large observational cohort studies showed that addition of bevacizumab to oxaliplatin-based 
chemotherapy improved survival compared to chemotherapy alone [3-10]. However, even 
patients with a pathologic response of their primary rectal tumor after treatment with 
bevacizumab have a bad prognosis [11, 12]. This illustrates that improvement of treatment 
strategies is warranted. 
A growing body of preclinical evidence suggests that the tumor microenvironment can 
contribute to resistance to anticancer therapy [13]. One of the key factors involved in the 
cross-talk between tumor cells and the microenvironment is chemokine receptor 4 (CXCR4). 
It belongs to the family of G protein-coupled receptors (GPCR) and binds its corresponding 
ligand chemokine CXCL12 (stromal-derived factor 1α, SDF-1α). This receptor is expressed 
on the cell surface, as well as in the cytoplasm and in the nucleus of cells of several cancer 
types, including (colo)rectal cancer [14-16]. Binding of the ligand activates downstream 
signaling and induces cell migration, proliferation, and angiogenesis [17]. Preclinical studies 
in colorectal cancer mouse models showed that the CXCR4/CXCL12 axis directs the 
establishment and outgrowth of metastases in organs that abundantly express the ligand, such 
as the liver and lungs [18, 19]. In addition, CXCR4 was activated and upregulated after 
irradiation in a glioblastoma mouse model and in irradiated human nasopharyngeal tumors, as 
analyzed by immunohistochemistry [20, 21]. In an orthotopic glioblastoma mouse model, 
tumor irradiation led to increased CXCL12 levels and influx of bone marrow-derived 
progenitor cells, thereby enhancing tumor vasculogenesis [20]. Moreover, an over 2-fold 
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increase in mRNA levels of CXCR4 and CXCL12 in tumors of rectal cancer patients was 
observed after bevacizumab monotherapy, as compared to pre-treatment values [22]. 
Altogether, these findings suggest that several anticancer treatments influence expression of 
CXCR4 and CXCL12. 
Therefore, we immunohistochemically analyzed CXCR4 and CXCL12 protein 
expression levels in pre- and post-treatment tumor tissue of metastatic rectal cancer patients 
enrolled in a phase 2 study in which patients were sequentially treated with pelvic irradiation 
followed by bevacizumab, oxaliplatin and capecitabine, and surgery [11]. Subsequently, we 
correlated pre-treatment CXCR4 and CXCL12 protein expression with post-treatment 
pathologic response in rectal tumors, as pathologic response provides early and accurate 
information about the local effect of radiochemotherapy plus bevacizumab.   
MATERIALS AND METHODS  
Study Population   
 This study included stage IV rectal cancer patients [23] enrolled in a phase 2 clinical 
trial [11]. Patients received short-course pelvic irradiation (total, 25 Gy; five fractions in 5 
days) followed within 2 weeks by bevacizumab (7.5 mg/kg, day 1) and oxaliplatin (130 
mg/m2, day 1) intravenously each in a 2-hour infusion, and capecitabine (1000 mg/m2 twice 
daily orally, days 1–14). Patients received six 3-weekly cycles of systemic treatment. After 
radiochemotherapy plus bevacizumab, rectal tumor resection was performed. An anonymous 
database was kept (T.H.v.D.), and included information on patient demographics, clinical and 
pathologic characteristics, and pathologic response to treatment. Tumors were categorized as 
low grade (well/moderately differentiated) and high grade (poorly/undifferentiated) according 
to Greene et al [24]. Histological typing was based on the World Health Organization (WHO) 
classification. 
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 Tumor Tissue Acquisition and Processing 
 Immunohistochemical analysis of CXCR4 and CXCL12 expression was performed on 
pre- and post-treatment rectal tumor tissue samples. Pre-treatment diagnostic rectal tumor 
biopsies (n=50) were obtained between 2006 and 2010 with informed consent from each 
patient prior to inclusion in the previously reported phase 2 clinical trial [11]. Post-treatment 
rectal cancer specimens were collected from resected primary tumors. All tumor specimens 
were fixed in formalin immediately after procurement and subsequently embedded in 
paraffin. All formalin-fixed paraffin-embedded tissue blocks were encoded for patient 
confidentiality and study blindness purposes.  
Immunohistochemistry 
 Tumor sections (4 μm) were mounted onto StarFrost® hydrophylic microscope slides 
(Waldemar Knittel) and dried overnight at 60 °C. Sections were thereafter deparaffinized with 
xylene and rehydrated in a three-step ethanol dilution series. Endogenous peroxidase was 
blocked by incubating the slides for 30 min with 0.3% hydrogen peroxide in phosphate-
buffered saline (PBS: 6.4 mM Na2HPO4, 1.5 mM KH2PO4, 0.14 mM NaCl, 2.7 mM KCl, 
pH=7.2–7.4). All sections were treated for 15 minutes with 1% AB serum in PBS 
supplemented with 1% bovine serum albumin (BSA) to reduce non-specific binding.  
 Sections were incubated overnight at 4 °C with polyclonal rabbit anti-human antibody 
directed against CXCR4 (ab2074, Abcam) diluted 1:100, or for 60 minutes at room 
temperature with polyclonal rabbit anti-human antibody against CXCL12 (ab25117, Abcam) 
diluted 1:50. Primary antibodies were diluted in PBS supplemented with 1% BSA. 
Subsequently, sections were incubated with secondary and tertiary antibodies conjugated to 
horseradish peroxidase (DAKO, Glostrup). Staining was visualized with 3, 3'-
diaminobenzidine (Sigma-Aldrich) and hematoxylin counterstaining.  
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 All controls underwent the same procedures as the experimental samples. Negative 
controls were the rectal cancer samples from the study patients with primary antibody omitted 
or replaced with non-specific rabbit immunoglobulin (DAKO) adjusted for protein 
concentration. External positive controls consisted of A2780 human ovarian xenograft tissue 
sections, known from previous experience to express CXCR4 and of human prostate cancer 
PC3-luc xenografts, known to express CXCL12 (Supplemental Fig. S1A, S1B). Internal 
positive controls were provided by the presence of vascular endothelium or inflammatory 
cells in some of the slides, whilst negatively stained erythrocytes provided an internal 
negative control, demonstrating the specificity of the staining. Hematoxylin and eosin (H&E) 
staining was routinely applied and used to analyze tissue viability and morphology. 
Slides were analyzed with a Leica DM 3000 microscope and images were processed 
with the LAS 3.7 software (Leica Microsystems). Cytoplasmic and nuclear staining intensities 
in tumor, adjacent stromal cells and in epithelial cells of tumor-neighboring rectal crypts with 
normal histology (thereafter referred to as normal rectal crypts) were recorded in three to five 
random high-power fields (HPF; 400x magnification). Staining negativity or positivity for a 
given marker was assigned using the predetermined cut-off value of 10% (staining 
≤10%=negative; >10%=positive). The definitive expression category (negative/absent vs 
positive/present) assigned to each sample was based upon the most frequently observed 
category amongst the three to five HPFs evaluated. In samples with positive expression, 
staining intensity of CXCR4 and CXCL12 was further subdivided as weak (±, 1), moderate 
(+, 2), and strong (++, 3). In case of divergent intensity within a positive HPF, the intensity 
score was determined by the predominating staining intensity (>50% of evaluable tumor 
tissue). Definitive staining intensities assigned to each sample were based on the most 
frequently observed intensity among the three to five HPFs evaluated. At least a quarter of the 
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tumor area had to be evaluable to be designated an intensity score. Artificial staining could be 
detected at the periphery of tumor sections, and these areas were not included in the analysis.  
Two observers (K.T. and U.M.D.) scored all samples independently from each other, 
and blinded for clinical data. A concordance of more than 90% for both stainings was found. 
The discordant cases were reviewed and scores were reassigned on consensus of opinion.  
Pathologic Response Evaluation 
 Pathologic response to treatment was prospectively assessed by Mandard's criteria in 
post-treatment surgical specimens of primary rectal tumors [25]. Pathologic complete 
response (pCR) of the rectal tumor to treatment was defined as the absence of residual 
adenocarcinoma cells in the rectal tumor specimen (Mandard category I). Partial pathologic 
response was defined as the presence of some residual adenocarcinoma cells in the rectal 
tumor specimen (Mandard categories II-IV), and no response as Mandard category V. 
Pathologic response data were retrieved from the anonymous database of the phase 2 clinical 
trial (T.H.v.D.) and assessed by the pathologist (A.K.).   
Statistical Analysis 
Clinical and pathologic characteristics were presented as frequency and median. 
Presence or absence of CXCR4 and CXCL12 expression before start of treatment was 
described as frequency, and correlated with the pathologic response observed after treatment 
by Fischer's exact test. For this, the rectal tumor specimens obtained after neoadjuvant 
treatment were dichotomized as presenting pathologic complete response or lacking 
pathologic complete response. Intensities of protein expression were presented as median 
(range 0–3) and comparatively assessed in tumor cells, adjacent stromal cells and normal 
rectal crypts by Chi-square test. Fisher's exact test was used to correlate presence or absence 
of protein expression in paired treated and untreated rectal tumors. McNemar's test was used 
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to determine statistical significance of change in protein expression presence or absence in 
paired treated and untreated rectal tumors. A two-tailed P value of less than 0.05 was 
considered significant. For statistical analyses GraphPad Prism (version 5.00 for Windows, 
GraphPad Software) was used.  
RESULTS 
Patients 
 Clinical and pathologic characteristics of the 46 patients of whom sufficient pre-
treatment (diagnostic) rectal tumor tissue was available for immunohistochemical analysis are 
presented in Table 1. At diagnosis, most tumors were low grade, located in the middle/lower 
rectum, invasive into the subserosa/ perirectal tissue (cT3), node positive (cN1-N2), and 
metastasized to the liver.    
CXCR4 and CXCL12 Expression in Diagnostic Primary Tumor Samples of Stage IV 
Rectal Cancer Patients 
We analyzed pre-treatment CXCR4 and CXCL12 expression in the primary tumor 
tissue of metastatic rectal cancer patients. Cytoplasmic and nuclear CXCR4 and CXCL12 
expression could be analyzed in tumor cells (n=46), tumor-adjacent stromal cells (n=44) and 
normal rectal crypts (n=33 for CXCR4, n=31 for CXCL12 staining). The absence of stromal 
cells or normal rectal crypts in some of the diagnostic rectal tumor samples explains the 
differences in the number of samples available for CXCR4/CXCL12 expression analyses in 
tumor, stromal and rectal crypt cells.  
CXCR4 and CXCL12 were extensively, but differentially expressed in the cytoplasm 
and nucleus of tumor cells, adjacent stromal cells and normal rectal crypts. Representative 
CXCR4 and CXCL12 stainings are illustrated in Fig. 1A. Cytoplasmic CXCR4 was present in 
tumor cells in 41 out of 46 samples (89%), in tumor-adjacent stromal cells in 43 out of 44  
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Table 1. Clinical and pathologic characteristics at diagnosis and information concerning 










































Results are presented as number of patients and percentage [n(%)], unless indicated otherwise; YpCR 
– pathologic complete response to neoadjuvant treatment;*Assessed in the 46 patients of whom upfront 
rectal tumor tissue for analysis was available; #Assessed in the 39 patients whom underwent surgical 
treatment of the primary rectal tumor after neoadjuvant therapy; † Assessed in the 30 patients with 
residual tumor in the surgical specimen following neoadjuvant therapy. 
Gender*                                                                                                                     n            % 
 
Female 19  41 
 
Male 27  59 
Age (years)* 
 
Median                                                      58    
 
Range                                                     35-75 
Primary tumor location* 
 
Upper 6  13 
 
Middle 21  46 
 
Lower 19  41 
Primary tumor invasion* 
 
cT2 4  9 
 
cT3 35  76 
 
cT4 7  15 
Tumor 
              Grade* 
 
Low 43  93 
 
High 3  7 
              Histological type* 
 
Classical 46  100 
 
Mucinous 0  0 
Local lymph node metastasis*  
 
cN0 6  13 
 
cN1 28  61 
 
cN2 12 26 
Distant metastasis status* 
 
Liver 39  85 
 
Lung 5  11 
 
Liver & lung 2  4 
Neoadjuvant treatment*  
 
Irradiation 46  100 
 
Bevacizumab 45  98 
 
Capecitabine-Oxaliplatin 45  98 
Treatment-free interval before the surgery (weeks)* 
 
Median                                                     9 
 
Range                                                   5-37    
Surgery* 
 
No 7  15 
 
Yes 39  85 
Pathologic response of the primary tumor# 
 
YpCR (Mandard I) 9  23 
 
Residual tumor (Mandard II-V) 30  77 
Residual local tumor invasion† 
 
YpT2 9  30 
 
YpT3 20  67 
 
YpT4 1  3 
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 (98%), and in normal rectal crypts in 23 of 33 samples (70%; Fig.1B). CXCL12 was present 
in the cytoplasm of tumor cells in 37 out of 46 tumors (81%), of stromal cells in 38 out of 44 
(86%), and of normal crypts in 22 out of 31 tumors (71%; Fig. 1B). Although the percentage 
of tumor and stromal cells expressing CXCR4 or CXCL12 was comparable, the intensity of 
CXCR4 and CXCL12 stainings was higher in tumor cells (n=46, median score 2) than in the 
adjacent stroma (n=44, median score 1; P=0.002 for CXCR4, and P=0.001 for CXCL12), or 
in the neighboring normal rectal crypts (n=33, median score 1; P=0.026 for CXCR4, and 
n=31, median score 1; P=0.473 for CXCL12; Fig. 1C). The reference staining scales showing 
negative, weak, moderate, or strong CXCR4 or CXCL12 expression are presented in 
Supplemental Fig. S2A, S2B. Nuclear CXCR4 or CXCL12 expression was observed in rectal 
tumor cells (30% and 35% respectively), in stromal cells (14% and 16% respectively), and in 
rectal crypts (30% and 39% respectively).  
Treatment-induced Changes in CXCR4 and CXCL12 Expression in Rectal Tumors 
We subsequently tested whether the expression of CXCR4 and CXCL12 in the 
primary tumors was affected by treatment with local radiotherapy followed by systemic 
bevacizumab and chemotherapy. Out of 39 patients who underwent radical rectal cancer 
surgery after this treatment, 30 had residual rectal tumor available for immunohistochemical 
analysis. Respectively 25 and 29 paired samples were available for the analysis of CXCR4 
and CXCL12 (Table 2). As complete pathologic responders had no residual rectal cancer cells 
in the surgical specimens following neoadjuvant treatment, in these patients, comparison was 
not possible between pre- and post-treatment tumor tissues. No significant differences were 
observed between CXCR4 or CXCL12 expression in the cytoplasm of tumor, stromal and 
normal rectal crypt cells before and after treatment. Nuclear CXCR4 expression showed a 
tendency toward upregulation after treatment in tumor cells and in the epithelial cells of  
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(A) Representative images of immunohistochemical CXCR4 (upper panels) and CXCL12 (lower 
panels) staining of tumor tissue including tumor and stromal cells, and of tumor-neighboring epithelial 
cells of rectal crypts with normal morphology (normal rectal crypts), as indicated in columns 
(magnification 400 x). (B)  Distribution of CXCR4 (left panel) and CXCL12 (right panel) staining (as 
present or absent) in the cytoplasm of tumor cells, adjacent stromal cells and in normal rectal crypts. 
(C) Distribution of staining intensity of CXCR4 (left panel) and CXCL12 (right panel) in the 
cytoplasm of tumor cells, adjacent stromal cells and in normal rectal crypts. 
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normal rectal crypts. In tumor cells, nuclear CXCR4 staining was present in 8 out of the 25 
(32%) tumor samples before treatment, as compared to 16 (64%) after treatment. In normal 
rectal crypts before treatment, only 5 out of 18 (28%) tumor samples showed nuclear CXCR4 
positivity, whereas rectal crypt cells after treatment were positive for nuclear CXCR4 in 12 
(67%) tumor samples. Furthermore, therapy altered CXCL12 nuclear expression. It increased 
the number of tumor samples with positive nuclear CXCL12 expression in tumor cells from 9 
(31%) to 23 (79%) out of 29 (P=0.001). Nuclear CXCL12 expression in normal rectal crypts 
was present in 4 out of 15 (27%) tumor samples before treatment, and in 11 (73%) after 
treatment (P=0.023). However, treatment did not affect the number of tumor samples with 
nuclear CXCR4 or CXCL12 expression in stromal cells. 
Correlation of CXCR4 and CXCL12 Expression with Pathologic Response to Treatment  
Finally, the pathologic response to treatment could be assessed for 39 patients that 
underwent surgery after neoadjuvant treatment (Table 3). Nine patients experienced a 
complete pathologic response. There were no significant differences in CXCR4 or CXCL12 
expression before treatment between the nine patients that had complete pathologic response 
and the 30 patients with residual disease.  
DISCUSSION  
In this study we investigated the expression of CXCR4 and CXCL12 in primary rectal 
tumors of stage IV patients, and showed that receptor and ligand are ubiquitously expressed in 
the majority of rectal tumor and stromal cells. Subsequently, we analyzed CXCR4 and 
CXCL12 expression prior to and after neoadjuvant treatment. After treatment with local 
radiotherapy followed by systemic bevacizumab, oxaliplatin and capecitabine, nuclear 
CXCL12 expression was upregulated in tumor cells of patients with residual cancer in the  
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Table 2. Treatment-induced changes in CXCR4 and CXCL12 expression. 
Marker expression Sample size (n) Positive expression [n (%)] P 
  Before After  
CXCR4 cytoplasmic     
Tumor cells 25 23  (92) 25  (100) 0.489 
                       Stromal cells 24 23  (96) 22   (92) 1.000 
Normal crypts 18 12  (67) 14  (78) 0.711 
     
CXCR4 nuclear     
Tumor cells 25 8  (32) 16  (64) 0.061 
                       Stromal cells 24 4  (16) 2  (8) 0.666 
Normal crypts 18 5  (28) 12  (67) 0.096 
     
CXCL12 cytoplasmic     
Tumor cells 29 24  (83) 28  (97) 0.193 
                       Stromal cells 25 23  (92) 20  (80) 0.417 
Normal crypts 15 11  (73) 11  (73) 1.000 
     
CXCL12 nuclear     
Tumor cells 29 9  (31) 23  (79) 0.001 
                       Stromal cells 25 3  (12) 5  (20) 0.701 
Normal crypts 15 4  (27) 11  (73) 0.023 
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resected specimen. Finally, we found no correlation between CXCR4 or CXCL12 expression 
and pathologic complete response.  
CXCR4 and CXCL12 research has been focused on analyzing their expression in 
tumor cells. Limited data are available on patterns and levels of CXCR4 and CXCL12 
expression in tumor microenvironment components such as stromal cells and in normal crypts 
adjacent to rectal cancers. Our study investigated cells from the tumor microenvironment. 
Tumor cells showed cytoplasmic CXCR4 staining, and, in 30% of cases nuclear staining. 
Nuclear CXCR4 expression was reported earlier in tumor cells of untreated stage I-IV 
colorectal cancer patients and rectal tumors of stage II-III patients [14, 15, 26]. CXCL12 was 
expressed in 81% of rectal tumors before therapy in the cytoplasm and in 35% in the nucleus 
of tumor cells. Unlike  cytoplasmic CXCL12 localization, its nuclear presence has drawn less 
attention. Its presence was reported only in patients with non-metastatic rectal carcinoma [22], 
recurrent glioblastoma [27] and clear-cell carcinoma [28]. Since nuclear CXCL12 might act 
as an intracellular ligand for CXCR4 localized at the nuclear membrane [29, 30], our findings 
may suggest that CXCR4/CXCL12 signaling in rectal cancer could also occur at the 
intracellular level.  
CXCL12 and CXCR4 expression in stromal cells was in our study localized mainly in 
the cytoplasm, and, to a lesser extent, in the nucleus. The relevance of stromal CXCL12 and 
CXCR4 expression in rectal cancer is underscored by a study, in which high mRNA 
expression of both factors in stromal cells of rectal tumors was shown to correlate with 
disease-free survival of 52 stage II/III rectal cancer patients [31]. Overall, cytoplasmic and 
nuclear CXCR4 and CXCL12 expression  in rectal tumor cells as well as stromal cells before 
treatment may suggest that, in  metastatic rectal cancer, autocrine, paracrine and intracrine 
CXCR4/CXCL12 signaling routes are active. 
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Table 3. Correlation of CXCR4 and CXCL12 expression with the pathologic response to 
treatment. 
 
Marker expression Sample size(n) Pathologic complete response P 
 Yes [n (%)] No [n (%)]  
CXCR4 tumor cells 39 9  30   
Cytoplasmic + 34     7  (20) 27  (80) 0.572 
Cytoplasmic - 5 2  (40) 3  (60)  
                       Nuclear + 10 2  (21) 8  (80) 1.000 
Nuclear - 29 7 (24) 22 (76)  
         
CXCR4 stromal cells 37 9  28   
Cytoplasmic + 36 9  (25) 27  (75) 1.000 
Cytoplasmic - 1 0  (0) 1  (100)  
Nuclear + 4 0  (0) 4  (100) 0.554 
Nuclear - 33 9 (27) 24 (73)  
         
CXCL12 tumor cells 39 8  31   
Cytoplasmic + 31 6  (19) 25  (81) 0.658 
Cytoplasmic - 8 2  (25) 6  (75)  
Nuclear + 11 2  (18) 9  (81) 1.000 
Nuclear - 28 6 (21) 22 (79)  
         
CXCL12 stromal cells 37 8  29   
Cytoplasmic + 32 6  (19) 26  (81) 0.291 
Cytoplasmic - 5 2  (40) 3  (60)  
Nuclear + 4 1  (25) 3  (75) 1.000 
Nuclear - 33 7  (21) 26  (79)  
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In the present study we had the opportunity to obtain paired rectal tumor samples. We 
found nuclear CXCL12 expression in residual tumor cells to be upregulated after 
radiochemotherapy and bevacizumab. In a mouse model of glioblastoma, irradiation alone 
induced CXCL12 upregulation in tumors, as well as an increase in CXCR4 phosphorylation, 
both visualized by immunofluorescent staining [20]. In addition, in 12 non-metastatic rectal 
cancer patients treated with bevacizumab only, 12 days later, CXCL12 and CXCR4 mRNA 
expression in tumor cells were upregulated [22]. Moreover, paclitaxel, but not gemcitabine or 
doxorubicin, resulted in a rapid increase in CXCL12 plasma levels in non-tumor bearing 
C57BL/6 mice [33]. CXCL12 induction by irradiation or paclitaxel induces acute 
mobilization of circulating vascular progenitor cells in mice, which could be blocked by 
CXCL12-neutralizing antibodies [33] and the CXCR4 inhibitor AMD3100 [20]. These data 
show that different types of anticancer treatment can upregulate CXCR4 or CXCL12 
expression, as also illustrated in our study to occur in patients. Further studies are therefore 
warranted to determine whether CXCR4/CXCL12 pathway inhibition can increase the 
efficacy of conventional therapies in rectal cancer. 
 In parallel with tumor cells, tumor-neighboring rectal crypts with normal histology 
also showed an augmented nuclear CXCL12 expression. There were already preclinical 
results suggesting that such an upregulation is likely a mechanism of cell adaptation to 
hypoxic stress. Hypoxia-dependent CXCL12 induction was seen in irradiated endothelial cells 
[34] and in normal endothelial cells of tumor-free ischemic mice [35]. We do however have to 
take into account that these histologically normal epithelial cells of rectal crypts adjacent to 
tumor cells might well contain a genetically altered subset of pre-cancerous lesions [36].  
We found no associations between baseline CXCR4 or CXCL12 expression and 
pathologic response to treatment. Other studies also reported no relation between CXCR4 or 
CXCL12 expression in rectal tumors and pathologic response to treatment [26, 31]. In a study 
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in 40 stage T3/T4 and/or lymph node positive rectal cancer patients treated with 
chemoradiotherapy containing 5FU, no correlation was found between nuclear CXCR4 
expression in pre-treatment biopsies and histologic tumor regression, defined as complete 
tumor sterilization or presence of macroscopic foci of adenocarcinoma after treatment [26]. 
Moreover, when stromal expression of CXCR4 and CXCL12 was analyzed post-treatment in 
relation to pathologic response, defined as less than one third of vital residual tumor cells 
present after chemoradiotherapy containing 5FU in 53 stage II/III rectal cancer patients, no 
associations was found either [31]. In studies including 338 [15], 53 [31], respectively 139 
[32] all stages (colo)rectal cancer patients, CXCR4 or CXCL12 expression in tumor cells 
correlated with disease-free, recurrence-free and overall survival of patients. Altogether, these 
data from relatively small studies suggest that CXCR4/CXCL12 expression might be 
associated with distant recurrences rather than local pathologic response of the primary tumor. 
In conclusion, CXCR4 and CXCL12 are extensively expressed at diagnosis in primary 
rectal tumors of stage IV patients, and the ligand is upregulated after treatment with local 
radiotherapy, followed by systemic bevacizumab, oxaliplatin and capecitabine. Combined, 
these data may suggest the CXCR4/CXCL12 receptor-ligand pair as a potential target in 
metastatic rectal cancer, for improving treatment outcome. Several CXCR4/CXCL12 
antagonists have been developed [37-41], and disrupting the interaction of solid cancer cells 
with their microenvironment by using the CXCR4 inhibitor AMD3100 is currently being 
tested in combination with bevacizumab in patients with recurrent high-grade glioma 
(ClinicalTrials.gov number, NCT01339039).  
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       Graphical Abstract  
 
 
CXCR4 and CXCL12 are extensively expressed in rectal cancer and stromal cells. Local 
radiotherapy followed by systemic bevacizumab, oxaliplatin, and capecitabine further 
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Supplemental Fig. (S1). Representative immunohistochemical CXCR4 (A) and CXCL12 (B) 
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Supplemental Fig. (S2). Reference scales of immunohistochemical CXCR4 (A) and 
CXCL12 (B) staining of the primary rectal tumors according to expression intensity 

















    Chapter 4 






[1] De Caluwe L, Van Nieuwenhove Y, 
Ceelen WP. Preoperative 
chemoradiation versus radiation alone 
for stage II and III resectable rectal 
cancer. Cochrane Database Syst Rev 
2013; 2: CD006041.  
[2]  Gérard J, Conroy T, Bonnetain F, et al. 
Preoperative radiotherapy with or 
without concurrent fluorouracil and 
leucovorin in T3-4 rectal cancers: 
Results of FFCD 9203. J Clin Oncol 
2006; 24: 4620-5. 
[3]  Hurwitz H, Fehrenbacher L, Novotny 
W, et al. Bevacizumab plus irinotecan, 
fluorouracil, and leucovorin for 
metastatic colorectal cancer. N Engl J 
Med 2004; 350: 2335-42.  
[4]  Kabbinavar FF, Schulz J, McCleod M, 
et al. Addition of bevacizumab to 
bolus fluorouracil and leucovorin in 
first-line metastatic colorectal cancer: 
Results of a randomized phase II trial. 
J Clin Oncol 2005; 23: 3697-705.  
[5]  Giantonio BJ, Catalano PJ, Meropol 
NJ, et al. Bevacizumab in combination 
with oxaliplatin, fluorouracil, and 
leucovorin (FOLFOX4) for previously 
treated metastatic colorectal cancer: 
Results from the Eastern Cooperative 
Oncology Group study E3200. J Clin 
Oncol 2007; 25: 1539-44.  
[6]  Grothey A, Sugrue MM, Purdie DM, 
et al. Bevacizumab beyond first 
progression is associated with 
prolonged overall survival in 
metastatic colorectal cancer: Results 
from a large observational cohort 
study (BRiTE). J Clin Oncol 2008; 26: 
5326-34.  
[7]  Van Cutsem E, Rivera F, Berry S, et 
al. Safety and efficacy of first-line 
bevacizumab with FOLFOX, XELOX, 
FOLFIRI and fluoropyrimidines in 
metastatic colorectal cancer: The 
BEAT study. Ann Oncol 2009; 20: 
1842-7.  
[8]  Jain RK, Duda DG, Clark JW, Loeffler 
JS. Lessons from phase III clinical 
trials on anti-VEGF therapy for cancer. 
Nat Clin Pract Oncol 2006; 3: 24-40.  
[9]  Saltz LB, Clarke S, Díaz-Rubio E, et 
al. Bevacizumab in combination with 
oxaliplatin-based chemotherapy as 
first-line therapy in metastatic 
colorectal cancer: A randomized phase 
III study. J Clin Oncol 2008; 26: 2013-
9.  
[10]  Bennouna J, Sastre J, Arnold D, et al. 
Continuation of bevacizumab after 
first progression in metastatic 
colorectal cancer (ML18147): A 
randomised phase 3 trial. Lancet Oncol 
2013; 14: 29-37.  
[11]  Van Dijk TH, Tamas K, Beukema JC, 
et al. Evaluation of short-course 
radiotherapy followed by neoadjuvant 
bevacizumab, capecitabine, and 
oxaliplatin and subsequent radical 
surgical treatment in primary stage IV 
rectal cancer. Ann Oncol 2013; 24: 
1762-9.  
[12]  Czito BG, Bendell JC, Willett CG, et 
al. Bevacizumab, oxaliplatin, and 
capecitabine with radiation therapy in 
rectal cancer: Phase I trial results. Int J 
Radiat Oncol Biol Phys 2007; 68: 472-
8.  
[13]  Bergers G, Hanahan D. Modes of 
resistance to anti-angiogenic therapy. 
Nat Rev Cancer 2008; 8: 592-603.  
[14]  Yoshitake N, Fukui H, Yamagishi H, 
et al. Expression of SDF-1α and 
nuclear CXCR4 predicts lymph node 
metastasis in colorectal cancer. Br J 
Cancer 2008; 98: 1682-9.  
[15]  Wang SC, Lin JK, Wang HS, Yang 
SH, Li AF, Chang SC. Nuclear 
expression of CXCR4 is associated 
with advanced colorectal cancer. Int J 
Colorectal Dis 2010; 25: 1185-91.  
[16] Heckmann D, Maier P, Laufs S, et al. 
The disparate twins: A comparative 
    Chapter 4 





study of CXCR4 and CXCR7 in SDF-
1α-induced gene expression, invasion 
and chemosensitivity of colon cancer. 
Clin Cancer Res 2014; 20: 604-16. 
[17]  Domanska UM, Kruizinga RC, 
Nagengast WB, et al. A review on 
CXCR4/CXCL12 axis in oncology: 
No place to hide. Eur J Cancer 2013; 
49: 219-30.  
[18]  Kollmar O, Rupertus K, Scheuer C, et 
al. Stromal cell-derived factor-1 
promotes cell migration and tumor 
growth of colorectal metastasis. 
Neoplasia 2007; 9: 862-70.  
[19]  Zeelenberg IS, Ruuls-Van Stalle L, 
Roos E. The chemokine receptor 
CXCR4 is required for outgrowth of 
colon carcinoma micrometastases. 
Cancer Res 2003; 63: 3833-9.  
[20]  Kioi M, Vogel H, Schultz G, Hoffman 
RM, Harsh GR, Brown JM. Inhibition 
of vasculogenesis, but not 
angiogenesis, prevents the recurrence 
of glioblastoma after irradiation in 
mice. J Clin Invest 2010; 120: 694-
705.  
[21]  Ou D, Chen C, Lin S, Hsu C, Lin L. 
Chemokine receptor expression 
profiles in nasopharyngeal carcinoma 
and their association with metastasis 
and radiotherapy. J Pathol 2006; 210: 
363-73.  
[22]  Xu L, Duda DG, Di Tomaso E, et al. 
Direct evidence that bevacizumab, an 
anti-VEGF antibody, up-regulates 
SDF1α, CXCR4, CXCL6, and 
neuropilin 1 in tumors from patients 
with rectal cancer. Cancer Res 2009; 
69: 7905-10.  
[23]  Greene FL, Fleming ID, Fritz AG, et 
al. AJCC cancer staging manual. 6th 
ed. New York (NY): Springer 2002; pp 
113-123.  
[24]  Greene FL, Stewart AK, Norton HJ. A 
new TNM staging strategy for node-
positive (stage III) colon cancer: An 
analysis of 50,042 patients. Ann Surg 
2002; 236: 416-21.  
[25]  Mandard AM, Dalibard F, Mandard 
JC, et al. Pathologic assessment of 
tumor regression after preoperative 
chemoradiotherapy of esophageal 
carcinoma. Clinicopathologic 
correlations. Cancer 1994; 73: 2680-6. 
[26]  Guedj N, Bretagnol F, Rautou P, et al. 
Predictors of tumor response after 
preoperative chemoradiotherapy for 
rectal adenocarcinomas. Hum Pathol 
2011; 42: 1702-9. 
[27]  Di Tomaso E, Snuderl M, Kamoun 
WS, et al. Glioblastoma recurrence 
after cediranib therapy in patients: 
Lack of “rebound” revascularization as 
mode of escape. Cancer Res 2011; 71: 
19-28.  
[28]  Zagzag D, Krishnamachary B, Yee H, 
et al. Stromal cell-derived factor-1α 
and CXCR4 expression in 
hemangioblastoma and clear cell-renal 
cell carcinoma: Von Hippel-Lindau 
loss-of-function induces expression of 
a ligand and its receptor. Cancer Res 
2005; 65: 6178-88. 
[29]  Boivin B, Vaniotis G, Allen BG, 
Hebert TE. G protein-coupled 
receptors in and on the cell nucleus: A 
new signaling paradigm? J Recept 
Signal Transduct Res 2008; 28: 15-28. 
[30]  Tadevosyan A, Vaniotis G, Allen BG, 
Hebert TE, Nattel S. G protein-
coupled receptor signalling in the 
cardiac nuclear membrane: Evidence 
and possible roles in physiological and 
pathophysiological function. J Physiol 
2012; 590: 1313-30.  
[31]  Saigusa S, Toiyama Y, Tanaka K, et 
al. Stromal CXCR4 and CXCL12 
expression is associated with distant 
recurrence and poor prognosis in rectal 
cancer after chemoradiotherapy. Ann 
Surg Oncol 2010; 17: 2051-8.  
[32]  Kim J, Takeuchi H, Lam ST, et al. 
Chemokine receptor CXCR4 
expression in colorectal cancer patients 
increases the risk for recurrence and 
    Chapter 4 





for poor survival. J Clin Oncol 2005; 
23: 2744-53. 
[33]  Shaked Y, Henke E, Roodhart JM, et 
al. Rapid chemotherapy-induced acute 
endothelial progenitor cell 
mobilization: Implications for 
antiangiogenic drugs as 
chemosensitizing agents. Cancer Cell 
2008; 14: 263-73. 
[34]  Lerman OZ, Greives MR, Singh SP, et 
al. Low-dose radiation augments 
vasculogenesis signaling through HIF-
1–dependent and –independent SDF-1 
induction. Blood 2010; 116: 3669-76.  
[35]  Ceradini DJ, Kulkarni AR, Callaghan 
MJ, et al. Progenitor cell trafficking is 
regulated by hypoxic gradients through 
HIF-1 induction of SDF-1. Nat Med 
2004; 10: 858-64. 
[36]  Zhu D, Keohavong P, Finkelstein SD, 
et al. K-ras gene mutations in normal 
colorectal tissues from K-ras mutation-
positive colorectal cancer patients. 
Cancer Res 1997; 57: 2485-92. 
[37] Jain RK. Normalizing tumor 
microenvironment to treat cancer: 
Bench to bedside to biomarkers. J Clin 
Oncol 2013; 31: 2205-18. 
[38] Kim SY, Lee CH, Midura BV, et al. 
Inhibition of the CXCR4/CXCL12 
chemokine pathway reduces the 
development of murine pulmonary 
metastases. Clin Exp Metastasis 2008; 
25: 201-11. 
[39] Wong D, Kandagatla P, Korz W, 
Chinni SR. Targeting CXCR4 with 
CTCE-9908 inhibits prostate tumor 
metastasis. BMC Urol 2014. doi: 
10.1186/1471-2490-14-12. 
[40] Hotte SJ, Hirte HW, Moretto P, et al. 
Final results of a phase I/II study of 
CTCE-9908, a novel anticancer agent 
that inhibits CXCR4, in patients with 
advanced solid cancers. Eur J Cancer 
2008; 6:127 (abstract). 
[41]  Galsky MD, Vogelzang NJ, Conkling 
P, et al. Phase I Trial of LY2510924, a 
CXCR4 peptide antagonist, in patients 
with advanced cancer. Clin Cancer Res 
2014; 20: 3581-8. 
 




























































VEGFA and PlGF Protein Signature of Primary 
Stage IV Rectal Cancer Pre and Post 
Neoadjuvant Radiotherapy, Bevacizumab, and 
Chemotherapy 
 
Karin Tamas1,#, Tonnis H. van Dijk2,#, Urszula M. Domanska1,7,  
Hetty Timmer-Bosscha1, Klaas Havenga2, Arend Karrenbeld3  
Wilfred F.A. den Dunnen3, Wim J. Sluiter4, Wouter B. Nagengast5,  
Jannet C. Beukema6, Marcel A.T.M. van Vugt1, Elisabeth G.E. de Vries1, 




Departments of 1Medical Oncology, 2Surgery, 3Pathology and Medical Biology, 
4Endocrinology, 5Gastroenterology and Hepatology, 6Radiation Oncology,  
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands;  
7Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar,  
Technische Universität München, Munich, Germany 
 
 
This research was originally published in Curr Angiogenes 2014;3:164-173 





Abstract   
Vascular endothelial growth factor-A (VEGFA) and placental growth factor (PlGF) can 
mediate cancer progression and anticancer treatment failure. We therefore analyzed 
(sub)cellular patterns of VEGFA and PlGF expression, and mean vessel density (MVD) in 
primary rectal tumor samples of stage IV patients, who could benefit from improved 
therapies. VEGFA, PlGF and MVD were measured immunohistochemically in paraffin-
embedded rectal tumor tissue before and after pelvic radiotherapy and systemic neoadjuvant 
treatment with bevacizumab, capecitabine, and oxaliplatin. The relation between baseline 
expression of VEGFA and PlGF, and MVD and pathologic response to treatment was also 
analyzed. At diagnosis, 91% of the 46 tumors expressed VEGFA in the cytoplasm and 50% in 
the nucleus of tumor cells. PlGF was expressed by 74% in the tumor cell's cytoplasm. There 
were no differences in VEGFA expression and MVD at baseline between the nine patients 
with pathologic complete response (pCR) and the 30 patients with residual tumor after 
treatment. All patients with pCR expressed PlGF in tumor cells at baseline, as did 19 of the 30 
patients with residual tumor. After treatment, nuclear VEGFA expression in tumor cells and 
MVD were lower in residual tumors as compared to the initial tumor [15% vs. 56%, P = 
0.024, and 10.3 (±4.2) vs.16.4 (±6.0), P < 0.0001]. PlGF expression in residual cancer did not 
significantly differ from the paired pre-treatment values. These data indicate the relevance of 
VEGFA and PlGF to rectal tumor biology, and might suggest PlGF blockade as being of 
interest to test in metastatic rectal cancer. 
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Rectal cancer is a major contributor to cancer-related morbidity and mortality, with 
approximately 450,000 new cases reported worldwide in 2008 [1]. The poor prognosis of 
rectal cancer patients is a consequence of distant visceral metastases, occurring mainly in the 
liver and lungs. The optimal treatment of patients with newly diagnosed metastatic rectal 
cancer remains a difficult task [2]. One of the approaches is to include bevacizumab, a 
monoclonal antibody against vascular endothelial growth factor-A (VEGFA) [3], early during 
treatment.  Phase 3 studies have shown that addition of bevacizumab to oxaliplatin-containing 
chemotherapy improves survival of patients with previously untreated and treated metastatic 
colorectal cancer (mCRC) [4, 5]. However, the clinical gain is rather modest and the two-year 
recurrence rate is high, despite initial good pathologic response [2]. This illustrates that 
further improvement of therapy is warranted.  
Targeting tumor-stroma interactions could provide potential alternative strategies, 
given the critical role played by the tumor microenvironment in cancer progression [3]. 
Placental growth factor (PlGF) is a VEGFA homolog initially isolated from placenta [6], but 
also expressed by tumor and stroma cells [7]. In addition to its  role in tumor angiogenesis [7, 
8], recently reported data bridge PlGF with a prosurvival function exerted through neuropilin 
1 (Nrp1) receptor [9]. The cerebellar stroma of a human medulloblastoma mouse model 
produced PlGF following stimulation by tumor-derived sonic hedgehog (Shh) signaling. 
Subsequently, stromal PlGF acted through Nrp1 expressed on tumor cells and promoted the 
survival of these tumor cells. PlGF/Nrp1 blockade resulted in direct antitumor effects in vivo, 
with medulloblastoma regression, decreased metastasis, and increased mouse survival. 
Furthermore, in 32 medulloblastoma patients, high expression of Nrp1 correlated with poor 
overall survival [9]. 
    Chapter 5 




These data underscore that insight into factors involved in the cross-talk between 
cancer and its microenvironment, such as VEGFA and PlGF, could provide insightful 
guidance for the development of novel clinical approaches. Therefore, the primary aim of the 
current study was to examine by immunohistochemical staining (sub)cellular patterns of 
VEGFA and PlGF expression in rectal tumor cells and microenvironment cells and their 
relation, and mean vessel density (MVD) in a cohort of stage IV rectal cancer patients with 
paired tissue samples prior to and after neoadjuvant local radiotherapy and systemic treatment 
containing bevacizumab. In addition, we correlated VEGFA and PlGF protein expression at 
diagnosis with pathologic response to treatment in rectal tumors, as pathologic response 
provides early and accurate information about the local effect of radiotherapy given in 
combination with systemic treatment. 
MATERIALS AND METHODS  
Patients and Database  
 Rectal tumor samples of stage IV patients [10], presenting with a primary rectal tumor 
and simultaneous metastases to the liver or lungs who participated in a phase 2 study were 
used for this work [2].  Patients received a total pelvic radiotherapy dose of 25 Gy, delivered 
in 5 fractions over five days. Systemic treatment was initiated within 2 weeks of radiotherapy. 
Patients received six 3-weekly cycles of bevacizumab, capecitabine and oxaliplatin. On the 
first day of each cycle, bevacizumab was administered in a dose of 7.5 mg/kg intravenously 
(IV) and oxaliplatin in a dose of 130 mg/m2 IV, each in a 2-hour infusion. Capecitabine was 
given in twice-daily doses of 1000 mg/m2 during the first 2 weeks of each cycle. Following 
the aforementioned treatment, surgical resection of the primary rectal tumor was carried out 
when feasible. An anonymous database had been maintained for this patient cohort 
(T.H.v.D.), encompassing prospective information on general patient characteristics, rectal 
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tumor histopathology, and pathologic response to treatment. Rectal tumors were divided into 
low grade (well/moderately differentiated) and high grade (poorly/undifferentiated) [11].The 
World Health Organization (WHO) classification was used for histological typing [12].  
Collection and Processing of Tumor Samples  
 Immunohistochemical analysis of VEGFA and PlGF expression and of MVD was 
carried out on archival (2006-2010) pre- and post-treatment rectal tumor tissue samples. The 
pre-treatment, diagnostic rectal tumor biopsies were obtained with informed consent from 50 
patients prior to inclusion in the previously reported phase 2 clinical study [2]. Post-treatment 
rectal cancer specimens were collected from the resected primary tumors. Formalin-fixed and 
paraffin-embedded rectal tumor blocks were constructed immediately after tissue 
procurement. All formalin-fixed paraffin-embedded tissue blocks were anonymized and 
encrypted with a unique code for patient confidentiality and study blindness purposes.  
Immunohistochemical Analysis   
 For each immunostaining, 4 μm-thick tissue sections were cut from the paraffin-
embedded primary rectal tumor blocks and subsequently placed on StarFrost® hydrophylic 
microscope slides (Waldemar Knittel, Braunschweig, Germany). Rectal tumor tissue sections 
intended for the immunostainings described herein were cut consecutively, to lessen the effect 
that intra-tumor heterogeneity could have when comparing protein expression within each 
patient sample. Tissue slides such constructed were prepared for immunohistochemical 
staining by deparaffinization in xylene and rehydration in ethanol. Endogenous peroxidase 
and non-specific binding were quenched as previously described [13]. Endogenous avidin-
biotin was blocked for the VEGFA and PlGF stainings by using a commercially available 
blocking kit (Vector Laboratories, Burlingame, CA, USA). Heat-induced antigen retrieval 
was performed for VEGFA, PlGF, and CD31, using a 400 W rotary microwave 
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(Supplementary Table S1). Sections were incubated with polyclonal rabbit anti-human 
antibody against VEGFA or against PlGF, and with monoclonal mouse anti-human antibody 
against CD31 (Supplementary Table S1). Subsequently, sections were incubated with 
secondary and tertiary antibodies with streptavidin-conjugated peroxidase (DAKO, Glostrup, 
Denmark). Diaminobenzidine (Sigma-Aldrich, Zwijndrecht, The Netherlands) was used as a 
chromogene and hematoxylin was applied for counterstaining. 
 Tissue sections of FaDu human hypopharynx cancer xenograft  for VEGFA, human 
placenta for PlGF, and human tonsil for CD31 were stained in parallel with the experimental 
rectal tumor samples, as external positive controls (Supplementary Fig. S2A). External 
negative controls were rectal tumor samples from the study patients with primary antibodies 
omitted (Supplementary Fig. S2B), whereas mostly negatively stained normal stromal tissue 
served as an internal negative control. Internal positive controls were provided by the 
presence of vascular endothelium in some of the slides. Hematoxylin and eosin (H&E) 
staining was used to assess tissue morphology and to ensure the selection of viable tumor 
tissue for immunohistochemical analysis (Supplementary Fig. S2B). 
A Leica DM 3000 microscope and the LAS 3.7 software (Leica Microsystems, 
Rijswijk, The Netherlands) were used for slide analysis and image processing. Two 
independent observers (K.T. and H.T.-B. for VEGFA and PlGF; K.T. and U.M.D. for CD31) 
scored all samples blinded for clinical and pathologic data. VEGFA and PlGF expression was 
assessed in the cytoplasm and nucleus of tumor cells, adjacent stromal cells with elongated 
spindle shape, and in epithelial cells of neighboring rectal crypts with normal histology. Three 
to five random high-power fields (HPF; 400x magnification) were recorded for each slide, 
and the definitive staining score was assigned based upon the most frequently observed 
category among the HPFs evaluated. Before scoring of VEGFA and PlGF expression, 
reference staining scales were selected  (Supplementary Fig. S3A, S3B). VEGFA and PlGF 
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expression scores were assigned using the following criteria: staining negativity (absence of 
expression) or positivity (presence of expression) was established using the predetermined 
cut-off value of 10% of the tissue analyzed (staining  ≤  10% = negative; > 10% = positive); 
in positive samples, staining intensity was further categorized  as weak (1), moderate (2), and 
strong (3). At least a quarter of the tumor area had to be assessable to be designated an 
expression score. Areas of artificial staining detected at the periphery of tumor sections were 
not included in the analysis. Tumor MVD was determined by counting the number of CD31 
positive vessels within three angiogenic hot-spot areas (400x) of the tumor microenvironment 
[14]. A < 10% inter-observer discrepancy was found for all immunostainings. Subsequent 
assessment of discordant cases was performed to reach a consensus score. 
Assessment of Pathologic Outcome 
 Pathologic response was prospectively assessed in post-treatment surgical specimens 
of primary rectal tumors by using Mandard's criteria [15]. Pathologic complete response 
(pCR) of the primary tumor to treatment was defined as no remaining residual 
adenocarcinoma cells in the rectal tumor specimen, and corresponded to Mandard tumor 
regression grade 1 (TRG 1). Residual rectal tumors with pathologic near-complete response 
contained rare residual cancer cells (TRG 2). Partial pathologic response was defined as some 
remaining adenocarcinoma cells in the rectal tumor specimen (TRG 3 or 4), and no response 
as the absence of regressive changes (TRG 5). Pathologic response data were retrieved from 
the anonymous database of the phase 2 clinical trial (T.H.v.D.) and confirmed by the 
pathologist (A.K.).  
Statistical Methodology 
Presence or absence of VEGFA and PlGF expression before treatment was described 
as frequency, and correlated with pathologic response after treatment by Fischer's exact test. 
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For this analysis, post-treatment rectal tumor samples were stratified as presenting or lacking 
pathologic complete response. Intensity of positive protein expression was shown as median 
(range, 1-3), and comparatively assessed in tumor cells, stromal cells and normal rectal crypts 
by Chi-square test. Fisher's exact test served to correlate presence or absence of protein 
expression in paired pre- and post-treatment rectal tumor samples. McNemar's test was used 
to determine the significance of change in protein expression presence or absence in paired 
pre- and post-treatment rectal tumors. Treatment-induced change in MVD of rectal tumors 
was analyzed in paired samples by paired T-test. For statistical analyses, GraphPad Prism 
(version 5.00 for Windows, GraphPad Software, La Jolla, CA, USA) was used. Tests were 
two-sided with a significance level of < 0.05. 
RESULTS  
VEGFA and PlGF Protein Signature of Rectal Tumors of Stage IV Patients 
The clinical and histopathologic characteristics and information concerning treatment 
of the 46 patients with sufficient diagnostic (pre-treatment) rectal tumor tissue available for 
VEGFA and PlGF expression analysis, as verified by H&E staining, are summarized in Table 
1. At diagnosis, most tumors were metastasized to the liver (39/46; 85%). Lung metastases, 
respectively combined liver & lung metastases were less frequent.  
Cytoplasmic and nuclear VEGFA and PlGF expression was recorded in tumor cells (n 
= 46), tumor-adjacent stromal cells (n = 46 for VEGFA, n = 45 for PlGF), and tumor-
neighboring normal rectal crypts (n = 36 for VEGFA, n =32 for PlGF staining). Tumor and 
stroma cellularity differences, respectively the absence of normal rectal crypts in some of the 
diagnostic rectal tumor samples account for disparities between the number of samples 
available for VEGFA and PlGF expression analysis in tumor, stromal, and rectal crypt cells.  
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Table 1. Patient and tumor characteristics at diagnosis and information concerning the 
treatment delivered during the phase 2 clinical trial in patients with sufficient rectal 
tumor tissue available for VEGFA  and PlGF expression assessment. 
            n      (%) 
Gendera   
 Female 18  (39) 
 Male 28  (61) 
Age (years)a  
 Median                        58  
 Range                     35-75  
Primary tumor localizationa  
 Upper 6  (13) 
 Middle 22  (48) 
 Lower 18  (39) 
Primary tumor invasiona  
 cT2 4  (9) 
 cT3 34  (74) 
 cT4 8  (17) 
Tumor  
   Gradea  
 Low 44  (96) 
 High 2  (4) 
   Histological typea  
 Classical 46  (100) 
 Mucinous 0  (0) 
Local lymph node metastasisa  
 cN0 6  (13) 
 cN1 27  (59) 
 cN2 13  (28) 
Distant metastasisa 
 Liver 39  (85) 
 Lungs 5  (11) 
 Liver & lung 2  (4) 
Neoadjuvant treatmenta  
 Irradiation 46  (100) 
 Bevacizumab 45  (98) 
 Capecitabine-oxaliplatin 45  (98) 
Treatment-free interval before surgery (weeks)a 
 Median                            9 
 Range                              5-37 
Surgerya 
 No 7  (15) 
 Yes 39  (85) 
Pathologic response of the primary tumorb  
 YpCR (TRG 1) 9  (23) 
 Residual tumor (TRG 2-5) 30  (77) 
Residual primary tumor invasionc 
 YpT2 9  (30) 
 YpT3 20  (67) 
 YpT4 1  (3) 
 
Results are presented as number of patients and percentage [n(%)], unless indicated otherwise; YpCR 
– pathologic complete response to neoadjuvant treatment; TRG – tumor regression grade; *Assessed in 
the 46 patients of whom upfront rectal tumor tissue for analysis was available; #Assessed in the 39 
patients whom underwent surgical treatment of the primary rectal tumor after neoadjuvant therapy; † 
Assessed in the 30 patients with residual tumor in the surgical specimen following neoadjuvant 
therapy.  
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VEGFA and PlGF were extensively, but differently expressed in the tumor tissue and in the 
neighboring normal rectal crypts. Representative VEGFA and PlGF stainings are depicted in 
Fig. 1A. Cytoplasmic VEGFA expression was present in tumor cells (n = 42/46; 91%), in 
stromal cells  (n = 7/46; 15%), and in the epithelial cells of normal rectal crypts (n = 33/36; 
92%) (Fig. 1B). PlGF expression was found in the cytoplasm of tumor cells (n = 34/46; 74%) 
and in the cytoplasm of epithelial cells in normal rectal crypts (n = 21/32; 66%), whereas this 
was absent in the adjacent stromal cells in 96% of tumor samples (n = 43/45) (Fig. 1B). 
Simultaneous VEGFA and PlGF expression was observed in the cytoplasm of tumor cells in 
30 of the 46 tumor samples (65%), while VEGFA expression or PlGF expression was found 
in 12 (26%) and 4 (9%) tumors respectively. The percentage of VEGFA or PlGF positivity in 
tumor cells and in bordering normal rectal crypts was comparable. However, the VEGFA 
staining intensity of tumor cells was higher (median score 2) than that of the normal rectal 
crypts (median score 1; P < 0.0001; Fig. 1C). The PlGF staining intensity pattern in rectal 
crypt cells mirrored that of tumor cells (Fig. 1C). Nuclear VEGFA expression was present in 
half of the rectal tumor samples in tumor cells (n = 23/46; 50%), in stromal cells (n = 21/46; 
46%), and in the epithelial cells of rectal crypts (n = 19/36; 53%). Distinct, no nuclear PlGF 
expression was observed in any of the cell types analyzed. Baseline MVD in the rectal tumor 
microenvironment was 15.91 ± 5.731 (median ± SD, n = 44). 
VEGFA and PlGF Expression in Relation to Pathologic Response to Treatment 
We subsequently correlated pre-treatment VEGFA and PlGF protein expression with 
post-treatment pathologic response in rectal tumors. This analysis was possible in the thirty-
nine patients that underwent rectal tumor surgery after neoadjuvant pelvic irradiation 
followed by bevacizumab, capecitabine and oxaliplatin treatment. Nine patients achieved a 
pCR and 30 patients had residual cancer cells in the surgical specimen. There were no  
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Figure 1.  Baseline VEGFA and PlGF expression in primary stage IV rectal tumors and 
in neighboring normal rectal crypts.  
 
 
(A)  Representative images of immunohistochemical VEGFA (upper panels) and PlGF (lower panels) 
staining in rectal tumor tissue (tumor and stromal cells), and in the neighboring rectal crypts with 
normal histology, as indicated in columns. Scale bars are indicated in the panels.  (B)  Quantification 
of the distribution of VEGFA (left panel) and PlGF (right panel) staining -- dichotomized as positive 
(i.e., present) or negative (i.e., absent) -- in the cytoplasm of tumor cells, stromal cells, and epithelial 
rectal crypt cells.  (C) Distribution of staining intensity of VEGFA (left panel) and PlGF (right panels) 
in the cytoplasm of tumor cells,  stromal cells, and in normal rectal crypts (median staining intensity 
presented as red line). 
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differences in VEGFA expression and MVD at baseline between the patients that had a pCR 
and those with residual tumor after treatment (Table 2). PlGF stained positive in tumor cells at 
baseline in all 9 patients who experience a pCR, and in 19 of the 30 patients with residual 
tumor (P = 0.040). Furthermore, all 9 patients who achieved a pCR presented simultaneous 
VEGFA and PlGF expression in the cytoplasm of tumor cells pre-treatment, as did 16 of the 
30 patients with residual rectal tumor (Fig. 2). Pathologic near-complete response (pNCR) 
was observed in 3 of the 16 rectal tumors that simultaneously expressed VEGFA and PlGF at 
baseline, and in 3 of the 11 VEGFA-expressing tumors, but not in PlGF-expressing tumors 
(Table 3). Pathologic partial regression or lack of regression were found across the 
VEGFA/PlGF expression subgroups (Table 3).  
Table 2.  Relation  between VEGFA and PlGF expression in rectal tumor tissue at 
baseline and pathologic response to treatment. 
 
Marker expression n Pathologic complete response P-value 
Yes [n (%)]  No [n (%)] 




Cytoplasmic + 36      9  (25) 27  (75) 1.000 
Cytoplasmic - 3 0  (0) 3  (100)  
                       Nuclear + 23 6  (26) 17  (74) 0.711 
Nuclear - 16 3  (19) 13  (81)  




Cytoplasmic + 5 3  (60) 2  (40) 0.070 
Cytoplasmic - 34 6  (18) 28  (82)  
Nuclear + 18 6  (33) 12  (67)   0.225 
Nuclear - 21 3  (14) 18  (86)  




Cytoplasmic + 28 9 (32) 19  (68) 0.040 
Cytoplasmic - 11 0 (0) 11  (100)  




Cytoplasmic + 20   1  (5) 19  (95) 0.095 
Cytoplasmic - 10  3  (30) 7  (70)  
 
n – number of rectal tissue samples analyzed 
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Figure 2.  Distribution of baseline cytoplasmic VEGFA and PlGF stain in rectal tumor 
cells in pathologic complete responders (pCR) and in patients with residual microscopic 




VEGFA + PlGF: simultaneous 
VEGFA and PlGF expression in 
rectal tumor cells at baseline; 
VEGFA: VEGFA expression in 
rectal tumor cells at baseline; 
PLGF: PlGF expression in 






Table 3.  Subgroup correlation of baseline VEGFA and PlGF expression in rectal tumor 
cells with the pathologic regression grade of the residual tumor. 
 
Residual rectal tumor 
 
 n Marker expression 
VEGFA + PlGF [n (%)] VEGFA [n (%)] PlGF [n (%)] 
Pathologic regression grade 30 16  11 3 
     TRG 2 (pNCR) 6 3  (19) 3 (27) 0 (0) 
     TRG 3 16 9 (56) 5 (46) 2 (67) 
     TRG  4 and 5 8 4 (25) 3 (27) 1 (33) 
 
n – number of rectal samples analyzed for baseline cytoplasmic VEGFA or PlGF expression in tumor 
cells; TRG – tumor regression grade of the residual tumor; pNCR – pathologic near-complete response 
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Treatment-Induced Changes in VEGFA and PlGF Expression, and MVD of Rectal 
Tumors 
Finally, we tested whether the expression of VEGFA and PlGF in rectal tumors was 
altered by local radiotherapy and systemic neoadjuvant treatment. VEGFA and PlGF 
expression could not be compared pre- and post-treatment in complete pathologic responders, 
as they had no residual rectal cancer cells in the post-treatment surgical specimen. Thirty 
patients presented residual tumor in the resected rectal cancer specimen. Respectively 27 and 
22 paired rectal tumor samples were available for the analysis of VEGFA and PlGF 
expression pre- and post-treatment (Table 4). Tissue lose that occurred in a few samples 
during staining procedures explains the difference in the number of paired samples used in the 
VEGFA and PlGF analysis. Therapy decreased the number of rectal tumors with nuclear 
VEGFA expression in tumor cells from 56% to 15% (P = 0.024). The number of tumors with 
cytoplasmic VEGFA expression remained the same (Table 4), but treatment decreased the 
intensity of VEGFA expression in residual tumor cells (median score 1) as compared to 
corresponding values before therapy (median score 2, P = 0.001; Fig. 3). Twelve of the 27  
tumors had less, 3 had more, and 12 had the same intensity of cytoplasmic VEGFA staining 
(Fig. 4A). Treatment did not affect significantly neither the number of PlGF-positive rectal 
tumors (Table 4), nor the intensity of PlGF protein expression in tumor, stromal and in normal 
rectal crypt cells (Fig. 3). Three tumors turned PlGF negative, 12 retained their pre-treatment 
PlGF expression in tumor cells, and 7 tumors turned PlGF positive after treatment (Fig. 4B). 
MVD went from 16.43 ± 6.00 before treatment to 10.34 ± 4.21 after treatment (median ± SD, 
P < 0.0001), as assessed in paired rectal tumor samples (n = 27). Representative images of 
CD31 tumor vasculature staining are presented in Supplementary Fig. S4. 
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Table 4.  Treatment-induced changes in the incidence of VEGFA and PlGF expression 
in rectal tumor tissue and in normal rectal crypts. 
Marker expression n Positive expression, n (%) P-value 
Pre-treatment Post-treatment 
VEGFA nuclear  
Tumor cells 27 15  (56) 4    (15) 0.024 
                       Stromal cells 26 10  (38) 4   (15) 0.116 
Normal crypts 21 12  (57) 6   (29) 0.118 
VEGFA cytoplasmic  
Tumor cells 27 24  (89) 27   (100) 0.235 
                       Stromal cells 26 2   (8) 4   (15) 0.668 
Normal crypts 21 20  (95) 20   (95) 1.000 
PlGF cytoplasmic  
Tumor cells 22 13  (59) 17   (77) 0.331 
                       Stromal cells 21 0   (0) 0   (0) 1.000 
Normal crypts 16 11  (69) 10   (63) 1.000 
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Figure 3.  Treatment-induced changes in the intensity of VEGFA and PlGF expression 
in rectal tumor cells. 
  
 
Distribution of staining intensity of VEGFA (left panel) and PlGF (right panel) in the cytoplasm of 
tumor cells pre- and post-treatment (median staining intensity presented as red line). 
 
Figure 4. Dot plots of VEGFA (A) and PlGF (B) expression of individual rectal tumors 





VEGFA and PlGF expression were 
comparatively assessed in rectal tumor 
cells in paired tissue samples collected 
before and after radiotherapy, 
bevacizumab, and chemotherapy. 
Paired cytoplasmic expression data 
were presented in 27 rectal tumor 
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In this study, we investigated the expression of VEGFA and PlGF in primary rectal 
tumors of stage IV patients by immunohistochemistry, as it preserves cell and tissue 
architecture. This allowed us to determine VEGFA and PlGF expression in cancer cells in the 
context of surrounding tumor microenvironment cells and cells of the neighboring normal 
histological structures. This, in turn, could advance our understanding of the role played by 
VEGFA and PlGF in rectal cancer. The study data show that rectal tumors of newly 
diagnosed stage IV patients apart from VEGFA also express PlGF extensively in tumor cells. 
VEGFA was expressed in the cell cytoplasm and nucleus, PlGF expression was confined to 
the cytoplasm. VEGFA and PlGF levels were elevated in rectal tumor cells compared to 
adjacent stromal cells. Subsequently we found that all patients who experienced a pCR 
following neoadjuvant radiochemotherapy and bevacizumab treatment showed simultaneous 
PlGF and VEGFA expression in rectal tumor cells at baseline. Finally, we tested VEGFA and 
PlGF expression and MVD before and after neoadjuvant treatment. VEGFA expression and 
MVD were lower in residual rectal tumors, whereas PlGF expression was not different from 
the pre-treatment values. 
  VEGFA expression has received much attention in rectal tumors, although precise 
subcellular localization of VEGFA was not the focus. We showed that apart from the cell 
cytoplasm, VEGFA expression was also present in the nucleus of tumor cells and adjacent 
stromal cells in 50% of the primary tumors before treatment. VEGFA functions are 
segregated according to its subcellular distribution in tumor cells. Release of cytoplasmic 
VEGFA by tumor cells promotes angiogenesis through a paracrine mechanism, as described 
in several cancer types [16]. Nuclear VEGFA localization has been reported in cell cultures of 
COS-7 fibroblasts under hypoxic conditions and in endothelial cells of the bovine adrenal 
cortex [17, 18], but is not yet reported in human tumors. This localization might be of interest 
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since VEGF receptors (VEGFR) are expressed at the cell surface of endothelial cell, but also 
at the cell and nuclear membrane of tumor cells [16]. VEGFA signaling via VEGFR1 or 
VEGFR2 localized at the nuclear membrane promoted survival of human breast cancer cells 
and human melanoma cells in preclinical models [19, 20].  
 PlGF expression is present in several solid tumor types [7]. However, the precise 
cellular pattern of PlGF expression at the protein level has not been studied. In the present 
study, PlGF was expressed before treatment in the cytoplasm of tumor cells in about 75% of 
the rectal tumors. Furthermore, the vast majority of cases simultaneously expressed PlGF and 
VEGFA in the cytoplasm of tumor cells. Synergism in the tumor microenvironment between 
extracellular VEGFA and PlGF homodimers enhances tumor angiogenesis [21]. But 
preclinical data show that PlGF can also inhibit tumor angiogenesis when overexpressed in 
tumor cells that simultaneously express VEGFA [22-24]. In that setting, VEGFA:PlGF 
heterodimers can be formed at the expense of the more proangiogenic VEGFA:VEGFA 
homodimers, with reduced angiogenic acitivity of such tumor cells. This could support the 
antiangiogenic effect of therapeutic bevacizumab [25, 26]. Not only can tumor cells produce 
PlGF themselves, but they can also ''educate'' stroma cells to produce PlGF via tumor cell-
stroma cross-talk. Breast cancer and leukemia cells upregulate PlGF production in bone 
marrow stromal cells by activating NF-κB signaling [27, 28]. Furthermore, medulloblastoma 
cells stimulate the production of PlGF in the cerebellar stroma via Shh signaling [9]. This role 
in the stroma seems to be absent in rectal tumors as in the current study spindle-shaped 
stromal cells in the primary rectal tumors did not express PlGF. Further studies are warranted 
to elucidate the precise role played by VEGFA  and PlGF in rectal cancer biology in relation 
to  their (sub)cellular distribution, and how this can be better influenced by anticancer 
treatments.  
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In our study, 12 of the 15 patients (80%) that achieved pathologic complete or near-
complete response simultaneously expressed PlGF and VEGFA in rectal tumor cells before 
neoadjuvant radiochemotherapy and bevacizumab administration. Bevacizumab neutralizes 
proangiogenic VEGFA:VEGFA homodimers produced by tumor cells that act on endothelial 
cells, thus induces regression and normalization of tumor vasculature [29, 30]. PlGF did not 
counteract this, since MVD was as expected [31, 32] lower following treatment in residual 
rectal tumors. The ''normalized'' vascular network provides a better delivery of chemotherapy 
followed by local pathologic regression [33]. Local radiotherapy, followed by systemic 
bevacizumab in combination with chemotherapy yielded a pathologic complete response rate 
of the primary rectal tumor of 23%, and a near-complete pathologic response rate of  15% in 
our study. These rates are comparable with other neoadjuvant chemoradiation schemes, which 
have  pathologic complete response rates from 10% to 30%  in patients with locally advanced 
rectal cancer [34]. Circulating levels of PlGF have shown no association with clinical 
outcome in colorectal cancer patients treated with bevacizumab and chemotherapy [35]. 
Whether in situ tumor PlGF is a biomarker of pathologic response of rectal cancer to 
bevacizumab, radiation, chemotherapy, or combination of them needs to be established in 
larger studies.  
In the present study we had the opportunity to access paired rectal tumor samples 
collected during a prospective phase 2 clinical trial in which patients were treated with local 
radiotherapy, and systemic bevacizumab in combination with chemotherapy [2]. The level of 
cytoplasmic and nuclear VEGFA went down in rectal tumor cells following therapy. Nuclear 
VEGFA localization was previously reported in fibroblasts under hypoxia, but not under 
normoxia [18]. Therefore, this response could be a potential readout for an improved 
oxygenation status of the residual rectal tumor after treatment. Elevated serum levels of PlGF 
were reported in 32 stage II-III rectal cancer patients following bevacizumab alone or in 
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combination with radiotherapy, and in 43 mCRC patients after bevacizumab in combination 
with chemotherapy [36, 37]. However, in a study in 12 rectal cancer patients treated with 
bevacizumab only, PlGF mRNA expression in tumor cells and tumor-associated macrophages 
was not upregulated at day 12 of treatment [38]. This data is complemented by our study, 
demonstrating that also combined treatment consisting of radiochemotherapy and 
bevacizumab causes no upregulation of PlGF expression in the primary rectal tumor and 
adjacent stroma. PlGF expression was, however, present in residual rectal tumors cells post-
treatment in our study. We previously performed a study with a radiolabeled humanized 
monoclonal antibody against PlGF in human tumor bearing mice and showed specific tumor 
uptake [39]. In patients, whole body imaging of PlGF distribution by positron emission 
tomography (PET) with an 89Zr labelled antibody against PlGF could potentially identify in a 
non-invasive way the source of circulating PlGF following anti-VEGFA treatment. 
In conclusion, rectal tumors of newly diagnosed stage IV patients express not only the 
well-known VEGFA but also PlGF extensively in tumor cells. Treatment with local 
radiotherapy followed by systemic bevacizumab, capecitabine and oxaliplatin reduces 
VEGFA in residual tumor cells and MVD in the microenvironment. PlGF expression is 
maintained in residual rectal tumors cells post-treatment. In view of the proangiogenic 
function of PlGF and the clinical readiness of PlGF inhibitors [40, 41], a possible implication 
of our findings is that PlGF blockade might be of interest to test in PlGF-expressing VEGFA-
depleted rectal cancers.  
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VEGFA and PlGF are extensively expressed in rectal cancer cells of stage IV patients. 
Radiotherapy followed by bevacizumab and chemotherapy downregulate VEGFA but 
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 SUPPLEMENTARY MATERIAL 
Supplementary Table (S1). Antibodies used for immunohistochemical staining. 
Antigen Antigen retrieval Primary 
antibody 
clone 




VEGFA 100 mM Tris/HCl(pH  9.0) 152 
Santa Cruz1 
Biotech. 1:50 60 minutes 
room 
temperature 
PlGF 10 mM citrate  (pH 6.0)  9542 Abcam
2 1:50 overnight 4 °C 
CD31 10 mM Tris/EDTA(pH 9.0) JC70A DAKO
3 1:50 60 minutes room temperature 
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Supplementary Fig. (S2). A. Representative immunohistochemical VEGFA (left panel), 
PlGF (middle panel), and CD31 staining (right panel) in FaDu human xenograft, human 
placenta, respectively human tonsil tissue. B.  Representative hematoxylin and eosin (H&E; 













    Chapter 5 






Supplementary Fig. (S3). Reference scales of immunohistochemical VEGFA (A.) and PlGF 
(B.) staining of primary rectal tumors. Staining intensities are categorized as negative (0), 
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Supplementary Fig. (S4). Representative examples of CD31 staining in rectal cancer, 
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Placental growth factor (PlGF) is a member of the proangiogenic vascular endothelial growth 
factor family which is upregulated in many tumors. RO5323441, a humanized monoclonal 
antibody against PlGF, showed antitumor activity in human tumor xenografts. We therefore 
aimed to radiolabel RO5323441 and preclinically validate this tracer to study drug tumor 
uptake and organ distribution by PET imaging. 89Zr-RO5323441 was tested for stability and 
immunoreactivity in vitro.  
Methods: The tumor uptake and organ distribution was assessed for 10, 50 and 500 μg of 
89Zr-RO5323441 was assessed in mice bearing human PlGF-expressing hepatocellular cancer 
(Huh7) xenografts or human renal cell carcinoma (ACHN) xenografts without detectable 
human PlGF expression. The effect of pretreatment with RO5323441 (20 mg/kg) on 89Zr-
RO5323441 tumor uptake was analyzed in Huh7 xenografts. 111In-IgG served as a control for 
nonspecific tumor uptake and organ distribution. Cy5-RO5323441 was injected to study the 
intratumor distribution of RO5323441 with fluorescence microscopy.  
Results: 89Zr-RO5323441 showed a time- and dose-dependent tumor accumulation. Uptake in 
Huh7 xenografts at 10 μg of 89Zr-RO5323441 was 8.2 ± 1.7 % injected dose (ID)/cm3 at 144 
h after injection, and in ACHN xenografts it was 5.5 ± 0.3 %ID/cm3 (P = 0.03). RO5323441 
pretreatment of Huh7 xenograft-bearing mice reduced 89Zr-RO5323441 tumor uptake to the 
level of nonspecific 111In-IgG uptake. Cy5-RO5323441 was present in the tumors mainly in 
the microenvironment.  
Conclusion: The findings show that RO5323441 tumor uptake is PlGF-specific and time- and 
dose-dependent. 
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 Angiogenesis is a key feature of tumors (1). Inhibition of angiogenesis by targeting 
vascular endothelial growth factor (VEGF) and VEGF-receptors (VEGFRs) has emerged as 
treatment for various tumor types (2). However, sustained clinical benefit of angiogenesis 
inhibitors can be hampered by compensatory mechanisms such as upregulation of 
proangiogenic factors like placental growth factor (PlGF) (2-5). Targeting PlGF could, thus, 
be a new strategy for tumor angiogenesis inhibition, complementary to VEGFR inhibition, 
and might circumvent resistance observed during current antiangiogenic therapies. 
PlGF, a VEGF homolog, can be expressed by tumor cells and is expressed by several 
other cells in the tumor microenvironment (e.g., endothelial and smooth muscle cells, 
macrophages, fibroblasts and leukocytes) in the tumor miroenvironment (4). PlGF is present 
in low levels in normal tissue. It contributes to the angiogenic switch in pregnancy, wound 
healing, ischemic conditions, and tumor growth (6). PlGF inhibition preclinically slows down 
growth and metastasis of various tumors, including those resistant to VEGFR inhibitors, and 
enhances the efficacy of chemotherapy and VEGFR inhibitors. Additionally, PlGF inhibition 
reduces angiogenesis, lymphangiogenesis, and tumor cell motility. Distinct from VEGFR 
inhibitors, PlGF inhibition preclinically prevents infiltration of angiogenic macrophages and 
severe tumor hypoxia and, thus, does not initiate the angiogenic rescue program responsible 
for resistance to VEGFR inhibitors (7, 8). 
These findings led to the clinical development of RO5323441 (TB-403) (9, 10). 
RO5323441 is a humanized monoclonal antibody against PlGF-1 and PlGF-2. In a phase I 
trial with RO5323441 in cancer patients, stable disease was observed in 6 out of 23 patients 
at different dose levels. No dose-limiting toxicities were observed with doses of up to 30 
mg/kg administered once every 3 wks. Because no maximum-tolerated dose could be defined 
(11), determination of the optimal dose for phase II studies was hampered. Rational dosing 
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might be obtained when tumor and normal tissue uptake of the antibody is defined with 89Zr-
RO5323441 PET. The feasibility of this approach for visualization of soluble angiogenic 
factors was already shown for the VEGFA antibody bevacizumab (12-14). The aim of the 
current study was therefore to study 89Zr-RO5323441 tumor uptake and organ distribution in 
human tumor xenograft models with different PlGF expression. 
MATERIALS AND METHODS 
Cell Lines  
Human hepatocellular carcinoma Huh7 (Health Science Research Resources Bank) 
with high human PlGF (hPlGF) expression (hPlGF mRNA expression 62-fold higher than 
HEK293 native) and the human renal cell carcinoma ACHN (American Type Culture 
Collection) without detectable hPlGF expression (hPlGF mRNA expression equal to HEK293 
native), were cultured in Dulbecco modified Eagle medium containing glucose (1 g/L) 
supplemented with 10% heat-inactivated fetal calf serum (Bodinco BV) at 37°C in humidified 
atmosphere containing 5% CO2.  
The Abelson murine leukemia virus-induced tumor BALB-c derived RAW264.7 
murine macrophage cell line (American Type Culture Collection) was cultured in Dulbecco 
modified Eagle medium containing glucose (4.5 g/L) supplemented with 10% fetal calf serum 
and 1% L-glutamine at 37°C in humidified atmosphere containing 5% CO2. 
Conjugation, 89Zr Labeling, and Quality Control of 89Zr-RO5323441 
RO5323441 was conjugated and labeled as described by Verel et al. (15). In short, 
RO5323441 (25 mg/mL; Roche) was first conjugated with a 5-fold molar excess of the 
chelator N-succinyldesferrioxamine-tetrafluorphenol (N-sucDf-TFP; provided by Dr. Guus 
van Dongen, VU University Medical Center). N-sucDf-RO5323441 was purified by 
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ultracentrifugation using a 30 kDa Vivaspin-2 filter (Sartorius), diluted in water for injection 
(2.5 mg/mL), and stored at -20°C. Labeling was performed with 89Zr (IBA) within 24 h before 
use. Radiochemical purity was evaluated by size-exclusion high-performance liquid 
chromatography using a Superdex 200 10/300 GL column (GE Healthcare) and showed no 
aggregates, fragments, free 89Zr, or other impurities (Supplementary Fig. 1A). 89Zr-
RO5323441 stability was evaluated at 4°C in solvent (0.9% NaCl) and at 37°C in phosphate- 
buffered saline (140 mMNaCl, 9 mM Na2HPO4, and 1.3 mM NaH2PO4; pH 7.4) and in 
human serum by trichloroacetic acid precipitation. 89Zr-RO5323441 was highly stable in 0.9% 
NaCl at 4°C and in phosphate- buffered saline or human serum at 37°C with less than 5% 89Zr 
release over 168 h in all tested conditions. The preservation of immunoreactivity was tested in 
a competition assay with unlabeled RO5323441 with recombinant human PlGF-1 (Peprotech) 
as the target antigen, according to the assay previously described (16). The RO5323441 
concentration required for 50% reduction in hPlGF-1 binding of 5 nM 89Zr-RO5323441 was 
5.1 ± 1.5 nM RO5323441, showing a fully preserved immunoreactivity (Supplementary Fig. 
1B). 111In-IgG was produced as described previously (16). 
Generation of Cy5-labeled RO5323441 
Purified RO5323441 was incubated in 100 mM potassium phosphate, pH 8.5, with a 
5-fold molar excess of Cy5 N-hydroxysuccinimide ester (GE Healthcare Life Sciences) 
dissolved in dimethyl sulfoxide. The reaction was stopped after 60 min by addition of 10 mM 
L-lysine and the surplus of the labeling reagent was removed by dialysis against 20 mM 
histidine, 200 mM sodium chloride, 5% saccharose, pH 6.0. The Cy5 labeling degree was 
determined at an absorbance of 280 nm and 650 nm, and was 2.7:1. The specificity of Cy5-
labeled RO5323441 was analyzed by confocal fluorescence microscopy using recombinant 
Hek293 cells expressing membrane-tagged PlGF. Cy5-labeled RO5323441 was bound to the 
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surface of the cells expressing membrane-anchored PlGF. Specificity was confirmed by 
competition with unlabeled RO5323441. 
Animal Studies 
All invasive procedures and imaging in animal experiments were performed with 
isoflurane inhalation anesthesia (induction, 5%; maintenance, 2%). Tumor cells were 
harvested by trypsinization, resuspended in culture medium and Matrigel (BD Biosciences) 
and inoculated subcutaneously (5 x 106 per mouse) in 6- to 8-wk-old male athymic nude mice 
(BALB-c/Ola HSD-fox nude; Harlan). Each subgroup consisted of 4 mice. Tumor growth was 
assessed 2 times per week with caliper measurement. When tumors measured 6-8 mm in 
diameter (~0.3 cm3), in vivo imaging studies were started using a small-animal PET Focus 
220 rodent scanner (CTI Siemens).  
 Huh7 xenograft bearing mice were coinjected in the penile vein with 10, 50 or 500 μg 
of 89Zr-RO5323441 (5 MBq) and corresponding protein doses of 111In-IgG (1 MBq). 
Coinjection with 111In-IgG provides insight into the behavior of an intraanimal nonspecific 
control for RO5323441 tumor uptake and organ distribution, improves the statistical power 
and reduces animal numbers. ACHN xenograft-bearing mice and non-tumor bearing mice 
were co-injected with 89Zr-RO5323441 (10 μg; 5 MBq) and 111In-IgG (10 μg; 1 MBq). In the 
pretreated group, mice were injected intraperitoneally with RO5323441 (20 mg/kg) 2 d before 
89Zr-RO5323441 injection (10 μg; 5 MBq). Animals were imaged at 24, 72 and 144 h  after 
injection, followed by ex vivo biodistribution analysis as described previously (16). 
For microscopic analysis of tumor localization of RO5323441, Huh7 and ACHN 
xenograft-bearing mice were injected intravenously with 50 μg Cy5-RO5323441, followed by 
tumor excision at 24 h after injection. In vivo stability of Cy5-RO5323441 was confirmed by 
near-infrared fluorescence imaging, which indicated accumulation in Colo205 tumors over 48 
h without specific accumulation in the liver or kidneys. 
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All animal experiments were approved by the animal experiments committee of the 
University of Groningen. 
Tumor Tissue Analyses 
Tumors were kept on ice during biodistribution analysis and subsequently processed 
for histology and fluorescence microscopy. Hematoxylin and eosin staining was performed on 
formalin-fixed, paraffin-embedded tumors to assess tumor morphology. For fluorescence 
microscopy, tumor slides were stained for cell nuclei with Hoechst 33258 (Invitrogen). 
Macrophages were visualized by a 2-step staining with goat-antimouse CD68 (Santa Cruz) 
and donkey-antigoatIgG-Alexa488 (Invitrogen). Slides were analyzed with a Leica DM6000B 
microscope and images were captured with a DFC360FX camera (Leica) and processed with 
LAS-AF2 software (Leica).  
Fresh-frozen tumors were lysed and analyzed for hPlGF and murine PlGF (mPlGF) 
protein levels using an enzyme-linked immuno sorbent assay (ELISA; R&D Systems) 
according to the manufacturers' protocol.  
89Zr-RO5323441 Cell-Binding Studies 
Binding of 89Zr-RO5323441 to the human Huh7 and ACHN cell lines and the murine 
RAW264.7 macrophage tumor cell line was studied in the presence or absence of hPlGF-1 
(Peprotech) or mPlGF-2 (R&D Systems). 89Zr-RO5323441 (0.22 nM; 10 kBq) was incubated 
for 24 h at 37°C with 1 x 106 cells per well. During incubation, PlGF (human or murine) was 
absent or added in 10:1, 1:1 and 1:10 molar ratio with RO5323441. An Fc receptor blocking 
reagent (20 μL; no. 130-059-901, [MiltenyiBiotec]) was used to block the Fcγ receptors (FcγR) 
in RAW264.7. After incubation, cells were washed before harvesting, and the cell bound 89Zr 
was measured in a well-type γ-counter (LKB Wallac). All conditions were tested in 3 
independent experiments. 
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Data are presented as mean ± SD. For statistical analysis, GraphPad Prism (version 
4.00 for Windows, GraphPad Software) was used. Statistical analysis was performed using 
the 2-tailed unpaired t test. A P value of less than 0.05 was considered significant. 
RESULTS 
89Zr-RO5323441 Uptake in hPlGF-Expressing Huh7 Xenografts 
In Huh7 tumors, 89Zr-RO5323441 uptake was seen at all dose cohorts, and uptake 
increased over time, indicating specific tumor uptake. The 144-h scan of the 10 μg89Zr-
RO5323441 dose cohort showed the best tumor visualization with a higher tumor-to- 
background ratio than the 50- and 500-μg89Zr-RO5323441 dose cohorts (Fig. 1A).  
Quantification of the 89Zr-RO5323441 presence in the small-animal PET scans showed that 
the 89Zr-RO5323441 blood-pool levels were similar for the 3 dose cohorts, with a decrease 
between 24 and 144 h (Fig. 1B). 89Zr-RO5323441 tumor uptake increased over time at all 
protein dose cohorts; the highest percentage injected dose per centimeter cubed  (%ID/cm3) in 
tumors occurred in the 10 μg cohort at 144 h. For the 50- and 500-μg cohorts, maximal tumor 
uptake was observed at 72 h which remained the same at 144 h (Fig. 1C). The absolute 89Zr-
RO5323441 tumor uptake levels were 0.8 ± 0.2, 3.1 ± 0.2 and 27.4 ± 3.98 μg/cm3 for, 
respectively, the 10, 50 and 500 μg injected dose cohorts. For 89Zr-RO5323441, the quantified 
small-animal PET data show a non-dose-dependent blood clearance and a time- and dose-
dependent tumor uptake.  
Ex vivo biodistribution analysis in Huh7 xenograft-bearing mice confirmed a normal 
IgG distribution of 89Zr-RO5323441 in nontumor organs. This distribution was hardly 
RO5323441 protein dose-dependent. In contrast, relative 89Zr-RO5323441 tumor uptake 
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Figure 1. (A) Representative small-animal PET examples of Huh7 xenografts injected with 10, 50, or 
500 μg of 89Zr-RO5323441 and scanned at 24, 72, and 144 h after tracer injection. (B and C) Small 
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showed a clear RO5323441 dose-dependent decrease in %ID per gram (%ID/g) of tumor (Fig. 
2A). In the 10-μg cohort, 89Zr-RO5323441 tumor uptake was, respectively, 72% (P = 0.016) 
and 109% (P = 0.023) higher than 111In-IgG at 72 and 144 h after tracer injection (Fig. 2B). 
At 144 h tumor uptake of 89Zr-RO5323441 was in the 50-μg cohort was 91% (P = 0.0041) 
and in the 500-μg 79% (P = 0.0004) higher than for 111In-IgG (Figs. 2C and 2D). These 
biodistribution data confirm the time- and dose-dependent 89Zr-RO5323441 tumor uptake in 
Huh7 xenografts observed with the small-animal PET quantification. 
On the basis of the high tumor-to-nontumor contrast on small-animal PET images,  the 
tumor accumulation over time showed by small-animal PET scans quantification and 
biodistribution data, and the high ratio with 111In-IgG observed in our biodistribution analysis, 
10 μg was chosen as the 89Zr-RO5323441 protein dose for further experiments. 
89Zr-RO5323441 Biodistribution in Non-Tumor-Bearing Mice 
For non-tumor bearing mice, organ distribution of 10 μg89Zr-RO5323441 was similar 
to that of 111In-IgG (Supplementary Fig. 2). There was no specific accumulation of 89Zr-
RO5323441 over time in most nontumor organs, except for liver (+26% from 24 to 144 h 
after injection; P = 0.027) and a nonsignificant trend in bone. Liver and bone uptake are 
possibly the result from binding to scavenging receptors in liver or could indicate in vivo 
tracer metabolism to 89Zr-labeled antibody fragments and release of free 89Zr, which could 
accumulate in bone. Organ distribution of 89Zr-RO5323441 was similar in non-tumor- and 
tumor-bearing mice. 
RO5323441 Pretreatment Reduces 89Zr-RO5323441 Uptake in Huh7 Tumors 
Small-animal PET quantification showed that a 20 mg/kg pretreatment of RO5323441 
reduced the tumor uptake of 10 μg of 89Zr-RO5323441 by 33% (P = 0.026) (Fig. 3A). 89Zr- 
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Figure 2. (A) 89Zr-RO5323441 biodistribution in Huh7 xenografts at 144 h after tracer injection in all 
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RO5323441 tumor uptake in RO5323441-pretreated mice was comparable to the tumor 
uptake in the 500 μg 89Zr-RO5323441 tracer dose cohort. Biodistribution data showed that 
pretreatment with RO5323441 in Huh7 xenografts reduced 89Zr-RO5323441 tumor uptake to 
background levels—that is, not higher than 111In-IgG (Fig. 3B)—confirming the small-animal 
PET quantification data. Biodistribution of 89Zr-RO5323441 in nontumor organs was not 
influenced by RO5323441 pretreatment (data not shown). 
89Zr-RO5323441 Uptake in ACHN Tumors That Do Not Express hPlGF 
Small-animal PET scans showed that 89Zr-RO5323441 tumor uptake in ACHN tumors 
was 33% lower (P = 0.021) than in Huh7 tumors at 144 h after injection (Fig. 4A). 
Biodistribution results revealed that 89Zr-RO5323441 uptake in ACHN tumors was 
comparable to 111In-IgG uptake. The ratio of 89Zr-RO5323441 to 111In-IgG in Huh7 tumors 
was higher than the ratioin ACHN tumors at all time points: 46% at 24 h (P = 0.0003), 61% at 
72 h (P = 0.023), and 89% at 144 h (P = 0.0005) after tracer injection (Fig. 4B). These results 
indicate PlGF tumor level specific uptake in Huh7 tumors. 
Ex Vivo Analysis of Huh7 and ACHN Tumors  
Tumor histology of Huh7 and ACHN xenografts obtained from the 10 µg 89Zr-
RO5323441 cohorts at 24, 72 and 144 h after injection showed areas of tumor cells, stromal 
cells, vasculature, and some necrotic areas (Fig. 5A shows representative hematoxilin and 
eosin staining).  
Fluorescence microscopy revealed that in Huh7 tumors, Cy5-RO5323441 accumulated 
in areas of tumor cells and in necrotic regions, vasculature and the surrounding connective 
tissue (Fig. 5A). In ACHN tumors, Cy5-RO5323441 accumulated only in the surrounding 
connective tissue, necrotic regions, and vasculature but not in the areas of tumor cells. 
Costaining of the Huh7 tumor slides with an anti-CD68 antibody to visualize macrophages  
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Figure 3. Influence of RO5323441 pretreatment on 89Zr-RO5323441 tumor uptake in Huh7 xenografts 





Figure 4. 89Zr-RO5323441 uptake in ACHN and Huh7 tumors as assessed by small-animal PET (A) 
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indicated that Cy5-RO5323441 was present in the CD68-positive regions and in the 
vasculature (Fig. 5C). 
hPlGF protein levels measured with ELISA were 153 ± 62 pg/mg protein in Huh7 
xenografts and nondetectable in ACHN xenograft tissue. Murine PlGF levels were 253 ± 177 
pg/mg protein in Huh7 and 1,063 ± 207 pg/mg protein in ACHN xenograft tissue. 
89Zr-RO5323441Binding to RAW264.7 Macrophages  
To further study the mechanism by which cells, such as macrophages, that are in a 
microenvironment might be involved in RO5323441 tumor uptake, we studied the uptake of 
89Zr-RO5323441 by RAW264.7 murine tumor macrophages in vitro. The binding of 89Zr-
RO5323441 to RAW264.7 concentration dependently increased in the presence of hPlGF 
with a 6.4-fold increase (P = 0.0018) at a 10-fold molar excess of hPlGF (Fig. 5B). The 
hPlGF-induced macrophage binding of 89Zr-RO5323441 was completely blocked by co-
incubation with a Fc receptor blocking reagent. mPlGF was not able to induce binding of 
89Zr-RO5323441 to RAW264.7 macrophages, indicating the higher affinity of RO5323441 
for hPlGF. 
The binding of 89Zr-RO5323441 to Huh7 cells was 2-fold higher than binding to 
ACHN cells (P = 0.0030, Supplementary Fig. 3), possibly due to the autocrine production of 
heparin-binding hPLGF by Huh7. 89Zr-RO5323441 binding to Huh7 and ACHN was not 
affected by the non-heparin-binding hPlGF-1 isoform. The addition of  mPlGF, which also 
binds heparin, induced a slight increase in both cell lines (1.6- and 1.9-fold, respectively). 
DISCUSSION 
In this study, we determined 89Zr-RO5323441 tumor uptake and organ distribution in 
human tumor-bearing mice. We used 3 different tracer doses and 3 different imaging and 
biodistribution time points, 2 tumor models with different target expression levels, an  
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Figure 5. (A) Representative examples of Huh7 and ACHN histology, as assessed by hematoxylin 
and eosin (H&E) staining, and the Cy5-RO5323441 microscopic tumor distribution, as assessed by 
fluorescence microscopy. (B) 89Zr-RO5323441 binding to RAW264.7 macrophages after 24 h 
incubation with hPlGF or mPlGF and an Fc receptor blocking reagent (αFcR). (C) Hoechst staining 
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unspecific IgG control and a RO5323441 pretreatment dose. All together, these data showed 
that 89Zr-RO5323441 tumor uptake was time-,dose- and PlGF-dependent, supporting the  
feasibility of implementing the use of 89Zr-RO5323441 with PET scanning for clinical 
studies.  
 Because this is the first study, to our knowledge, on in vivo visualization of  PlGF, the 
best possible comparison is with result obtained with 89Zr-labeled bevacizumab. For optimal 
comparison, the antibody tracer should be considered. 89Zr-bevacizumab showed a SKOV-3 
tumor uptake of  6.8 ± 1.8 %ID/g with 100 μg antibody (12), which is similar for 89Zr- 
RO5323441 tumor uptake. Higher levels of 89Zr-RO5323441tumor uptake, expressed at 
%ID/g, might have been obtained when lower antibody doses would have been used. 111In- 
bevacizumab biodistribution studies showed uptake levels of up to 25 %ID/g for a 1 μg 
bevacizumab dose (17). In the present study, we used 10 μg of 89Zr-RO5323441 because this 
was the lowest dose that allowed sufficient counts for PET quantification at 6 d after 
injection. It would have been possible to perform a biodistribution-only experiment with a 
lower dose (e.g., 1 µg), and this would likely have resulted in a higher tumor uptake when 
expressed as %ID/g. However, ex vivo biodistribution studies are nonsequential and not 
translational, and we aimed to validate 89Zr-RO5323441 as an imaging tool. Overall, 89Zr-
RO5323441 PlGF PET preclinical performance is comparable to that of 89Zr-bevacizumab 
VEGF PET. 
Fluorescent-labeled RO5323441 was present in the tumor microenvironment at 24 h 
after injection. Our mouse models were engrafted with human Huh7 and ACHN tumors, and 
therefore the microenvironment of these human tumor xenografts consisted of human tumor 
cells and murine stroma. This microenvironment, as shown with ELISA, contained both 
hPlGF and mPlGF. RO5323441 binds both hPlGF and mPlGF, with a Biacorekoff rate of 80 
and 35 min, respectively, indicating a more tight binding to hPlGF than mPlGF (data not 
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shown). Additionally, RO5323441 binding experiments with RAW264.7 cells support the 
higher affinity for binding to hPlGF. This higher affinity explains the PlGF-specific uptake of 
89Zr-RO5323441 in the hPlGF-overexpressing Huh7 tumors. As expected, binding of 89Zr-
RO5323441 to Huh7 and ACHN tumor cells in vitro was low. mPlGF induced a small 
increase in 89Zr-RO5323441 binding to Huh7 and ACHN cells. One explanation could be that 
we used hPlGF isoform 1 as hPlGF and mPlGF isoform 2 as mPlGF, because mice only 
express this isoform. One of the differences between PlGF1 and PlGF2 is that PlGF1 lacks 
aheparin-binding domain, which is necessary for binding to the neuropilin-1 coreceptor (18). 
mPlGF2 therefore could have been bound to Huh7 and ACHN cells via heparin, allowing 
binding of 89Zr-RO5323441. 
The in vitro experiments with RAW264.7 macrophages suggest that 89Zr-RO5323441 
forms immune complexes preferably with hPlGF. The 89Zr-RO5323441 and hPlGF complex 
in turn binds to the Fcγ receptors on macrophages, followed by phagocytosis of the immune 
complex; this is especially supported by the finding that 89Zr-RO5323441 itself shows little 
interaction with macrophages. Only in the presence of hPlGF is there hPlGF concentration- 
dependent 89Zr-RO5323441 binding. Because hPlGF is the target of RO5323441, competition 
of RO5323441 binding would intuitively be expected when hPlGF is added and thus 
decreased cellular binding. However, our results and those of others (19), provide evidence 
for the Fcγ receptor-mediated macrophage uptake of IgG immune complexes, such as the 
complex of RO5323441 with hPlGF. This evidence can be explained by the fact that 
macrophages express Fcγ receptor subtypes II and III (FcγRII and FcγRIII), which have a low 
affinity for monomeric IgG. However, FcγRII and FcγRIII interact with high avidity with IgG 
immune complexes, with consequential selective phagocytosis of IgG immune complexes 
(19). The relevance of Fcγ receptor interactions of antibody-antigen immune complexes in the 
tumor accumulation of soluble antigen-targeted antibodies such as RO5323441 is not exactly 
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clear yet. Our Cy5-RO5323441 ex vivo data and 89Zr-RO5323441 in vitro data however 
indicate that PlGF-specific tumor uptake of RO5323441 might be modulated by macrophages. 
The Fcγ receptor-mediated uptake of antibody-antigen complexes is rather generic. It is 
therefore unlikely that this mechanism is specific for the RO5323441-PlGF complex. Tumor 
uptake of other soluble antigen-targeted antibodies like the VEGFA antibody bevacizumab 
might therefore also be dependent on immune complex formation. Bevacizumab-VEGFA165 
immune complexes can interact with platelets via FcγRIIA potentially playing a role in the 
thrombotic events often seen during bevacizumab therapy (20). 
Conflicting opinions exist on the significance of PlGF as a target for treatment in 
oncology (21). In preclinical models, PlGF plays a role in resistance to antiangiogenic 
therapies. PlGF inhibition showed antitumor activity in tumor models resistant to VEGFR 
inhibitors (7). Additionally, elevated serum levels of PlGF were reported in patients following 
antiangiogenic therapy with bevacizumab or sunitinib (22-24). In a preclinical study with the 
VEGF- and PlGF-neutralizing decoy receptor sFLT01, increased serum PlGF levels reflected 
a systemic host response instead of a tumor response. In addition, circulating PlGF was 
upregulated in mice with responding as well as progressing tumors (25). These findings 
suggest limited potential and utility of serum PlGF as a biomarker for anti-angiogenic 
therapies. 89Zr-RO5323441 tumor uptake was found to be PlGF-dependent. Therefore, 89Zr-
RO5323441 PET imaging might well be superior to measuring circulating PlGF levels to 
monitor PlGF tumor expression during antiangiogenic treatment. When the angiogenic rescue 
program is activated in the tumor, this will coincide with a local PlGF upregulation in the 
tumor microenvironment and an increased 89Zr-RO5323441 uptake and possibly support the 
rationale for combining RO5323441 with VEGFR inhibitors. The vasculature normalization 
effect of bevacizumab can hamper the tumor penetration of simultaneously injected large 
molecules (e.g., antibodies such as RO5323441) (26). PlGF PET with 89Zr-RO5323441 might 
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therefore also be of value in the optimization of scheduling combined antiangiogenic 
treatments. 
The therapeutic potential of PlGF inhibition has recently drawn additional attention. In 
contrast to the initially published antitumor effects of an anti-PlGF antibody, other PlGF- 
neutralizing antibodies had no significant effect on tumor growth and angiogenesis in several 
preclinical tumor models (27). There is no unifying explanation for these conflicting results; 
however, differences in physicochemical properties, posttranslational modifications, or other 
alterations may have influenced the efficacy of the different PlGF antibodies (8). Moreover, it 
was found that a functional VEGFR-1 in tumor cells is required for an anti-tumor effect of 
anti-PlGF antibodies (28). It is as of yet unclear how the antibody dose affects the efficacy 
(9). In the clinical phase I dose-escalation studies with RO5323441, no dose-limiting 
toxicities were found with doses of up to 30 mg/kg (10, 11). It is possible that the maximum 
effective dose was already reached with optimal target saturation of its target. Insight in 
biodistribution of RO5323441 by quantification of 89Zr-RO5323441 tumor uptake may offer 
an interesting support for this dosing dilemma by serving as readout for target saturation by 
different doses of RO5323441. Our results showed that a 20 mg/kg dose of RO5323441 
reduced the human tumor uptake of the 89Zr-RO5323441 tracer dose in mice to background 
111In-IgG levels. These results likely reflect PlGF saturation by the treatment dose but could 
also be a consequence of RO5323441-induced vessel normalization. Vessel normalization, 
which is now widely acknowledged for bevacizumab, also occurs following PlGF inhibition 
(8, 29). Dynamic contrast-enhanced MR imaging to monitor changes in tumor perfusion in 
the clinical evaluation of 89Zr-RO5323441 and RO5323441 could potentially be used to 
distinguish PlGF saturation effects and vessel normalization. 
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The performance of 89Zr-RO5323441 PET for PlGF detection is of interest because 
89Zr-bevacizumab and 111In-bevacizumab have already proven to be a valuable VEGFA 
imaging tracer in clinical studies. The 89Zr-bevacizumab uptake in tumor lesions in renal cell 
cancer and melanoma patients is beyond even the expectations based on preclinical results 
(13, 14). Given the extensive similarity between VEGFA and PlGF, an enhanced 89Zr-
RO5323441 tumor-to-background ratio versus findings in the xenograft model is expected 
also in the human setting. Because in the human setting both tumor cell- and stromal cell-
derived PlGF are of human origin and will thus be recognized by 89Zr-RO5323441, it is 
possible that our preclinical findings with 89Zr-RO5323441 PET underestimate the tumor 
uptake that will be seen in cancer patients. In addition, the antibody tracer dose of 10 µg in a 
mouse of 25 g versus a typical 5 mg in a human of 70 kg, favors the antibody-antigen ratio in 
humans. To determine RO5323441 human tumor uptake and how this is affected by 
bevacizumab, we will quantify the tumor uptake of RO5323441 by serial 89Zr-RO5323441 
PET scans in patients with recurrent glioblastoma (EudraCT number: 2011-004974-27). 
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      SUPPLEMENTAL DATA 
 
SUPPLEMENTAL FIGURE 1: Quality control of 89Zr-RO5323441. Typical SE-HPLC result of 
89Zr-RO5323441 with detection at 280 nm for the protein signal (A; upper panel) and co-registration 
of radioactive signal (A; lower panel). Immunoreactivity of 89Zr-RO5323441 was determined in a 
competition binding assay with unlabeled RO5323441 (RO5323441). Competition curve (with 95% 
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SUPPLEMENTAL FIGURE 2:  89Zr-RO5323441 biodistribution in non-tumor bearing mice at 24, 
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SUPPLEMENTAL FIGURE 3:  89Zr-RO5323441 binding to RAW264.7 macrophages and Huh7 
and ACHN tumor cells after 24 h incubation with 10-fold molar excess of human PlGF (hPlGF) or 
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Drug development in oncology was initially focused on inducing DNA damage in 
proliferating cancer cells, with currently more emphasis on targeted agents and 
immunotherapy. Tumor cells and their microenvironment interact and this gives opportunities 
for potential targets for treatment. New approaches are critical as many patients still have 
recurrence disease and develop resistance to their cancer treatment. 
 
Angiogenic factors and chemokines 
The aim of this thesis was to explore targets in the microenvironment of rectal cancer 
with a focus on angiogenic growth factors and chemokines. 
In this thesis, two key pathways of tumor-microenvironment interaction were studied 
with emphasis on rectal cancer, namely the vascular endothelial growth factor A (VEGFA)-
mediated pathway promoting tumor angiogenesis, and the chemokine ligand 12 
(CXCL12)/chemokine receptor 4 (CXCR4) signaling pathway primarily directing cellular 
migration toward distant metastatic sites.  
Chapter 1 gives the outline of the content of the thesis.  
The clinical and biological differences and similarities between rectal and colon 
cancer are presented in a literature review in Chapter 2. Several hallmarks establish rectal 
cancer as distinct from colon cancer. The rectum and colon have a different embryological 
origin and anatomy, and have a different function. Moreover, rectal and colon cancer differ in 
their metastatic pattern, and contain a different set of drug targets, such as v-raf murine 
sarcoma viral oncogene B (BRAF), which is preferentially mutated in proximal colon 
carcinomas, and the epidermal growth factor receptor (EGFR), that is prevalently amplified or 
overexpressed in the distal colorectum. Differences in anatomy led to different surgical 
approaches and administration of neoadjuvant (chemo)radiotherapy solely for rectal cancer. 





Adjuvant systemic treatment increases overall survival of patients with stage III colon cancer, 
whereas its role in rectal cancer is not proven. Metastatic rectal and colon cancer are 
commonly regarded as one entity, and treated alike. Insights in difference between rectal and 
colon cancer are of importance, since they may provide guidance for the design of novel 
clinical approaches. 
In Chapter 3 we evaluated the efficacy and tolerability of preoperative radiotherapy, 
followed by systemic capecitabine-oxaliplatin (CapeOx) treatment in combination with 
bevacizumab – a humanized monoclonal antibody against VEGFA – and subsequent radical 
surgical treatment of all tumor sites of in 50 de novo metastatic rectal cancer patients. 
Treatment comprised radiotherapy (5x5 Gy), followed within 2 weeks by bevacizumab (7.5 
mg/kg, day 1) and oxaliplatin (130 mg/m2, day 1) intravenously and capecitabine (1000 
mg/m2 twice daily orally, days 1-14) for up to six 3-weekly cycles. Surgery and/or 
radiofrequency ablation (RFA) was performed 6 to 8 weeks after the last bevacizumab dose. 
The most commonly observed clinical stage was cT3N1-2 in 64% of the patients, with liver 
metastases. Of 50 included patients, 42 had liver metastases, five had lung metastases, and 
three had both liver and lung metastases. Preoperative radiotherapy was given to all 50 
patients, and subsequent preoperative bevacizumab-CapeOx treatment was started in 49 
(98%) patients. Forty two (84%) patients received all six cycles of bevacizumab-CapeOx. 
Toxic effects were tolerable. The most common nonsurgical grade ≥3 toxic effects were 
diarrhea and pulmonary embolism. The most frequent grade 1-2 adverse reactions to the 
systemic drug treatment were fatigue, sensory neuropathy and nausea. No metastatic disease 
progression was detected by radiological reassessment during or at the completion of 
preoperative treatment. Radical surgical treatment of all tumor sites (R0) was possible in 36 
of the 50 patients. The most frequent postoperative complications within 60 days after surgery 
were wound and abdominal cavity infections. No treatment-related deaths occurred. A 





complete pathologic response of the primary tumor was found in 26% of patients, and in 16% 
near-complete response, with only a few residual tumor cells present. Rectal tumor 
downstaging occurred in 47% of patients who had primary tumor resection. The 2-year 
overall survival rate was 80% in the intent-to-treat group (n=50; 95% confidence interval 
(CI), 66.3 to 90.0%). The 2-year recurrence rate was 64% (23/36 patients; 95% CI, 49.8 to 
84.5%) after R0 resection. Median time to recurrence was 13 (range 7-20) months. Local 
pelvic relapse occurred in two out of the 23 patients, and distant recurrences – mainly in the 
liver/lungs – in 21 out of the 23 patients. This study shows that radical surgical treatment of 
all tumor sites carried out after short-course radiotherapy and systemic bevacizumab-CapeOx 
combination treatment is a feasible and potentially curative approach in primary metastasized 
rectal cancer patients. This approach may enable both treatment of metastatic disease and 
good control of the primary rectal tumor. 
Results in Chapter 3 show that about 65% of the primary metastasized rectal cancer 
patients experienced, mainly distant, disease recurrence within 2 years after radical surgical 
treatment of all tumor sites. Therefore, in Chapter 4 we studied the expression of CXCR4 
and CXCL12 in 46 primary rectal tumors before and after patients underwent local 
radiotherapy and systemic treatment with bevacizuma-CapeOx and subsequent radical 
surgery. At diagnosis, cytoplasmic CXCR4 and CXCL12 expression in cancer cells was 
present in 89% and in 81% of the tumor samples, respectively. Nuclear CXCR4 and CXCL12 
expression in cancer cells was observed in 30% and 35% of the cases. Stromal cells expressed 
cytoplasmic CXCR4 and CXCL12 in 98% and 86% of the tumor samples respectively. 
Nuclear CXCR4 and CXCL12 expression was present in stromal cells in 14% and 16% of the 
tumor samples. At baseline, there were no differences in CXCR4 or CXCL12 expression 
between the nine patients that had and the 30 that did not have a pathologic complete response 
to treatment. After treatment, nuclear CXCL12 expression in cancer cells was present in 79% 





of residual tumors, as compared to only 31% of the paired tumor samples expressing nuclear 
CXCL12 before treatment (P=0.001). In conclusion, CXCR4 and CXCL12 are extensively 
expressed in rectal tumors of patients presenting with metastatic rectal cancer, and treatment 
further upregulates expression of CXCL12. These data indicate that the CXCR4 receptor and 
its ligand CXCL12 are potential therapeutic targets in rectal cancer. 
Expression of placental growth factor (PlGF) – a VEGFA homolog – is related 
preclinically to tumor angiogenesis and survival of cancer cells, and correlates with poor 
survival in colorectal cancer patients (1-3). Moreover, bevacizumab alone or in combination 
with radiotherapy or chemotherapy increases circulating PlGF levels in (colo)rectal patients 
(4, 5). Hence, in Chapter 5 we studied the VEGFA and PlGF protein signature, and the mean 
vessel density (MVD) in rectal tumors of 46 patients before and after they underwent local 
radiotherapy and systemic bevacizumab-Capox and participated in the study described in 
Chapter 3. At diagnosis, VEGFA was expressed in 91% of the tumor samples in the 
cytoplasm and in 50% in the nucleus of tumor cells, whereas PlGF was expressed in 74% 
only in the cytoplasm of tumor cells. Simultaneous VEGFA and PlGF expression was present 
in the cytoplasm of tumor cells in 65% of the tumor samples. PlGF expression was absent in 
tumor-adjacent stromal cells in 96% of the tumor samples. There were no differences in 
VEGFA expression and MVD at baseline between the nine patients that had and the 30 who 
did not have a pathologic complete response. All nine patients with pathologic complete 
response had PlGF expression in tumor cells at baseline, as did 19 of the 30 patients with 
residual tumor. In the 11 rectal tumors of patients without PlGF expression at baseline no 
pathologic complete response was found. After treatment, nuclear VEGFA expression in 
tumor cells and MVD were lower in the residual tumors as compared to pretreatment values 
(15% vs. 56%, P=0.024, and 10.3 (±4.2) vs.16.4 (±6.0), P<0.0001). PlGF expression in the 
residual tumors did not differ from the pretreatment values. This study shows that rectal 





tumors of newly diagnosed stage IV patients express not only the well-known VEGFA but 
also PlGF extensively. In view of the proangiogenic function of PlGF and in conjunction with 
the clinical efficacy and safety profile of available PlGF inhibitors, a possible implication of 
this finding is that PlGF blockade might be of interest to study in rectal cancer patients.  
PlGF inhibition showed antitumor activity in preclinical tumor models resistant to 
VEGF receptor (VEGFR) inhibitors (6). These findings led to the clinical development of 
RO5323441, a humanized monoclonal antibody against PlGF. Since its administration in 
humans did not lead to dose-limiting toxicities, no optimal therapeutic dose was defined (7, 
8). In vivo RO5323441 imaging could allow dynamic non-invasive assessment of target 
(PlGF) saturation during treatment, thus support rational drug development. Therefore, in 
Chapter 6 we labeled RO5323441 with 89Zr to develop a PlGF-specific PET tracer and 
investigate 89Zr-RO5323441 tumor uptake and organ distribution in human tumor bearing 
mice. We used three different tracer doses, as well as three different imaging and 
biodistribution time points, two tumor models with different PlGF expression levels, an 
unspecific IgG control, and a RO5323441 pretreatment dose. The fluorescent Cy5-
RO5323441 was injected to study the intra-tumor distribution of RO5323441 with 
fluorescence microscopy. RO5323441 could be readily labeled with 89Zr with high specific 
activity (up to 1 GBq 89Zr/mg RO5323441), a radiochemical purity of >95%, stability in 
human serum at 37 °C of >1 week, and a fully preserved immunoreactivity. 89Zr-RO5323441 
showed a time- and dose-dependent tumor accumulation. We found that uptake in PlGF-
expressing Huh7 xenografts at 10 μg 89Zr-RO5323441 was 8.2 ± 1.7 % injected dose 
(ID)/cm3 at 144 hours after injection, whereas in PlGF not expressing ACHN xenografts it 
was 5.5 ± 0.3 %ID/cm3 (P=0.03). RO5323441 pretreatment (20 mg/kg) of Huh7 xenograft-
bearing mice reduced 89Zr-RO5323441 tumor uptake to the level of nonspecific 111In-IgG 
uptake. Cy5-RO5323441 was present in the tumors mainly in the microenvironment. Overall, 





these data showed a PlGF specific, time- and dose-dependent RO5323441 uptake in tumors. 






























(1) Dewerchin M, Carmeliet P. PlGF: a 
multitasking cytokine with disease-
restricted activity. Cold Spring Harb 
Pespect Med 2012;2:a011056. 
(2) Snuderl M, Batista A, Kirkpatrick ND, 
et al. Targeting placental growth 
factor/neuropilin 1 pathway inhibits 
growth and spread of medulloblastoma. 
Cell 2013;152:1065-1076. 
(3) Escudero-Esparza A, Martin TA, 
Davies ML, Jiang WG. PGF isoforms, 
PlGF-1 and PGF-2, in colorectal cancer 
and the prognostic significance. Cancer 
Genomics Proteomics 2009;6:239-246. 
(4) Willett CG, Duda DG, Di Tomaso E, et 
al. Efficacy, safety, and biomarkers of 
neoadjuvant bevacizumab, radiation 
therapy, and fluorouracil in rectal 
cancer: A multidisciplinary phase II 
study. J Clin Oncol 2009;27:3020-
3026. 
(5) Kopetz S, Hoff PM, Morris JS, et al. 
Phase II trial of infusional fluorouracil, 
irinotecan, and bevacizumab for 
metastatic colorectal cancer: efficacy 
and circulating angiogenic biomarkers 
associated with therapeutic resistance. J 
Clin Oncol 2010;28:453-459. 
(6) Fischer C, Jonckx B, Mazzone M, et al. 
Anti-PlGF inhibits growth of 
VEGF(R)-inhibitor-resistant tumors 
without affecting healthy vessels. Cell 
2007;131:463-475. 
(7) Martinsson-Niskanen T, Riisbro R, 
Larsson L, et al. Monoclonal antibody 
TB-403:A first-in-human, phase I, 
double-blind, dose escalation study 
directed against placental growth factor 
in healthy male subjects. Clin Ther 
2011;33:1142-1149. 
(8) Lassen U, Nielsen DL, Sørensen M, et 
al. A phase I, dose-escalation study of 
TB-403, a monoclonal antibody 
directed against PlGF, in patients with 











    Chapter 8 




Discussion and Future Perspectives 
It is becoming increasingly clear over the last years that normal cells such as endothelial and 
immune cells, pericytes and cancer-associated fibroblasts, and other stromal cells 
substantially influence tumor growth, metastasis and sensitivity to cancer treatment through 
their interactions in the microenvironment with cancer cells (1-5). This insight opens new 
treatment possibilities as new targets are learned (6, 7).   
CXCL12/CXCR4 axis as therapeutic target in rectal cancer 
Potential cure is possible for patients with rectal cancer in case of limited metastatic spread to 
the liver or lungs. A reason for the limited chance to obtain this goal might be de novo or 
acquired resistance to anticancer treatment (2). In Chapter 4 we showed that rectal tumor and 
stromal cells express chemokine receptor CXCR4 and its ligand CXCL12 extensively at 
baseline, and that combined radiotherapy, chemotherapy and bevacizumab further upregulate 
expression of CXCL12. Stromal derived CXCL12 can directly stimulate proliferation and 
migration of CXCR4-expressing cancer cells. This specific prosurvival influence of stromal 
cells on tumor cells is thought to protect them from cytotoxic chemotherapy (8). CXCL12-
mediated resistance to etoposide was described for small cell lung cancer cells when co-
cultured with bone marrow stroma (9). In co-cultures of tumor and stromal cells and in 
murine models of chronic lymphocytic leukemia (10), acute myeloid leukemia (11, 12) and 
prostate cancer (8), inhibitors that block the binding pocket of CXCR4 (AMD3100, 
AMD3465, T140 analogs) sensitized cancer cells to chemotherapy (cytarabine, docetaxel) and 
the tyrosine kinase inhibitors sorafenib. Therefore, CXCL12/CXCR4 blockade could be 
tested in rectal cancer to rescue acquired resistance. 
Although the CXCL12/CXCR4 ligand-receptor pair represents a potential clinical 
target in rectal cancer therapy, little is known about its role and dynamics in this disease. It 
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has a pleiotropic role in in several malignancies, and is ubiquitously present in both cancer 
and normal cells in various tissues (13). Therefore, in future studies in rectal cancer models 
the impact of CXCL12/CXCR4 blockade on tumor growth, survival and invasiveness, tumor 
cell mobilization and formation of metastasis, local stroma and tumor vasculature, 
mobilization of hematopoietic stem cells, and tumor infiltration with immune cells deserves 
attention (14).    
Targeting PlGF in rectal cancer 
Placental growth factor (PlGF) is a member of the VEGF family and is involved in bone 
marrow-derived cell activation, endothelial stimulation, pathologic angiogenesis and wound 
healing (7). In Chapter 5 we show that rectal tumors express PlGF extensively at diagnosis, 
and also after radiotherapy followed by bevacizumab, capecitabine and oxaliplatin treatment. 
A possible implication of this finding is that PlGF blockade might be of interest to test in 
rectal cancer patients. However, PlGF blockade resulted in antiangiogenic and antitumor 
effects in some models, but not in other (7). In this respect it would be of interest when a 
clinical study is considered to study PlGF expression by the tumor and to verify how much of 
the radioactive labeled antibody against PlGF gets into the tumor.     
Molecular imaging to guide the use of antiangiogenic drugs 
The administration of humanized monoclonal anti-PlGF antibody RO5323441 did not 
coincide with dose-limiting toxicity in early clinical trials (15, 16). Therefore, no optimal 
therapeutic dose is yet defined. Rational dosing might be achieved when tumor and normal 
body tissues uptake of the antibody is defined by 89Zr-RO5323441 positron emission 
tomography (PET), using the tracer we developed in Chapter 6. By quantifying 89Zr-
RO5323441 tumor uptake we could get insight into target (PlGF) saturation by different doses 
of RO5323441. This could help defining the optimal therapeutic dose. 
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Furthermore, in a randomized trial in patients with recurrent glioblastoma, 
RO5323441 combined with bevacizumab did not improve the response rate compared to 
single agent bevacizumab (17). Vessel normalization is acknowledged for bevacizumab (18), 
and this could hamper the tumor penetration of large molecules such as antibodies (e.g., 
RO5323441 (19). 89Zr-RO5323441 brain PET scanning could be used together with dynamic 
contrast-enhanced magnetic resonance imaging (MRI) to determine whether vessel 
normalization precluded RO5323441 penetration into the tumor. This might be of value for 
optimizing combined antiangiogenic treatment. 
Fluorescent imaging in rectal cancer  
The distance between the edge of the rectal tumor and the mesorectal fascia represents the 
circumferential resection margin (CRM), and constitutes the anatomical cornerstone for the 
feasibility of curative total mesorectal excision (TME). As presented in Chapter 2, MRI is the 
current preoperative examination of choice for establishing the CRM. However, there is room 
for improvement.  
CXCR4 was found to facilitate cancer cell invasion in a mouse model of glioma and in 
colon carcinoma cells in culture (20, 21). CXCR4 antagonist TY14003 could be readily 
labeled with a fluorescent probe (carboxyfluorescein) (22). Fluorescent TY14003 specifically 
binds urothelial cancer cells and was used to image bladder cancer in mice by endoscopy. As 
shown in Chapter 4, CXCR4 is expressed at lower levels in epithelial cells of normal rectal 
crypts than in rectal cancer cells. Therefore, it could be envisioned that after injection, 
fluorescent-CXCR4 antagonist will most likely accumulate in the rectal tumor area. If 
CXCR4 is present at the invasive front (tumor rim) of rectal tumors, the fluorescent light 
emitted following light beam excitation would enable precise intraoperative CRM assessment 
during rectal tumor resection (23). Therefore, fluorescent CXCR4 antagonists constitute an 
option to be evaluated in this setting. 
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Advancing the understanding of tumor microenvironment-mediated disease progression and 
resistance to treatment in rectal cancer should help to define novel, rational and successful 
clinical approaches. New insights into angiogenic growth factors and chemokines as 
therapeutic targets in rectal cancer are presented in this thesis. Our clinical study shows that 
radical surgical treatment carried out after short-course radiotherapy, and capecitabine-
oxaliplatin chemotherapy in combination with the VEGFA inhibitor bevacizumab is a feasible 
approach in primary metastasized rectal cancer. By examining the protein expression profiles 
of rectal cancer and stromal cells before and after therapy, we identified PlGF and the 
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Medicijnontwikkeling in de medisch oncologie was in het verleden met name gericht op 
celdeling en DNA verdubbeling, waarbij dit zich nu meer richt op specifieke 
tumorceleigenschappen en het immuunsysteem. Tumorcellen en hun omgeving 
communiceren met elkaar, en dit inzicht biedt mogelijkheden voor potentiële 
aangrijpingspunten voor behandeling. Nieuwe behandelingen zijn nodig omdat nog veel 
kankerpatiënten overlijden aan uitgezaaide ziekte. 
 
Angiogene factoren en chemokines 
Het doel van dit proefschrift was om meer inzicht te krijgen in potentiële 
aangrijpingspunten voor behandeling in de omgeving van rectumtumorcellen waarbij de focus 
ligt op angiogene factoren en chemokines.  
In dit proefschrift, worden voor het rectumcarcinoom twee belangrijke tumor-
omgevingsfactoren interacties bestudeerd namelijk de vascular endothelial growth factor A 
(VEGFA)-gemedieerde route ten aanzien van tumor angiogenese én de chemokine ligand 12 
(CXCL12)/chemokine receptor 4 (CXCR4) signaal route welke belangrijk is voor 
verplaatsing van cellen naar locaties elders in het lichaam om metastasen te vormen.  
In Hoofdstuk 1 wordt het proefschrift kort ingeleid.  
Hoofdstuk 2 beschrijft op basis van literatuurgegevens klinische en biologische 
verschillen en overeenkomsten tussen het rectum- en het coloncarcinoom. Embryologisch, 
anatomisch en functioneel zijn het rectum en colon verschillend. Tumoren ontstaan in het 
rectum of colon verschillen in metastaseringspatroon en verschillen in potentiële 
aangrijpingspunten voor medicatie zoals het meer voorkomende gemuteerde v-raf muizen 
sarcoom virale oncogen homoloog B (BRAF)-eiwit in het proximale colon heeft en in het 
distale colon en rectum de amplificatie/overexpressie van de epidermale groeifactor receptor 
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(EGFR). De verschillen in anatomie hebben geleid tot verschillen in operatietechnieken en in 
aanvullende behandelingen waarbij neoadjuvante chemoradiotherapie standaard is voor het 
rectumcarcinoom en adjuvante chemotherapie standaard bij het stadium III coloncarcinoom. 
Winst van adjuvante chemotherapy na neoadjuvante (chemo)radiotherapie is bij het 
rectumcarcinoom niet bewezen. Ondanks al deze verschillen wordt het gemetastaseerd 
rectum- en coloncarcinoom in het algemeen als één ziekte gezien met de dezelfde 
behandelopties. Inzicht in de verschillen tussen het rectum- en coloncarcinoom kan mogelijk 
leiden tot betere studie protocollen zowel ten aanzien van stagering als nieuwe 
behandelopties.   
In Hoofdstuk 3 wordt de klinische studie beschreven waarin 50 patiënten met een 
rectumcarcinoom met resectabele metastasen deelnamen. In deze fase 2 studie werd 
kortdurend radiotherapie (5 x 5 Gy) op de rectumtumor  gegeven, gevolgd door 6 kuren met 
capecitabine en oxaliplatin (CapeOx) in combinatie met bevacizumab  – een gehumaniseerd 
monoclonaal antilichaam tegen VEGFA) met aanvullend een lokaal curatieve behandeling 
operatie en/of RFA op alle tumor lokalisaties. De systeemtherapie werd op z’n vroegst op dag 
10 na de bestraling gestart bestaande uit bevacizumab (7.5 mg/kg, dag 1), oxaliplatin (130 
mg/m2, dag 1) intravenous en capecitabine (1000 mg/m2 twee keer per dag oraal dag 1-14) in 
een cyclus van 21 dagen en in totaal 6 kuren. Operatief ingrijpen kon 6-8 weken na de laatste 
bevacizumab kuur worden ingepland. Van de 50 geïncludeerde patiënten, met veelal een 
cT3N1-2 rectumtumor (64%) waren er 42 patiënten met levermetastasen, 5 met 
longmetastasen en 3 patiënten met zowel lever- als longmetastasen. Alle patiënten kregen de 
preoperatieve radiotherapie, in 49 patiënten werd de preoperatieve bevacizumab- dit begrip al 
eerder introduceren CapeOx gestart, waarbij 42 patiënten (84%) de geplande 6 cycli kregen. 
De meest voorkomende niet-chirurgische graad 3/4 toxiciteit waren diarree en longembolie en 
graad 1-2 toxiciteit met moeheid, sensore neuropathie en misselijkheid. Tijdens de 
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preoperatieve behandeling werd radiologisch geen progressie van ziekte gediagnosticeerd. 
Radicale behandeling van alle tumorlokalisaties (R0) was mogelijk in 36 van de 50 patiënten. 
De meeste voorkomende postoperatieve complicatie binnen 60 dagen was wondinfectie. Er 
was geen behandelingsgerelateerde mortaliteit. Een complete response van de primaire tumor 
werd gevonden in 26% van de patiënten met een bijna complete response (enkele 
tumorcellen) in 16%. In 47% van de patiënten met een resectabele rectum tumor werd 
downstaging aangetoond. De 2-jaars overleving is 80% (n=50; 95% betrouwbaarheidsinterval 
66.3-90.0%). Het aantal recidieven na 2 jaar na een R0 resectie was 64% (23/36; 95% CI, 
49.8-84.5%), met een mediane tijd tot recidief van 13 maanden (7-20). Van deze 23 
recidieven waren er 2 in het kleine bekken en bij 21 patiënten werden metastasen op afstand 
gevonden (mn lever/long). Deze studie laat zien dat radicale lokale behandeling van alle 
tumorlokalisaties na neoadjuvante behandeling met 5 x 5 Gy radiotherapie en systeemtherapie 
met  bevacizumab-CapeOx een haalbare behandeling lijkt voor patiënten met een 
rectumcarcinoom en potentieel operabel gemetastaseerde ziekte. Deze behandelvolgorde  
maakt het mogelijk de metastasen op afstand te behandelen met daarbij goede controle van de 
primaire tumor. 
Hoofdstuk 3 laat zien dat in primair gemetastaseerde patiënten met een rectumtumor 
na systeemtherapie en lokale curatieve behandeling van alle lokalisaties bij 65% van de 
patiënten recidief ziekte wordt gevonden. Daarom is het zoeken naar nieuwe drug-target 
belangrijk. In Hoofdstuk 4 wordt de expressie van eerste keer voluit CXCR4 and CXCL12 
bestudeerd in 46 primaire rectumtumoren voor en na behandeling met lokale radiotherapie 
gevolgd door bevacizumab-CapeOx en radicale resectie. Voor behandeling wordt in de 
tumoren CXCR4 en CXCL12 expressie gevonden in het cytoplasma in  respectievelijk 89% 
en 81% en in de kern respectievelijk 30% en 35% en met in de stromale cellen in het 
cytoplasma respectievelijk 98% en 86%  en in de kern 14% en 16%. Vooraf behandeling was 
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er geen verschil in CXCR4 en CXCR12 expressie tussen de negen patiënten met een complete 
respons en de 30 patiënten zonder een complete respons. Na de behandeling werd in 79% van 
de tumoren met restweefsel CXCL12 expressie in de kern gevonden en vergeleken met de 
gepaarde tumorsamples had vooraf behandeling 31% van de tumoren CXCL12 expressie in 
de kern (P=0.001). Concluderend kan gezegd worden dat de CXCR4 en CXCL12 expressie 
hoog is in de rectumtumoren bij patiënten met gemetastaseerde ziekte en dat de 
voorbehandeling de CXCL12 expressie opreguleert. Dit betekent dat CXCR4 of CXCL12 
mogelijke drug-targets zouden kunnen zijn voor patiënten met rectumtumoren.  
Expressie van de placenta groei factor (PlGF) – een VEGFA homoloog – is 
preklinisch gerelateerd aan tumorangiogenese en overleving en in patiënten met colorectale 
tumoren is het gecorreleerd met een slechte overleving (1-3). Daarnaast worden hogere 
circulerende PlGF spiegels gezien na behandeling met mono bevazicumab dan wel in 
combinatie met radiotherapie of chemotherapie (4, 5). In Hoofdstuk 5 hebben we VEGFA- 
en PlGF eiwit expressie en de vaatdichtheid (MVD) bepaald in de rectumtumoren van 46 
patiënten die hebben deel genomen aan de M1 studie (zie hoofdstuk 3) voor en na 
behandeling met locale radiotherapie en systemische behandeling met bevacizumab-CapeOx. 
In deze tumoren werd bij diagnose VEGFA expressie in 91% in het cytoplasma gevonden en 
in 50% in de kern en PlGF expressie in 74% met alleen expressie in het cytoplasma.  In de 
tumorbiopten werd  in het cytoplasma in 65% zowel VEGFA als PlGF expressie gevonden. In 
96% van de tumorbiopten werd in het stroma geen PlGF expressie gevonden. Er werd geen 
verschil gevonden in VEGFA expressie en MVD bij start tussen de 9 patiënten met een 
complete response en de 30 patiënten zonder een complete response. Alle 9 patiënten met een 
pathologisch complete respons hadden PlGF-expressie bij start ten opzichte van 19 van de 30 
patiënten met nog rest tumor na de voorbehandeling. In de 11 patiënten met een rectumtumor 
zonder PlGF-expressie bij start werd geen pathologisch complete respons gezien. Na 
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behandeling was de VEGFA expressie en de MVD lager  bij  de patiënten met resttumor 
vergeleken met deze tumoren vooraf start van de behandeling (15% vs. 56%, P=0.024, en 
10.3 (±4.2) vs. 16.4 (±6.0, P<0.0001). De PlGF expressie in de patiënten met resttumor was  
gelijk aan de expressie in de tumorbiopten vooraf aan de behandeling. Deze studie laat zien 
dat primaire rectumtumoren bij stadium IV patiënten zowel de bekende VEGFA als de PlGF  
sterk tot expressie brengt. In het licht van de proangiogene functie van PlGF en in samenhang 
van de klinische effectiviteit  en veiligheid van de beschikbare PlGF remmers laat deze studie 
zien dat PlGF-blokkade mogelijk zinvol zou kunnen zijn voor patiënten met rectumtumoren.  
In een in-vivo VEGF receptor (VEGFR) resistent tumor model laat  PlGF remming 
antitumoractiviteit zien (6). Deze data hebben de ontwikkeling van RO5323441 – een 
gehumaniseerd monoclonaal tegen PlGF  – gestimuleerd (7, 8). In hoofdstuk 6 hebben we 
RO5323441 gelabeld met 89Zr om zo een PlGF–specifieke PET tracer te ontwikkelen. 
Hiermee werd de 89Zr-RO5232441 uptake en orgaan distributie  in tumordragende muizen 
bestudeerd. In twee verschillende diermodellen met verschillen in PlGF expressie, een 
aspecifieke IgG controle en RO5323441 behandeldosis werden drie verschillende 
tracerdoseringen beoordeeld in combinatie met drie verschillende scan momenten en 
biodistributie. Het fluorescent Cy5RO5323441 werd geïnjecteerd om de intra-tumorale 
distributie van RO5323441 te bestuderen met fluorescentie microscopie. RO5323441 kon 
worden gelabeld met 89Zr met een hoge specifieke activiteit (tot 1 GBq 89Zr/mg RO5323441) 
met een radiochemische zuiverheid van >95%, stabiel in humaan serum bij 37 °C van meer 
dan 1 week met volledig behoud van immuunreactiviteit. 89Zr-RO5323441 liet en tijd en dosis 
afhankelijke tumoraccumulatie zien. De opname in PlGF positieve xenografts  (PlGF positive 
Huh7) met 10 ug 89Zr-RO5323441 als tracer was 144 uur na de injectie 8.2 ± 1.7% van de 
geïnjecteerde dosis (ID)/cm3, en in de ACHN xenografts zonder PlGF expressie was de 
opname 5.5 ± 0.3% ID/cm3 (P=0.03). De behandeling met RO5332441 (20 mg/kg) in Huh7 
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tumordragende muizen reduceerde de 89Zr-RO5323441 opname tot het nivo van aspecifieke 
111In-IgG opname. Cy5-RO5323441 werd met name waargenomen in het weefsel rondom de 
tumor. Samenvattend laten deze data zien dat 89Zr-RO5323441 PET scanning toepasbaar lijkt 
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Az onkológiai gyógyszerfejlesztés eredetileg DNS-károsodást indukáló vegyületekre 
összpontosított, melyek az osztódó rákos sejteket célozzák meg. Jelenleg, nagy hangsúly 
fektetődik a célzott terápia és immunterápia fejlesztésére. Az új terápiás megközelítések 
rendkívülien fontossak mivel sok beteg rezisztenssé válik a használatban levő kemoterapiás 
kezelésekre és sok betegnél daganatos recidiva alakul ki. 
A rákos sejtektől eltekintve, a roszzindulatú daganatok endothel sejteket, csontvelő-
eredetű progenitor sejteket, immunsejteket, rákhoz kapcsolódó fibroblasztokat, és más stroma 
sejteket is tartalmaznak. A kölcsonhatás rákos es mikroközegi sejtek között egyre inkább 
elismerést nyer mint a roszzindulatú daganat egyik fő jellemzője, és ezáltal egy lehetséges 
kezelési célponttá válik.  
 
Angiogén növekedési faktoroknak és kemokineknek 
A jelen dolgozat célja, hogy új kezelési célpontokat tárjon fel a végbélrák 
mikroközegében, különös figyelmet szentelve az angiogén növekedési faktoroknak és 
kemokineknek. Két jellátviteli utat vizsgáltuk meg ebben a dolgozatban, melyek reszt vesznek 
a rákos sejtek es mikroközegük közti kommunikácioban. A vaszkuláris endoteliális 
növekedési faktor-A (VEGFA) jellátviteli utat, mely elsősorban a daganatos angiogenezisben 
játszik lényeges szerepet, valamint a 12-es kemokin (CXCL12)/kemokin receptor 4 (CXCR4) 
jelátviteli utat, mely elsősorban a rákos sejtek migrációját segiti elő, így szerepet játszva a 
távoli áttétek kialakulásában.  
Az 1. fejezetben a tumor mikroközeg fogalma kerül bevezetésre, majd bemutatjuk a 
dolgozat tartalmát. 
  A végbélrák és a vastagbélrák közötti klinikai és biológiai különbségek és 
hasonlóságok kerülnek bemutatásra a 2. fejezetben, szakirodalom áttekintés által. Számos 





jellemzők különböztetik meg a végbélrákot a vastagbélráktól. A végbélnek valamint 
vastagbélnek  más-más a fejlődéstani eredetetük,  anatómiájuk és funkciójuk. A végbélrák 
esetében gyakoribbak a tüdő, csont es agyi áttetek, mig a vastagbélrákhoz gyakrabban 
társulnak intraabdominális áttetek. A végbél és vastagbél karcinómák különböznek olyan 
lehetséges kezelési célpontok szempontjábol is mint például a BRAF, amely elsödlegesen a 
proximális vastagbél karcinómákban mutált, és az EGFR, mely jellemzöen amplifikált vagy 
expreszált a disztális vastagbél és végbél karcinómákban. Az anatómiai sajátoságok 
különböző sebészeti kezeléshez vezetnek végbélrák és a vastagbélrák esetén, valamint 
neoadjuváns (kemo) radioterápiához kizárólag végbélrákban. Az adjuváns szisztémás kezelés 
növeli az ossztúlélést vastagbélrákban szenvedo betegek esetén, mig szerepe a végbélrákban 
nem bizonyított. Ugyanakkor, jelen álláspont szerint, az áttétes végbélrák és vastagbélrák egy 
entitásnak tekintendő és ugyanolyan ellátásban részesül. Bepillantás a végbélrák és a 
vastagbélrák közti különbségekben fontos, mivel útmutatást adhat új, hatékony kezelések 
tervezéséhez. 
A 3. fejezetben, kombinált preoperatív sugárkezelés és szisztémás capecitabin, 
oxaliplatin (CapeOx)-bevacizumab kezelést értékeltük 50 áttétes végbéldagnatban szenvedő 
betegben, melyek ezt követően radikális (R0) sebészi kezelésben és/vagy radiofrekvenciás 
ablációban (RFA) részesültek. Két héttel a sugárterápia (5x5 Gy) után bevacizumab (7,5 
mg/kg, az 1. napon) és oxaliplatin (130 mg/m2 az 1. napon) kezelésre került sor intravénásan, 
valamint capecitabin adásárá (1000 mg/m2 naponta kétszer, orálisan, 1-14. nap). Legfeljebb 
hat ciklus CapeOx-bevacizumab kezelésre került sor. A sebészeti beavatkozas az utolsó 
bevacizumab után 6-8 héttel történt. A leggyakrabban megfigyelt klinikai stádium cT3N1-2 
volt az esetek 64%-ban. Az 50 beteg közül, 42-ak volt a máj áttéte, 5-ek tüdő áttéte, és 3-ak 
úgy máj mint tüdő áttéte. Ötven beteg részesült preoperatív sugárkezelésben, és 49-él (98%) a 
preoperatív CapeOx bevacizumab kezelést időben el lehetett kezdeni. Negyvenkét (84%) 





beteg kapta meg mind a hat CapeOx-bevacizumab ciklust. Hasmenés és a tüdőembólia voltak 
a leggyakoribb nem-sebészi grade ≥3 mellékhatások. A leggyakoribb grade 1-2 
mellékhatások: fáradtság, szenzoros neuropathia és hányinger. Radiológiai progresszió a 
preoperatív kezelés alatt nem volt kimutatható. Radikális sebészi kezelés (R0) 36 betegnél 
volt kivitelezhető. Seb és hasüregi fertőzés voltak a leggyakoribb sebészi szövődmény a műtét 
utáni 60 napban. Kezeléssel összefüggő halálozás nem történt. Teljes patológiai végbél 
daganat regresszió a betegek 26%-an, közel-teljes patológiai regresszió a betegek 16%-an volt 
kimutataható. Végbél daganat downstaging a betegek 47%-ál fordult elő. A 2-éves össztúlélés 
80% volt (n=50, 95%-os konfidencia intervallum (CI), 66.3-90.0%). A 2-éves kiújulási arány 
R0 rezekció után 64% volt (23/36 beteg, 95% CI, 49.8-84.5%). A medián kiújulási idő 13 (7-
20) hónap volt. Helyi kismedencei recidiva két betegnél, távoli recidiva 21 betegnél alakult, 
főleg a májban és tüdőben. Ez a tanulmány azt mutatja, hogy radikális sebészet lehetséges 
preoperatív helyi sugárterápia és szisztémás CapeOx-bevacizumab kezelés után, áttétes 
végbélrákban szenvedő betegek esetében. Ez a megközelítés lehetővé teszi mind a primér 
végbél daganat mind a távoli áttétek kuratív kezelését. 
A 3. fejezet eredményei azt mutatják, hogy mintegy 65%-a azon áttétes végbélrákban 
szenvedő betegek közül akik kuratív célú sebészeti kezelésben részesültek, recidiváltak, főleg 
a májban es a tüdőben. Ezért, a 4. fejezetben, a CXCR4 és CXCL12 expresszióját 
tanulmányoztuk 46 betegtől származó primér végbélrák mintában. A szövet minták a 3. 
fejezetben leírt preoperativ kezelés előttről (diagnosztikus biopsia) és utánrol (sebészeti 
minta) származtak. Diagnózisnál, citoplazmatikus CXCR4 expresszió volt észlelhető a rákos 
sejtekben a minták 89%-an, és citoplazmatikus CXCL12 expresszió a minták 81%-an. 
Nukleáris CXCR4 expresszió volt megfigyelhető a rákos sejtekben a minták 30%-an és 
nukleáris CXCL12 expresszió a minták 35%-an. A stroma sejtek expresszálták úgy a 
receptort mint a ligandot a citoplazmában (a minták 98%-a valamint 86%-a), es kisebb 





mertekben a nukleusban (a minták 14%-a valamint 16%-a). Nem volt különbség a CXCR4 
valamint CXCL12 expresszióban a 9 és 30 betek között akinél kialakult vagy nem alakult ki 
teljes patológiai végbél daganat regresszio. Kezelés után, a nukleáris CXCL12 expresszió 
elofordulasa gyakoribb volt a rákos sejtekben (a mintak 79%-a) összehasonlítva a kezelés 
elotti elofordulashoz (a mintak 31%-a), párosított végbél tumormintákban (P=0.001). 
Összefoglalva, a CXCR4 és CXCL12 elterjedten expresszálodnak áttétes betegek (IV. 
stádium) primér végbéldaganataiban, és a kezelés tovább fokozza a CXCL12 expressziót. 
Ezen adatok azt jelzik, hogy a CXCR4 receptor és a CXCL12 ligand lehetséges terápiás 
célpontok végbélrákban. 
Preklinikai tanulmányokban azt mutatják, hogy a placenta növekedési faktor (PlGF) - 
egy VEGFA homológ – szerepet játszik a tumor angiogenezisben és a rákos sejtek 
tulélésében, valamint klinikailig rosszabb túlélésel korrelál colorectális daganatos betegekben 
(1-3). Továbbá, a bevacizumab, monoterapiában vagy sugárterápiával/kemoterápiával 
kombinálva emeli a keringő PlGF szintet (colo)rektális betegekben (4, 5). Ezért, az 5. 
fejezetben a VEGFA és PlGF fehérje expressziót, valamint a daganat erezettséget (MVD) 
tanulmányoztuk, 46 betegtől származó primér végbélrák szövettmintában. E betegek részt 
vettek a 3. fejezetben ismertetett klinikai vizsgálatban. A szövet minták preoperativ kezelés 
előttről (diagnosztikus biopsia) és utánrol (sebészeti minta) származtak. Diagnózisnál, a 
minták 91%-an volt kimutatható VEGFA expresszió a rákos sejtek citoplazmájában és a 
minták 50%-an a nukleusban. PlGF expresszió a rákos sejtek citoplazmájában a minták 74%-
ban volt megfigyelhető. Egyidejű VEGFA és PlGF expresszió a rákos sejt citoplazmájában a 
minták 65%-an volt jelen. A tumor stroma sejtek nem expresszáltak PlGF-et a minták 96%-
an. Nem volt különbség a VEGFA expresszióban valamint a MVD-ben a 9 és 30 betek között 
daganat regresszió. Mind a kilenc betegek akinél teljes patológiai végbél daganat regresszió 
alakult ki expresszálta a PlGF-et  a rákos sejtek citoplazmájában diagnózisnál, csakúgy mint 





19 beteg a 30-ból akinél reziduális tumort igazoltak a kezelés utáni szövetmintában. Azon 11 
beteg akinek végbél daganata nem expresszálta a PlGF-et a rákos sejtek citoplazmájában a 
kezelés elötti diagnósztikus szövetmintában, nem ert el teljes patológiai végbél daganat 
regressziót a kezelés után. A kezelés után, a nukleáris VEGFA expresszió a rákos sejtekben és 
a tumor MVD alacsonyabb volt a kezelés előtti értékeknél, párosított végbél tumormintákban 
(15% vs. 56%, P=0.024, és 10.3 (±4.2) vs.16.4 (±6.0), P<0.0001). A PlGF fehérje expresszió 
reziduális végbél daganatokban nem különbözött a kezelés előtti értékektől, párosított 
tumormintákban. Ez a tanulmány azt mutatja, hogy az újonnan diagnosztizált végbél 
daganatokban IV. stádiumu betegeknél nem csak a jól ismert VEGFA hanem a PlGF is 
elterjedten expresszálódik, úgy kezelés előtt mint után. Tekintettel a PlGF proangiogén 
funkciójára, továbbá a PlGF gátló szerek klinikai hatékonyságára és toxicitas profiljára, a 
jelen tanulmány egyik lehetséges következtetése az, hogy célszerű lehet a PlGF blokád 
tesztelése végbél rákos betegekben.  
A PlGF preklinikai gátlássa tumorellenes aktivitást eredményezett VEGF-receptor 
(VEGFR) inhibitorokra rezisztens tumor modellekben (6). Ez a RO5323441 klinikai 
fejlesztésehez vezetett, mely egy PlGF-elleni humanizált monoklonális antitest. Fázis 1. 
RO5323441 klinikai vizsgálatokban nem mutatkoztak dózislimitáló toxicitások. 
Következéskeppen, a RO5323441 optimális terápiás dózisának meghatározása nem vált 
lehetövé (7, 8). In vivo RO5323441 képalkotás lehetővé tenné a non-invazív, dinamikus PlGF 
telítettség megitélését RO5323441 kezelés alatt, így támogatva a racionális 
gyógyszerfejlesztés. Ezért, a 6. fejezetben egy PlGF specifikus PET nyomjelzőt fejleztettünk 
ki, nevezetesen a 89Zr jelölt RO5323441-t. Ez által megvizsgáltuk a 89Zr-RO5323441 tumor 
halmozódást és a tumor mentes szervekbeli elosztást humán daganattal xenografált egerekben. 
Három különböző 89Zr-RO5323441 nyomjelző dózist, három különböző képalkotási (kisállat 
PET) és biodisztribúció időpontot, két, PlGF expressziós szintben különböző tumor modelt, 





egy aspecifikus IgG-kontrolt, és egy RO5323441 előkezelési dózist használtunk a 
kísérletekhez. Fluoreszkáló Cy5-RO5323441 injekciót alkalmaztunk, hogy tanulmányozzuk 
az intra-tumor RO5323441 eloszlást fluoreszcens mikroszkóppal. A RO5323441-t 
hatékonyan tudtuk jelölni 89Zr-al, magas specifikus aktivitással (1 GBq 89Zr/mg RO5323441), 
95% feletti radiokémiai tisztasággal, tobb mint 1 hetes stabilitással 37 ° C humán szérumban, 
és teljesen megtartott immunreaktivitással. A 89Zr-RO5323441 nyomjelző idő és a dózis-
függő tumor halmozódást mutatott. Azt találtuk, hogy a PlGF-et expresszáló Huh-7 
xenograftokban a 10 μg 89Zr-RO5323441 halmozódás 8,2 ± 1,7% injektált dózis (ID) /cm3 
volt 144 órával az injekció beadása után, míg a PlGF-et nem expresszáló ACHN 
xenograftokban 5,5 ± 0,3% ID/cm3 volt (P=0.03). RO5323441 előkezelést követően (20 
mg/kg), Huh-7 xenograftot hordozó egerekben a 89Zr-RO5323441 daganat-halmozódás az 
aspecifikus 111In-IgG daganat- halmozódás szintjére csökkent. A Cy5-RO5323441 főként a 
tumor mikroközegben volt jelen. Összességében, ezen adatok PlGF specifikus, dózis- és idő-
függő RO5323441 halmozódast igazolnak a tumorban. Ez alátámasztja a 89Zr-RO5323441 
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